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GENERAL INTRODUCTION 
History of occupational cancer 
The first description of occupational cancer is known from 1775 (see 
fig.l). It was Percival Pott who, being a proficient surgeon, had noticed 
that many chimney-sweepers had cancer of the scrotum and testicles. He 
supposed that this disease originated from a lodgement of soot in the 
rugae of the scrotum. In fact, by Pott's observation, the way was opened 
to the prevention of this disease and to the isolation and synthesis of 
the first known oure carcinogen. It took over a hundred years, however, 
before results of experimental research were published showing the causal 
relation between exoosure to chemicals and cancer. In 1915, the Jaoanese 
researchers Yamagiwa and Ichikawa (1918) induced cancer on a rabbit's ear 
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caft ai peculiar to a certain fet of people 
which hai not, at ІеаЛ io my knowlec^e, 
beta publlckly noticed j I mno the cbim-
ncf-fwcepcn' cancer. 
ft il a dJfafe which ilwari mafcei iti 
firft attick on, and it% firft appearance in 
die Inferior part of the fcrotum j where it 
jKoducei a fuperficial, painful, raggeri, 
ill-looking ibre, with hard and liGng edges. 
The'trade call ¡t 'the fooi-wart. f never 
faw it under the age of puberty, which it, 
1 fuppofe, one reafon, why ¡t ¡a generally 
taken, both by pal ¡ent and furgeun, for 
f cnereal, and being treated with mercuriali, 
if Aerebylbon, and much nafpetited : in 
во great length of time. It pervada the 
u io, dartel, and membranes of the /сяк 
Hua» and feite· the teftiele, which Й to-
brgea, harden·, and reader· truly ami tbo-
rpvfhly UiAemperedi frcm wheoc« Il 
•lakes its way up the fpcrmitk proceu in-
m the abdomen^ mort frequently iniun-
tiag. and fpoiting the inguinal glands : 
when arrived within the abdomen, it af-
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fed» Готе of the vilcer·, tnd then »ery 
ibon becomes painfully dcrtni£hvc 
The fate of ihefc people Гест« fingularly 
bard, in their early infancy, they are meft 
frequently treated with great brutftlity, and 
ûlmofl íbrved with cold and hunger, they 
•re thruft up narrow, and fomctimes hot 
chimnies, where they are bru ι fed, burned, 
and almoft fu if oca ted , and when the} get 
to puberty, become peculiarly liable to a 
moil noifome, painful» and fatal difeaJe. 
Ol this tail circumiUnce there 19 not 
the Icart doubt« though perhaps it oiay not 
ha\e been fuffioently attended to, to make it 
generally known Other people have can­
cers of the fame parts , and fo have others, 
befide Jead-workcre, the Poiftou colic, and 
the confequent paralyfisj but it u ncver-
thelefs a difeafe to which they ire peculi­
arly liable 1 and Го arc chimney·fweepcrs 
to the cancer of the fcrotum and teni­
d o . 
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If cxtirpitron ever bids für Ar the eun 
o f t cancer, it feenntobcin th l tnfc i bof 
then the operition Ihoiild be Immediate, 
end before the habit i4 Minted. The dif* 
etfe, ш thefe peojflc, kernt*to dtr in ht 
origin from • lodgment of fbdt In The 
roga of the fcTonirn, end at firft irot to be 
ψ difeafe of the habit In mhetc4cs of • 
caneerous nature, «α which the habit и toa 
frequently concerned, we have not often 
fo lair a profpeft of Гиссеіа by the removal 
of the diftcmpercd part j and are obliged 
to be content with mcani* which I wiih I 
could fay were truly palliative j but here 
the fubjeil· are yotmg, in general in good 
health, at Icafl at fiilt, the difeafe brought 
on them by their occupation, and in all 
probability local 1 which left cirfumibnce 
may, I think, be fairly prefumed from us 
always fcizing the (¡une part all this 
reakei it (at firft) a very different cafe 
from a cancer which appear* m an elderly 
man, whofe fluids are become acnmomoui 
from lure, as well as other caofes i or from 
F a the 
Fiq. 1 Description of the occurrence 
testicles in chimney-sweeoers 
Jl there lie any chance of putting а Лор 
•о, or preventing this mifchief, it muft be 
by the immediate removal of the part af-
fe¿ted, I mran that part of the fcrotum 
where the fore 19, for if it be fuffered to 
remain until the ν tra» has feized the lefti-
cle, it u generally too Ule even for nilra 
bon I have many times made the еж pé-
riment j but though the fores, after iuch 
operation, have, tn feme inflances, healed 
kindly, and the pananti have gone from the 
bofpital feemingly well, yet, in the fpace of 
a few months, it has generally happened, 
•hat they bave returned cither with the 
Cune difeafe in the other telitela, or in the 
glands of the groio, or with fach wan com-
plexion», fuch pale, leadoi, countenances, 
fiich a total lofe of ilrcogth, and fuch fre-
quent and acute internal pains, aa bave fuf-
¿cienily proved a difcafed flue of Гоом of 
the vifcera, and which have Акт bee» fal­
lowed by a painful death 
If 
t 68 1 
die feme kind of complsint In woihen « -a 
have ceafed to meoftruate. But be all this 
as 11 may, the fcrottun fe 00 vital organ, 
nor can the lofs of a part of it ever be at­
tended with any, the imaUeft degree of 
Inconvenience j and if a life can be prefcr-
ved by the removal of all that portion 
that u diftempered, it will be a very good 
and eafy compoutcm 1 for when the difeafe 
baa got head, it is rapid io tu progrtft, 
painful in all Hi attacks, and rnoft cer­
tainly deftrufbve m its event. 
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of cancer of the scrotum and 
by Percival Pott (1775). 
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by painting it with tar. The isolation of benzo(a)pyrene from coal tar was 
not described until 1933 (Cook, Hewett and Hieger). 
At the end of the 19th century, skin cancers were observed not only in 
chimney-sweepers but also in workers exposed to shale oil, tar and products 
in several industries (Pott 1775, Syme 1Θ35, Baum 1874, Volkmann 1874) . The 
occurrence of lung tumours in the Schneeberg miners at Joachimstahl in 
Bohemia was reported in 1879 by Härting and Hesse. The tumours in all these 
cases had arisen at the place of contact in the skin or respiratory tract, 
but no occupational tumours were recognized in organs remote from the place 
of contact. 
In 1895 at a congress of the German Surgical Society, Rehn a surgeon in 
Frankfurt-am-Maln, reported three cases of bladder tumours in patients who 
had worked in the same factory, namely in the so-called fuchsin room, where 
at the most a total of 45 men were ever known to have worked. Thus, the 
incidence of this relatively uncommon disease was extraordinary high. These 
tumours were associated with exposure to aniline which gave rise to the 
introduction of the name "aniline cancer". Later on this turned out to be 
the wrong name when it was finally accepted that aniline was not the 
significant cause. Since the end of the 19th century, occupational bladder 
tumours were found more frequently in workers in aromatic amines 
(Leichtenstern 1898, Rehn 1904, 1906). Hueper et al. (1938) found tumours of 
the bladder in dogs treated with 2-aminonaphthalene (ß-naphthylamine). 
Finally it became evident that 2-aminonaphthalene, 4-aminobiphenyl and 
benzidine were compounds producing bladder tumours in men (Clayson 1962, Koss 
et al. 1969) . 
In 1920 Oppenheimer supposed that it was a metabolite of benzidine or 
aniline which was especially active on the bladder epithelium. The possible 
role of metabolism in the carcinogenesis of aromatic amines has been discussed 
extensively by Bonser et al. (1951). It was found that in most of the 
experimental animals, tumours have been induced in various organs, yet the 
dog was the only animal in which bladder tumours appeared. Besides species-
differences in the metabolism as a possible cause for the difference in 
response, it was found that the pH of the urine, which is acid in man and 
dog, can play a role. On the basis of their carcinogenicity experiments 
Walpole and his coworkers (1952) suggested an important working rule that; if 
a carcinogen does not produce tumours at the site of injection, then it is 
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not a direct or local carcinogen and that, if tumours are produced in organs 
remote from the site of administration, then the carcinogen must be a 
metabolite. Studies on the metabolism of carcinogenic compounds have played 
an important role in the elucidation of their mechanism of action. (Miller 
1970, Weisburger and Williams 1975, Heidelberger 1975). 
At present, 23 chemicals or groups of chemicals and 7 industrial processes 
or occupational exposures appear carcinogenic to humans on the basis of 
sufficient evidence from epidemiological studies (table 1). It can be noted 
that in 18 out of these 30 cases the main type of exposure is occupational. 
For hundreds of other chemicals some evidence of carcinogenicity was found 
in experimental animals (IARC Monographs). 
TABLE 1 
CHEMICALS, INDUSTRIAL PROCESSES AND OCCUPATIONAL EXPOSURES CAUSALLY ASSOCIATED 
WITH CANCER IN HUMANS 
4-Aminobiphenyl 
Analgesic mixtures containing phenacetin 
Arsenic and arsenic compounds 
Asbestos 
Auramine manufacture 
Azathioprine 
Benzene 
Benzidine 
Ν,Ν-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine> 
Bis(chloromethyl)ether and technical-grade chloromethyl methyl ether 
Boot and shoe manufacture and repair (certain occupations) 
1,4-Butanediol dimethanesulphonate (Myleran) 
Certain combined chemotherapy for lymphomas (including MOPP) 
chlorambucil 
Chromium and certain chromium compounds 
Conjugated oestrogens
 ч 
Cyclophosphamide 
Diethylstilboestrol 
Furniture manufacture 
Isopropyl alcohol manufacture (strong-acid process) 
Melphalan 
Methoxsalen with u l t ra-v io le t A therapy (PUVA) 
Mustard gas 
2-Naphthylamine 
Nickel refining 
Rubber industry (certain occupations) 
Soots, tars and oils 
Treosulphan 
Underground haematite mining (with exposure to radon) 
Vinyl chloride 
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Mutagenesis and carcinogenesis 
The first experimental laboratory data about a possible mechanism of 
carcinogenesis vrere published by Boven (1914). According to this author the 
development of malignant tumours is connected with abnormal divisions of 
cell nucleus and chromosomes. This theory did not meet with the approval of 
well-known, contemporary pathologists. A new attempt to correlate mutagenesis 
and carcinogenesis was the formulation of the somatic cell mutation theory 
of cancer by Bauer (1928). According to his concept, mutation of a somatic 
cell should be the first step in the development of cancer. The theory of 
Bauer had a serious limitation: a mutational change in the genome of a cell 
is a very rapid process and could hardly account for the long period of 
latent carcinogenesis. The work of Berenblum (1941, 1949) suggested a 
multistage mechanism of carcinogenesis and instigated the concept of 
initiating and promoting agents. In principle, mutagenic agents have 
initiating properties. Recently, it was shown that a point mutation in an 
identified gene (oncogene) is responsible for the transformation of a normal 
human bladder cell in a tumour cell (Tabin et al. 19Θ2, Reddy et al. 1982). 
Besides chemicals that are carcinogenic via interactions with DNA (genotoxic) , 
there are substances that act via other (epigenetic) mechanisms. 
Salmonella/mutagemcity assay 
The development of bacterial systems for the detection of mutagenic 
properties of chemicals started in the early igSO's (Demerec et al. 1951, 
Hemnerly and Demerec 1955) . At first it was supposed that testing of chemicals 
for mutagenicity with bacteria might be useful for the identification of 
potential anticancer agents, since many chemicals having mutagenic properties 
were both carcinogenic and carcinostatic in animal model systems. A few years 
later Iyer and Szybalski (1958) introduced the plate assay technique. This 
method appeared to be suited for the rapid evaluation of potential 
antineoplastic properties of large numbers of chemicals. A particular strain 
of Eeoheviohia aoli was used in these cases as the indicator organism. The 
majority of the mutagens identified in these studies were alkylating agents 
that were directly mutagenic. Because these bacterial systems tended to give 
false negatives for pre-mutagenic compounds which are converted into an active 
state in mammals. Gabridge and Legator (1969) developed a procedure in which 
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a microbial indicator was incorporated in an animal system to identify pre-
mutagenic agents. This orocedure in which the activation of ore-mutagens is 
performed by the maramalian metabolism, is commonly specified as "host-
mediated assay". In 1973 Ames and coworkers introduced an in vitro test 
system for the screening of pre-mutagenic compounds. In the Ames assay the 
bioactivation process is mimicked by the addition of liver homogenates to 
the Salmonella typhirmrium strains. Some of these strains were especially 
sensitive because of a deficient lipopolysaccharide barrier and because of 
lack of DNA excision repair. All of them were histidine auxotrophe mutants. 
The introduction of R plasmids in some of the strains increased their 
sensitivity to a broader range of chemicals (McCann et al. 1975, Levin et 
al. 1982a). Recently new tester strains which are especially sensitive in 
the detection of oxidative mutagens were introduced (Levin et al. 1982b, 
Levin et al. 1983) . After ample evaluation of the method described by Ames 
et al. in 1975, revised methods for the Salmonella mutagenicity test were 
recently published by Maron and Ames (1983). Salmonella typhimurium strains 
used in this thesis are summarized in table 2. 
TABLE 2 
TESTER STRAINS 
Additional Markers Histidine Mutation 
LPS Repair R-Factor hisC3076 hisD3052 hiaG46 
+ + - hisG46 
rfa buvrB - ТА15Э7 TA1538 TA1535 
rfa LuvrB + TA98 TA100 
Lipopolysaccharide 
All strains were originally derived from Salmonella typhimurium LT2. Wild-
type genes are indicated by +. Abbreviations for the additional markers were: 
rfa = deep rough (defective lipopolysaccharide); huvrB = deletion of the 
ultraviolet-repair В gene; R-Factor = plasmid pKMlOl (increases error-orone 
DNA repair). (The strains were a gift from Dr. B.N. Ames, Berkeley, U.S.A.). 
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Besides the Salmonella/microsome assay many other so-called short-term 
assays have been developed for the detection of genotoxic effects, such as 
gene or point mutations, DNA repair, structurel or numerical chromosomal 
aberrations and neoplastic transformation, in prokaryotic as well as 
eukaryotic cell systems (Hollstein et al. 1979). 
Many studies have been performed on the validation of the Salmonella/ 
microsome assay for its competence to predict carcinogenic properties of 
chemicals (Teramshi et al. 1975, McCann and Ames 1976, Purchase et al. 
1976, Sugimura et al. 1976, Rinkus and Legator 1979, Rosenkranz and Poirier 
1979, Simmon 1979, and Bartsch et al. 1980). 80 - 90% of known carcinogens 
tested in these studies appeared to be mutagenic. The percentage of the non-
carcinogens being non-mutagenic turned out to be somewhat lower. All the 
validations showed, at first glance that, the Salmonella/microsone assay 
fails to detect a few classes of carcinogens e.g. dinethylamino- and 
hydrazine compounds, polychlonnated pesticides and sone other non-alkylating 
chlorinated hydrocarbons (Ames and McCann 1981) . However, some of the 
carcinogens that were reported to be negative, can now be detected using the 
new tester strains (Maron and Ames 1983). A question that still has to be 
solved however, is what proportion of chemicals selected at random, without 
prior knowledge as to their carcinogenic activity will give a positive 
result in this test. It should be noted that Burdette'ç analysis in 1955 of 
the lack of correlation between mutagenicity and carcinogenicity is explicable 
due to the methods available at that time for the mutagenicity screening. No 
notice was taken of the fact that most mutagens and carcinogens are inactive 
as such and need metabolic activation. Microorganisms applied in the 
mutagenicity test are insufficiently equiped with bioactivating enzymes. In 
this respect the incorporation of a 9000 ^_ liver suoernatant (S9 fraction) 
in the Salmonella/microsome assay appeared to be adequate. Although there now 
exists a reasonably good qualitative relationship between carcinogenicity and 
mutagenicity, it appears that a quantitative relationship is failing. Most 
likely this can be attributed to different metabolic activation processess 
in гі о and in vivo (Bartsch et al 1980). 
The enormous number of chemicals that have to be tested for their 
carcinogenic potency is still increasing. Animal carcinogenicity assays are 
relatively expensive and laborious. So, there is a growing need for a cheap 
and reliable short-term bio-assay. Because none of the currently used short-
term assays has an acceptable predictive value, it has been advised to use a 
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battery of these test systems to minimize the chance of scoring "false 
negatives". (ICPEMC 1982). 
Bioactivation and bioinactivation 
Xenobiotic compounds may enter the body by ingestion via food or drink, 
by inhalation or by absorption through the skin. They are distributed 
throughout the body depending on their physical chemical properties. Animal 
cells possess highly lipoid outer membranes and offer poor resistance to the 
penetration of lipophilic compounds. The excretory systems of cells are 
geared for the removal of water soluble-, rather than fat soluble compounds. 
Drug-metabolizing enzymes are able to convert lipophilic substances to more 
hydrophilic products by introduction of polar groups. High activities of 
these enzymes are found mainly in the liver, but also in the kidney, the 
lungs and the gastrointestinal tract (Weisburger and Williams 1975). 
Furthermore, the microbial flora present in the mammalian intestine may 
contribute to the metabolism of xenobiotics in the intact organism. 
The metabolic transformations of xenobiotic substances are divided into 
two types of reaction, phase 1 and phase 2 reactions (Williams 1959). The 
phase 1 reactions primarily concern oxidative conversions, but also reductive 
and hydrolytic processes. The polar groups that arise by these reactions 
provide the necessary chemical structure for the phase 2 reactions. These 
are conjugations resulting, for instance, in the formation of glucuronides, 
sulfates, acetates or glutathione conjugates. 
Primarily due to oxidative conversions - in a number of cases in combination 
with conjugative reactions - some chemicals can be activated to electrophilic 
species, which are able to react irreversibly with nucleophilic functions 
of cellular macromolecules, such as proteins, RNA and DIJA. 
In recent years, more and more evidence is furnished that conjugating 
processes can lead to more toxic reaction products. For instance, it is known 
that the N-sulfate, the N-acetate and the N-O-glucuronide of N-acetyl-2-
aminofluorene are more reactive towards nucleic acids or proteins than 
N-hydroxy-N-acetyl-2-aminofluorene (Irving 1979). The carcinogenic effects of 
7-methylbenz(a)anthracene and 7,12-dimethylbenz(a)anthracene are also related 
to their conversion into hydroxymethyl derivatives and subsequent formation 
of an ester bearing a good leaving group, which generates the ultimate 
electrophilic intermediate (Cavalieri et al. 1970, Brouns et al. 1980). 
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Conjugation with glutathione is usually considered as a reaction that 
de-activates electrophilic products. However, it has recently been 
discovered that conjugation of certain substances, such as 1,2-dihalogen 
compounds, with glutathione can lead to the formation of highly reactive 
metabolites (Rannug et al. 197Θ, van Bladeren et al. 1979, 1980). 
It is also known that phase 2 conjugations can be followed by ohase 1 
oxidations, resulting m the production of very reactive metabolites. For 
instance, benzidine is first acetylated to diacetylbenzidme, after which 
oxidation yields the highly mutagenic N-hydroxy-N,N ' diacetylbenzidme (Morton 
et al. 1979). 
Metabolic activation in the Salmonella/mutagenicity assay 
Ideally, in terms of carcinogenicity screening, drug-metabolizing enzyme 
preparations should be used in the Salmonella/microsome assay that are able 
to produce all active metabolites formed in man ги vivo. For practical 
reasons it is impossible to use fresh human tissue in mass screening. Animal 
tissue able to produce the same metabolites in Vitro as those formed in man 
in VÌVO would be an acceptable alternative. However, no such animal tissue 
is available. As a rule, rat liver S9 (9000 £ supernatant) is incorporated 
in the test system. With respect to the prediction of the carcinogenicity in 
man, results from these experiments are subject to two extapolations: The 
extrapolation from in vitro to in г о and from rat to man. Many examples of 
differences between in VÌVO and гп intro metabolism are known. In general, 
in the common Salmonella/microsome assay using the rat liver S9 fraction, 
phase 1 reactions prevail over the phase 2 reactions. In search after optimal 
experimental conditions approaching biotransformation in Vivo, the balance 
between activating and inactivating enzymes seems to be very important. In 
this thesis we have tried to bridge the gap between biotransformation in 
Vitro and in VÌVO by the application of isolated rat hepatocytes as the 
metabolizing system in the Salmonella/mutagenicity assay. 
Diagnosis of carcinogenic hazards 
Although therapy of some forms of human cancer has improved in recent 
years, there are still types of tumour for which treatment is relatively 
unsuccesful. Without neglecting this important area of anti-cancer research 
most attention should be paid to prevention. Because environmental factors, 
15 
in particular the chemical ones, are larqely held responsible for the 
occurrence of human cancer (Fraumeni 1973, Higginson and Muir 1979, 
Fishbein 1982), minimization of the disease may be accomphished by reducing 
exposure to these factors. A survey of different strategies to fight the 
cancer problem is depicted in fig. 2. During the last two decades a great 
deal of progress has been made in the field of the identification of 
potentially cancer-causing chemicals. In vitro screening techniques have 
been developed which are very helpful to denounce the presence in the 
environment of man-made carcinogens, to avoid introduction of newly 
synthesized genotoxic chemicals and to produce safe alternatives if necessary. 
However, there still remains a background burden of natural and hardly 
eradicable factors, causing human cancer, related to personal habits and 
life-style. Among these are smoking tobacco and drinking of alcoholic 
beverages (Bridges et al. 1979, Obe and Ristow 1979, DeMarini 1983). Coffee 
and tea also contain substances mutagenic in Salmonella typhimwñim (Nagao 
et al. 1979, Aesbacher et al. 1980). Genotoxic compounds have also been 
found among other natural substances, like flavonoids, anthraquinones and 
related compounds (Brown 1980). Mycotoxins like the powerful hepatocarcinogen 
aflatoxin B. produced by certain strains of Aspergillus, are common 
contaminants of several human foods (Campbell and Hayes 1976). Heating of 
protein-containing foodstuffs also results in the formation of very potent 
mutagenic substances (Commoner et al. 1978, Yoshida et al. 1980, Sugimura 
1982). Intestinal bacteria are involved in the production of very potent 
nitrosamines from nitrite and amines e.g. present in food (Lintas et al. 1982) . 
Although most of these examples may represent only a minor risk, which as such 
seems to be negligible, it has to be taken into account that a summation of 
many minor risks may stand for a potential hazard. This is particularly true 
when carcinogenic factors are also present in the working environment, in which 
levels of exposure can be relatively high. 
To minimize genotoxic risk, when the working environment is contaminated 
with carcinogenic chemicals, the most obvious approach is to monitor the 
concentrations in the air. Such measurements, commonly referred to as 
"environmental monitoring", can give an indication of the external exposure. 
In addition, in many cases the possibility exists to measure the "internal 
exposure", through analysis of a biological specimen, e.g. blood, urine, 
expired air. This type of monitoring, so-called biological monitoring, gives 
16 
Factors determining the 
occurrence of cancer 
^Carcinogenic chemicals^ 
ί in the environment 4 
fxposure tocarcmogens^ 
/'/////УУ//////'///"////?////* 
I 
'yW/////////////////////' 
^Initiation, promotion^: -«-
^ a n d development of vTy 
^malignant disease ^ 
'¿/////////////////////////УУ 
Anti - cancer strategies 
at different levels 
Identification ofcaranogemc 
properties of chemicals 
(epidemiology, animal experiments, 
short-term assays) 
Early detection of exposure 
(exposure test) 
ί% Fate of the ¿%% Interference with uptake, 
Ш
^ (pre)carcinogens/%% - ^ distribution, biotransformation 
in the organism ¿%£ and elimination 
У//////////Р////////Ш 
\ 
Chemoprevention 
Therapy of cancer 
Fig. 2 A survey of different possibilities to fight the cancer problem. 
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a better approximation of the total load of the body and is more directly 
related to the health risk (Zielhuis, 1978). Whenever possible, selective 
methods are preferable in biological monitoring, in particular when the 
genotoxic chemical is knov.-n. Up to now only a limited number of tests has 
been evaluated. Add to this, that people may often be exposed to a mixture 
of chemicals (industrial chemicals, hobby-agents, food contaminants, drugs). 
In such cases as a first approach in the protection of health, non-selective 
teats may be of great value, because they have a signal function. 
Recently, several reports have appeared on the detection of exposure to 
electrophilic compounds, including mutagens and carcinogens, by measurement 
of increased urinary thioether concentrations (Vainio et al. 197Θ, v. Doorn 
1981). This non-selective assay is based on the ability of alkylating-, or 
otherwise covalently binding-compounds, to react with glutathione. The 
amount of thioethers excreted in urine may reflect the detoxication of such 
compounds. It has to be noted that in the case of either incomplete or not 
any detoxication via conjugation with SH-groups, false negative values are 
obtained. 
The problem of false negative results seems to be inherent in the 
application of non-selective methods. To overcome this, it is important to 
combine several non-selective exposure assays which might be complementary 
to each other. (Analogous to the use of a combination of several short-term 
assays in the screening for carcinogenic potency of chemicals). Such a 
battery of assay procedures should include a selection of exposure tests, 
among which methods for detection of early health effects. Some examples of 
non-selective methods for detection of exposure to genotoxic compounds are 
described below. 
- Measurement of products of the alkylation of proteins 
Most (potential) alkylating agents tend to react in the body with 
nucleophilic groups in e.g. peptides, proteins or nucleic acids. Alkylated 
proteins can be measured in blood for example by determining the degree of 
alkylation of hemoglobin amino acids in erythrocytes (Osterman-Golkar et 
al. 1976). Dependent upon the relationship between alkylation of proteins 
and alkylation of DNA such assays may be used for the detection of exposure 
to genotoxic substances. At this moment this relationship is not entirely 
clear. 
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- Measurement of DNA adducts 
Genotoxic alkylating agents or metabolites can react with various sites in 
DNA. Promising HPLC and/or immunochemical methods are being developed now 
for the detection of specific DNA adducts in e.g. blood cells (Baan et al. 
1983). 
- Analysis of chromosomal changes in human lymphocytes 
The observation of chromosomal aberrations in peripheral blood lymphocytes 
can be considered as an early effect of exposure to genotoxic agents, since 
most of the chemicals that cause visible chromosomal damage are known or 
suspected carcinogens (Vainio et al. 1981). This method is very laborious. 
For a review on this subject see Natara]an and Obe (1980). 
- Analysis of sister chromatid exchanges (SCE) 
Sister chromatid exchanges are visualized intrachromosomal rearrangements 
of DNA helices. SCE's can be detected rather easily in human lymphocytes. 
Determination of the SCE-frequency seems to be a simpler, faster and less 
expensive technique of biological monitoring than determination of 
chromosomal aberrations. However, the molecular mechanism is still unclear 
and it is known that there are several drugs with a pronounced genotoxic 
activity which do not increase the SCE-frequency significantly over control 
values. (Lambert et al. 1982). 
- Urinary mutagenicity assay 
Durston and Ames (1974) and Commoner et al. (1974) have suggested that a 
mutagenicity assay on urine samples would have great potential for 
screening the human population to detect environmental mutagenic and 
carcinogenic agents. It is one of the main objectives of the present thesis 
to evaluate the applicability of this assay. 
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OUTLINE OF THE THESIS 
This thesis is composed of pre-published studies, most of which deal 
with the application of bacterial mutagenicity assays in the exploration 
of genotoxic hazards of chemical compounds. This extensive field of 
problems was approached at three different levels: by investigations in 
vitvo, animal studies and studies on human subjects. 
Part 1 includes studies of IN VITRO methods aimed at the detection of 
mutagenic properties of chemicals. In particular, attention was paid to 
the following aspects: 
-Application of the Salmonella/microsome assay in combination with 
analytical chemistry-methods to identify mutagenic components in a 
complex chemical product (chapter 1) . 
-The question whether the excretion of glutathione conjugation products, 
which can be considered as an indication of detoxification of electrophilic 
intermediates, is also indicative of previous exposure to mutagens 
(chapter 2). 
-Optimization of the in vitro mutagenicity assay by alterations in the 
metabolic activation system. Special attention was paid to the usefulness 
of intact isolated rat hepatocytes as the metabolic factor (chapter 3). 
Part 2 describes the experimental studies IN VIVO with precarcinogenic 
compounds. Intact animals served as models to explore the possibilities and 
to refine the methods for the detection of genotoxic exposures by means of 
measurement of urinary mutagenicity. As substrates we used aromatic amines 
and azo dyes, in the biotransformation of which different pathways and 
various enzymes are involved (chapter 4). 
Part 3 shows some typical applications of the Salmonella/mutagenicity 
assay for the detection of HUMAN EXPOSURE to environmental genotoxic 
compounds. This part of the thesis deals with the usefulness of the urinary 
mutagenicity assay as a tool in the evaluation of the genotoxic risk. 
Chapter 5 demonstrates the presence of mutagenicity in the urine of either 
active or passive smokers. Further, a study is presented on the urinary 
mutagenicity of nurses during occupational exposure to cytostatic drugs 
(chapter 6). Chapter 7 describes approaches to detect mutagenic substances 
in the work place by studying contaminations of the environment and by 
measuring urinary mutagenicity of workers involved in the preservative 
treatment of wood with creosote. 
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Summary 
Creosote (type PI) was assayed for mutagenicity in the Salmonella/microsome 
assay. It showed mutagenic properties towards Salmonella typhimurium TAI537, 
TA1538, TA98 and TA100 in the presence of S9 mix. This mutagenicity is probably 
caused by the presence of mutagenic aromatic hydrocarbons. 
Creosote is well known as a pesticide in use for wood preservation. It is a mixture 
of oils that are separated in the distillation of coal tar and consists principally of 
liquid and solid -hydrocarbons. It has a distinctive smell. 
Production workers in the wood-preserving industry receive some level of ex-
posure to creosote by inhalation of vapours or through skin contact. Apart from 
symptoms such as contact dermatitis and photosensitization, creosote oil may also 
cause skin cancer [5]. This is not unexpected because creosote may contain many 
PAHs that are present in coal tar, the source of creosote. It is striking, however, 
that creosote was recently denoted as non-mutagenic in bacterial assays [6]. For this 
reason we re-investigated the mutagenic properties of creosote (type PI) in the 
Salmonella/microsome assay. 
Materials and methods 
Chemicals 
Benzo[fl]pyrene and l,2-epoxy-3,3,3-trichloropropane were purchased from 
Aldrich Europe (Beerse, Belgium). Creosote type PI was from Cindu Chemicals BV 
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(Uithoorn, The Netherlands). D-3iotin and L-histidine-HCl were obtained from 
Sigma (St. Louis, U.S.A.). Nicotinamide adenine dinucleotide phosphate (NADP) 
disodium salt and glucose 6-phosphate (G-6-P) disodium salt were obtained from 
Boehringer (Mannheim, F.R.G.). Purified agar was purchased from Difco 
Laboratories (Detroit, U.S.A.) and nutrient broth No. 2 from Oxoid Ltd. (Bas­
ingstoke, Great Britain). 
Mutagenicity testing 
The mutagenicity test was performed according to Ames et al. [1] with Salmonella 
typhimurium TA1535, TA1537, TA1538, TA98 and TA100. We used Oxoid 
nutrient broth instead of Difco nutrient broth. 
Rat-liver S9 (9000 g supernatant) fractions were prepared from male Wistar rats, 
pretreated with Aroclor 1254. S9 mix contained 0.1 ml S9 per ml. 
A portion of rat-liver S9 was centrifuged at 105000 g for 1 h. The resulting pellet 
was resuspended in 0.15 M KCl. The microsome mix contained 0.1 ml of this 
suspension per ml. 
In one experiment the epoxide hydratase inhibitor l,2-epoxy-3,3,3-trichloropro-
pane (TCPO) was added at 2.3 μΐηοΐ65/ρΐ3ί6 [2]. 
Results 
Mutagenicity of creosote 
The mutagenicity of coal-tar creosote PI towards Salmonella typhimurium strains 
TA1537, TA1538, TA98 and TA100 is shown in Fig. 1. Strain TA1535 appeared to 
be insensitive to the mutagenic activity of creosote. With the other strains the 
mutagenic activity became evident after the addition of S9 mix. We studied the tox­
icity of creosote for Salmonella typhimurium with strains TA98 and TA 100. At 50 
/ig/plate, the survival of TA98 and TA100 was 100%. 
The presence of mutagenic polycyclic aromatic hydrocarbons in creosote 
Oesch et al. [4] reported that inhibition of epoxide hydratase in rat-liver 
microsomes leads to a dramatic potentiating of the mutagenic effect of ben-
zo[a]pyrene in Salmonella typhimurium TA1537. This effect was explained by ac­
cumulation of the intermediate benzo[fl]pyrene-4,5-oxide, which- is mutagenic 
towards Salmonella typhimurium TA1537 [7]. 
In Fig. 2b we show that addition of the epoxide hydratase inhibitor 1,1,1-trichlo-
ropropane-2,3-oxide to liver microsomes from Wistar rats pretreated with Aroclor 
1254 substantially enhanced the mutagenic effect of benzo[j]pyrene. This effect was 
also found when creosote was plated instead of benzo[fl]pyrene (Fig. 2a). From these 
results we may conclude that polycyclic aromatic hydrocarbons are, at least partly, 
responsible for the mutagenicity of creosote PI. 
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Fig. 1. Number of revertant colonies per plate of 5 Salmonella typhimurium strains as a function of the 
dose of creosote. Each point represents the average of the counts of 3 plates. Liver 9000 g supernatant 
(S9 mix) was added. 
Discussion 
Our results* (Fig. 1) are in contrast with results of examinations of the mutagenic 
activity of coal-tar creosote PI conducted by Litton Bionetics Ltd. and presented 
in a Report of the U.S. Department of Agriculture [6]. This report states that both 
non-activation and activation test results were all negative. The present demonstra­
tion of a mutagenic effect of creosote in Salmonella typhimurium indicates a genetic 
hazard for humans exposed to this substance and correlates well with the car­
cinogenicity data mentioned by Sax [5]. 
Mutagenicity of epoxides towards Salmonella typhimurium TA1537 is only 
known for some epoxides of polycyclic aromatic hydrocarbons (benzo[fl]pyrene-
4,5-oxide, dibenz[a,/j]anthracene-5,6-oxide and chrysene-5,6-oxide) [3, 7]. In addi-
* After completion of this paper we were notified by Dr. D.J. Brusick (personal communication) that 
positive data have now likewise been obtained at Litton Bionetics. 
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Fig. 2. The influence of the epoxide hydratase inhibitor TCPO on the number of Salmonella 
typhimurium TA1537 revenant colonies per plate as a function of the dose of creosote (a) or ben-
zo(a]pyrene (b). The dark hatched bars represent the number of revenant colonies in the absence of 
TCPO. Creosote and benzo[o)pyrene were plated in the presence of microsome mix. The values are 
averages of determinations in triplicate. 
tion, a number of polycyclic aromatic hydrocarbons such as benzo[a]pyrene, 
dibenz[ûr,c]anthracene, dibenz[a./i]anthracene, 3-methylcholanthrene and 
7,12-dimethylbenzanthracene are mutagenic towards Salmonella typhimurium 
TAI537 in the presence of S9 mix [3]. From this and from the results presented in 
Fig. 2 it is tempting to conclude that mutagenic polycyclic aromatic hydrocarbons 
are present in creosote PI. Further studies are in progress to identify the chemical 
structure of the mutagen(s) present in creosote PI. 
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THE PRESENCE OF THE MUTAGENIC POLVCYCLIC AROMATIC HYDROCARBONS 
BENZO(A)PYRENE AND BENZ (A) ANTHRACENE IN CREOSOTE PI 
R.P. Bos, J.L.G. Theuws, Ch.-M. Leijdekkers and P.Th. Henderson. 
Institute of Phamiacology, Toxicology Unit, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
Several fractions of creosote Pi separated by TLC showed mutagenicity 
towards Salmonella typhimurium TA98. This mutagenicity is probably caused 
by the presence of mutagenic aromatic hydrocarbons. The mutagenic polycyclic 
aromatic hydrocarbons, benzo(a)pyrene and benz(a)anthracene were detected 
in concentrations.of 0.18 and 1.1 per cent, respectively. Because these 
compounds are probably not essential for the wood-preserving properties of 
creosote, a more selective composition of the product should be considered. 
INTRODUCTION 
In a previous paper we have shown that creosote (type Pi), well known as 
a pesticide in use for wood preservation, has mutagenic properties in the 
Salmonella/microsome assay (4). In that study, the influence of the epoxide 
hydratase inhibitor TCPO on the mutagenicity of creosote towards Salmonella 
typhimurium TAI537 suggests the presence of mutagenic polycyclic aromatic 
hydrocarbons. Our present data actually show the presence of the mutagenic 
PAH's benzo(a)pyrene and benz(a)anthracene in creosote by means of a 
combination of mutagenicity testing and analytical methods. 
Accepted for publication by Mutation Research 
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MATERIALS AND METHODS 
Chemicals 
1,2-epoxy-3,3,3-trichloropropane was purchased from Aldrich Europe 
(Beerse, Belgium). Benz(a)anthracene was obtained from ICN Pharmaceuticals, 
Inc. Creosote type Pi was from Cindu Chemicals B.V. (Uithoorn, The 
Netherlands). D-Biotin, L-histidine-HCl, benzo(a)pyrene, nicotinamide 
adenine dinucleotide phosphate (NADP) disodium salt and glucose-6-phosphate 
(G-6-P) disodium salt were obtained from Sigma (St. Louis, U.S.A.). Purified 
agar was purchased from Difco Laboratories (Detroit, U.S.A.) and nutrient 
broth No. 2 from Oxoid Ltd. (Basingstoke, Great Britain). 
Thin-layer chromatography 
200 μΐ of a solution of creosote in ethanol (10 mg/ml) was applied to a 
TLC-plate in a continuous streak with a line applicator. 
Glass plates (20 χ 20 cm) coated with a 0.25 mm thick layer of silicagel 
60 obtained from Merck (Darmstadt, F.R.G.) were employed. Pentane/ 
diethylether (95 : 5; v/v) was used as solvent system. Benzo(a)pyrene and 
benz(a)anthracene were visualized on the TLC-plate under UV-light of 254 nm. 
Some fractions on the TLC-plate were scraped off. The contaminated silicagel 
was suspended in 5 ml of acetone. Silicagel residues were removed by 
centrifugation. The acetone was evaporated under nitrogen at 60 С and the 
residues were dissolved in 0.25 ml of methanol or 1 ml of dimethylsulphoxide. 
Mutagenicity testing of the TLC fractions 
The mutagenicity test was performed according to Ames et al. (2). Samples 
of 0.1 ml of the solution of the residues in DMSO were added per plate and 
assayed for mutagenicity with the Salmonella typhimurium strain TA98 in the 
presence of S9 mix. S9 was prepared from male Wistar rats, pretreated with 
Aroclor 1254. These fractions were also tested for mutagenicity in 
Salmonella typhimurium TA1537 after activation by mix made from liver 
microsomes of male Wistar rats pretreated with Aroclor 1254. In this 
experiment the influence of the addition of the epoxide hydratase inhibitor 
1,2-epoxy-3,3,3-trichloropropane (TCPO) (2.3 umoles/plate) was studied (3,4). 
Rat liver microsomes were prepared by centrifugation of rat-liver S9 at 
105000 g for 1 h. 
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Hiah-performanoe liquid ahromatography (HPLC) 
Aliquots of the solubilized residue were filtrated (0.22 um) and 
injected into the 0.020 ml sample loop of a Pye Unicam HPLC equipped with a 
3 XP Pump, a variable wavelength detector and a 10 mV Kipp recorder. The 
stainless steel column was 150 mm long (l.d. 4.6 mm) and filled with 
Lichrosorb RP 18, particle size 5 vm. The flow rate was 1.00 ml/min and the 
wavelength was adjusted to 254 nm. Simultaneously with sample injection, the 
following solvent programme was commenced: 10 min linear gradient from 100% 
solvent A (70% aquapur, 30% methanol) 80 μΐ acetone/1) to 100% solvent В 
(10% aquapur, 90% methanol; 80 yl acetone/1), followed by 20 min solvent B. 
Fluorometric assay (qualitative) 
The methanol samples supposed to contain benzo(a)pyrene, or 
benz(a)anthracene were diluted and measured with a Perkin-Elmer 650-40 
spectrofluorometer at an excitation wavelength of Э80 or 285 nm and an 
emission wavelength of 433 or 391 nm for benzo(a)pyrene and benz(a)anthracene, 
repectively. The excitation and emission slits were 5 and 10 nm, respectively. 
Quinine.HBr in 0.1 N H-SO was used for the calibration of the fluorometer. 
Quantification of benzo(a)pyrene and benz(a)anthracene 
A Hewlett-Packard ΗΡ10Θ4Β high-performance liquid Chromatograph 
equipped with a variable-volume injector and a fluorescence spectrometer 
Model 3000 (Perkin-Elmer) was used. The stainless steel column was 150 mm 
long i.d. 4.6 mm and filled with Lichrosorb RP18, particle size 5 iim. The 
oven temperature was 37 С and the injection volume was 10 yl. The excitation 
wavelength was 380 and 285 nm, the emission wavelength was 433 and 391 nm 
for benzo(a)pyrene and benz(a)anthracene, respectively. The excitation slit 
was 10 nm, the emission slit 5 nm. The solvent programme was as described 
under HPLC. Dilutions of total creosote, benzo(a)pyrene and benz(a)anthracene 
in methanol were injected. 
RESULTS 
Different mutagenic fractions of creosote 
After the application of creosote in a continuous streak to a TLC-plate, 
several fractions were recognized under UV-light of 254 nm. Fractions were 
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scraped off and tested for mutagenicity towards Salmonella typhimurbum TA98 
in the presence of S9 mix. The results are shown in figure 1. In a 
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Fig. 1 Number of revertant oolonies per plate of Salmonella tyvhinrurium TA98 
as a function of the TLC fraction. The mutagenicity was detected in 
the presence of S9 mix. Mutagenicity values represent averages of 
counts of S plates. 
preliminary experiment no obvious mutagenicity was detected in the area 
between fraction 1 and fraction 3 and the area between fraction 7 and the 
finish line. It was observed that the fractions 1,4 and 6 show most of the 
mutagenicity of creosote. In figure 2 it is demonstrated that addition of 
the epoxide hydratase inhibitor 1,1,l-trichloropropane-2,3-oxide to liver 
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microsomes enhanced the mutagenic effect of the TLC-fractions. As reported 
earlier (4) such results may indicate the presence of mutagenic polycyclic 
aromatic hydrocarbons. We may conclude that the highly mutagenic fractions 
1,4 and 6 contain different polycyclic aromatic hydrocarbons. 
revertant colonies/plate TA1537 
100 
8 0 
6 0 
ДО 
20 
2 3 Д 5 
TLC fraction 
Fig. 2 Influenae of the epoxide hydratase inhibitor TCPO on the number of 
Salmonella typhimurium TA1537 revertant aolonies per plate after 
testing of the different TLC fractions (see fig. 1). The dark hatched 
bars represent the number of revertant colonies in the absence of 
TCPO. The values are averages of determinations in triplicate. 
Identification of benzo(a)pyrene and benzla)anthracene 
Benzo(a)pyrene and benz(a)anthracene were found on TLC-plates under 
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UV-light of 254 nm having Rf values of 0.43 and 0.50 respectively. On the 
basis of these Rf values it might be possible that the TLC-fractions 4 and 
6 contain benzo(a)pyrene and benz(a)anthracene, respectively. To support 
this assumption the TLC-fractions 4 and 6 were tested for the presence of 
these compounds. 
The chromatographic behaviour of the TLC-fractions studied with the HPLC 
method as described under materials and methods, suggested the presence of 
benzo ta)pyrene in TLC-fraction 4 and benz(a)anthracene in TLC-fraction 6. 
In addition the fluorescence characteristics of the methanol solutions 
derived from the TLC-fractions 4 and 6 were compared with those of benzo(a)-
pyrene and benz(a)anthracene. By scanning at an excitation wavelength of 
380 nm or an emission wavelength of 433 nm it was found that the TLC-fraction 
4 showed the characteristics of benzo(a)pyrene (fig. 3a,b). 
units of fluorescence 
100 η 
units o* fluorescence 
TOO 
300 340 3Θ0 
wavelength (nm) 
4Θ0 520 
wavelenglht nm) 
Fig. 3 Excitation (a) and fluorésaenae (b) speatra of TLC-fractions 4 (see 
fig. 1) from pure benzo(a)pyrene (solid lines) and from creosote 
(dotted lines). 
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In a similar way the presence of benz(a)anthracene was confirmed in 
TLC-fraction б at an excitation wavelength of 285 nm or an emission 
wavelength of 391 nm (fig. 4a,b). 
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Fig. 4 Excitation (a) and fluorescence (b) spectra of TLC-fraations 6 (see 
fig. 1) from pure benz(a)anthracene (solid Tines) and from creosote 
(dotted lines). 
Quantification of benzo(a)pyrene and benz(a)anthracene 
Concentrations of benzo(a)pyrene and benz(a)anthracene in creosote type 
PI were assayed with HPLC equipped with fluorescence detection. In case of 
benzo(a)pyrene an excitation wavelength of 380 nm was used; the emission 
was measured at 433 nm. It was calculated that creosote contains 1.8 gram of 
benzo(a)pyrene per kg. To determine the concentration of benz(a)anthracene 
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an excitation wavelength of 285 ran was used. Emission was measured at 391 ran. 
It was calculated that creosoot type PI contains 11 gram of benz(a)anthracene 
per kg. 
DISCUSSION 
Our previous suggestion that polycyclic aromatic hydrocarbons might, at 
least partly, be responsible for the mutagenicity of creosote (4) has been 
confirmed by the present results, which clearly show that creosote type PI 
contains substantial concentrations of benzo(a)pyrene and benz(a)anthracene, 
0.18 and 1.1 per cent, respectively. We were not able to identify the 
mutagen(s) present in the TLC-fraction around the application line (fig. 1). 
This mutagenicity must be due to the presence of more polar aromatic 
hydrocarbons. 
Creosote PI consists of several distillation fractions from coal tar. 
Lijinski et al. (5) demonstrated the presence of many polycyclic aromatic 
hydrocarbons in coal tar. Analysis with gas chromatography showed 
concentrations of benzo(a)pyrene and benz(a)anthracene of about 1.9 and 6.6 
g/kg, respectively. Creosote type Pi is much richer in materials boiling 
below 355 С and much leaner in residual materials (19%) than coal tar (65%) 
(1). Therefore, considering the boiling points of 495 and 438 С of 
benzo(a)pyrene and benz(a)anthracene, respectively, much lower concentrations 
in creosote type PI should be expected. However, the concentrations we 
detected were equal or even higher. Because we think that benzo(a)pyrene and 
benz(a)anthracene are not essential for the wood-preserving action of 
creosote, a more selective composition of the product, should be considered 
in particular with regard to the residual fractions. 
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Chapter 2 
Is excretion of glutathione conjugation products 
indicative of mutagenic exposure? 
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Effect of Toluene and Xylenes on Liver Glutathione 
and Their Urinary Excretion as Mercapturic Acids 
in the Rat 
R. van Doom, R. P. Bos, R. M. E. Brouns, Ch.-M. Leijdekkers, and 
P. Th. Henderson 
Institute of Pharmacology and Toxicology, University of Nijmegen, 
Nijmegen, The Netherlands 
Abstract. Administration of toluene and xylenes to rats caused a decrease in liver 
glutathione concentration. The effect was most pronounced after the adminis-
tration of o-xylene. 26% of the initial glutathione level was found three hours after 
treatment with o-xylene (4.0 mmoles/kg). 
No in vitro conjugation of o-xylene with glutathione was observed, neither 
spontaneously nor in the presence of 105,000 g supernatant from rat liver ho-
mogenate, containing glutathione S-transferases. Thus, a metabolite of o-xylene, 
which is not formed during incubation with 105,000 g supernatant, reacts with glu-
tathione. 
A thioether was isolated from urine of rats given o-xylene; the compound was 
identified as o-methylbenzyl mercapturic acid by GC-MS and NMR. Chromato-
graphic evidence was found for the presence of benzyl mercapturic acid in the urine 
of toluene-treated rats. The amounts of mercapturic acids excreted in the urine after 
administration of toluene, p-xylene, m-xylene, and o-xylene were 0.4—0.7,0.6,1.3, 
and 10—21% of the dose, respectively. 
These results demonstrate the involvement of a thusfar unknown pathway in 
the biotransformation of toluene and xylenes. 
Key words: Toluene and Xylenes metabolism — Glutathione — Mercapturic 
acids. 
Introduction 
Benzene, toluene and xylenes are major constituents of coal tar naphtha and crude oil. 
There is a widespread use of these aromatic hydrocarbons as solvents. Occupational 
exposure to benzene, toluene and xylenes is very common. An association between 
long-term exposure to benzene and leukemia in man has been described (Mallory et al., 
1939; Vigliani and Saita, 1964; Sanità, 1973). For this reason there have been many at-
tempts to lower exposure levels. 
Today there is a tendency to substitute benzene by toluene and xylenes, which are 
regarded less toxic and are used as "safe" replacement in several industries. Thusfar, 
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however, there is a paucity of knowledge on the chronic toxicity of toluene and 
particularly of the xylenes (Dean, 1978). 
The presumed safety of toluene and xylenes is mainly based on metabolic consider­
ations. Unlike unsubstituted aromatic compounds toluene and xylenes are thought to 
be metabolized almost exclusively by side-chain oxidation (Williams, 1959; Ogata, 
1970) and not via aromatic epoxidation. Thus, reactive electrophiles that are re­
sponsible for many toxic effects, are believed to be formed only to a minor extent from 
toluene and xylenes. Bakke and Schelme ( 1970) demonstrated that in rat 0.4 to 1.1% of 
a dose of toluene is hydroxylated to o- and p-cresol. Further, they found dimeth-
ylphenols in the urine of rats after administration of p-, m-, and o-xylene (1.0,0.9, and 
0.1% of the doses, respectively). Small amounts of o-cresol were also found in the urine 
of printing workers exposed to toluene (Angerer, 1979). These findings suggest that 
epoxidation of the aromatic nucleus is a minor pathway in the metabolism of toluene 
and xylenes. 
Aromatic epoxides, however, not only rearrange spontaneously to phenols, but can 
also be metabolized to dihydrodiols by a reaction with water or to glutathione conju­
gates by combining with glutathione (Jollow et al., 1974). Glutathione conjugates 
commonly appear in urine as mercapturic acids or cysteine conjugates (Chasseaud, 
1976). Such thioethers also appear in urine as a result of detoxication of reactive, 
electrophilic substances other than epoxides (Johnson, 1965; Jones, 1973). Elevated 
urinary levels of thioether compounds may, therefore, generally be connected with the 
elimination of potentially alkylating agents. 
In the current investigation we studied the urinary excretion of thioethers and the 
concomitant effects on hepatic glutathione concentrations in the rat after admin­
istration of toluene and xylenes, in order to ascertain whether or not these benzene de­
rivatives are eliminated exclusively via "safe" metabolic routes. 
Materials and Methods 
Chemicals. Tnethylamine, sodium borohydnde, toluene, o-, m-, and p-xylene were obtained from Merck-
Schuchard (Hohenbrunn, FRG). Glutathione and 5,5' dithiobis-(2-nitrobenzoic acid) (DTNB) were 
purchased from Boehnnger (Mannheim, FRG). a-Bromo-o-xylene and S-benzyl-L-cysteine were ob­
tained from Aldnch-Europe (Beerse, Belgium) Amberlite, type XAD-2 was obtained from Serva (Heidel­
berg, FRG). 
Animals. Adult male Wistar rats, weighing 180—220 g, were purchased from TNO (Rijswijk, The 
Netherlands). The animals were housed in individual stainless steel metabolism-cages, with free access to 
water and food (Hope Farms, Woerden, The Netherlands). Unne was collected daily and frozen until re­
quired. 
Toluene and xylenes were administered intrapentoneally in 0.5 ml arachis oil. In one experiment rats 
were given toluene orally in 1.0 ml propylene glycol. 
Thin Layer Chromatography (TLC). Urine was adjusted to pH 2 with 5 N HCl. The samples were applied 
to Amberlite filled columns (bed volume 20 ml) The absorbed material was eluted with acetone The eluate 
was evaporated to dryness and the residue was dissolved in aqua dest. The aquous solution was extracted 
with ethyl acetate. The ethyl acetate layers were evaporated to dryness, the residue dissolved in methanol 
and applied to TLC-plates. Glass plates (5 χ 20 cm) coated with a 0.25 mm thick layer of silica gel 60 F254 
obtained from Merck (Darmstadt, FRG) were used. 
50 
Mercaptunc Acid Formation from Toluene and Xylenes 
Three solvent systems were used in the TLC experiments 
a) butanol water ammonia (25%) (3 1 1, v/v), 
b) methylene chloride methanol acetic acid (10 4 1, v/v), 
c) butanol water acetic acid (3 1 1. v/v) 
The spray reagent K,Cr207 (0 1 M in glacial acetic acid, 1 1. v/v) followed by AgNO, (0 1 M) was 
applied to developed plates for the detection of divalent sulfur 
Spectra Nuclear magnetic resonance spectra were obtained with compounds dissolved in CD,OD or 
CDC!, using a 90 MHz Bruker LH 90 NMR spectrometer and tetramethylsilane as an internal reference 
(Λ = 0 00 ppm) 
Mass spectra were obtained with a V G Micromass 70—70F mass spectrometer at 160° С ion source 
temperature and 70 eV The compounds were introduced by direct probe insertion at 40° C, ion source 
pressure 1 3 χ 10 4 Pa 
Détermination of Liver Glutathione Rats were killed at 2 00 ρ m by decapitation under light ether 
anaesthesia three hours after having received the various compounds The livers were perfused in situ with 
saline, rapidly removed and kept in ice Liver portions (0 4—0 6 g) were homogenized in 20 volumes of ice 
cold 0 15 M KCl For the estimation of reduced glutathione, 2 ml of homogenate were deprotemized by the 
addition of 3 ml of a reagent consisting of 120 g NaCl, 6 68 g metaphosphoric acid and 0 8 g EDTA dis 
solved in 400 ml aqua dest After centnfugation at 40,000 ,pfor 20 min, 0 5 ml of the supernatant was added 
to 2 0 ml of 0 3 M Na,HP0 4 2 H 2 0 solution SH groups were assayed by the method described by Ell 
man (1959). 0 2 ml of a DTNB solution (0 4 mg/ml 1% sodium citrate) was added and the absorbance at 
412 nm was read immediately after mixing 
Assay of Glutathione Conjugation in Vitro Both enzymatic and spontaneous conjugation ofo xylene with 
GSH were measured in vitro The amount of conjugated product was assayed indirectly by determining 
the GSH consumption The incubation mixture consisted of 2 0 ml КН 2 Р0 4 - Na 2HP0 4 buffer (0 1 M, 
pH = 8 0), 0 25 ml GSH ( 12 mM), and 0 50 ml of 105,000^ rat liver supernatant The reaction was started 
by the addition of o-xylene in 0 10 ml ethanol, final concentrations of o-xylene were 0,0 5, 1 0, and 2 0 
mM After 10 mm incubation at 37е С the reaction was stopped by the addition of 4 0 ml of the 
deprotemizing reagent, mentioned above After centnfugation at 40,000 g for 20 mm the GSH con 
centration in the supernatant was determined 
Determination of Urinary Thioether Excretion The unnary excretion of thioethers was determined by a 
modification of the procedure described previously (van Doorn et al, 1979) 
Urine samples (0—24 h) were diluted about twofold and centnfuged at 3,000^ for 5 mm Aliquot por 
lions of 5 ml were transferred into glass stoppered tubes, the pH was adjusted to 1 5—2 0 with 4 N HCl and 
8 0 ml ethyl acetate was added The layers were shaken vigourously for 15 mm using a shaking apparatus 
The layers were separated by centnfugation at 3,000 g for 5 mm The extraction procedure was repeated 
with another 8 0 ml of ethyl acetate The ethyl acetate layers were collected and subsequently evaporated 
to dryness using a rotary evaporator The residue was taken up in 2 0 ml aqua dest 
TheSH concentration was determined according to Ell man (1959) aO 25 ml aliquot of the aqueous 
solution was added to a mixture consisting of 2 0 ml 0 5 M Sorensen phosphate buffer (pH 7 1) and 0 3 ml 
DTNB solution (0 4 mg DTNB per ml 1% sodium citrate solution) 
Absorbances were read at 412 nm Corrections w ere made for the attribution to the absorbance by the 
colour of the unne extract and the DTNB solution 
Alkaline hydrolysis was performed on 1 0 ml of the rest of the unne extract in brown glass stoppered 
test tubes by the addition of 0 5 ml of 4 N NaOH, saturation of the resulting solution with N2, and keeping 
the closed tubes in a boiling water bath for 50 mm After hydrolysis the tubes were cooled in ice for 10 mm 
Then 0 5 ml 4 N HCl was added under mixing Exactly 5 mm later the SH-concentration was determined 
as described above The difference in SH concentration after and before alkaline hydrolysis reflects the 
thioether concentration 
Further corrections for the presence of disulfides in the extracts were found to be unneces 
sary 
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Determination of Creatinine The creatinine concentration of each urine sample was determined as 
described by Gorter and De ОгааГГ(1955) The urinary levels of thioether compounds were expressed as 
mmoles — SH/mole creatinine 
Synthesis of 'Mercapturic Acids. N Acetyl S benzyl-L-cysteine (benzylmercapturic acid) was prepared by 
the reaction of S benzyl-L-cystemewith acetic anhydnde. Ten mmoles (2 43g)S-benzyl L cysteine was sol-
ubilizedm 10ml INNaOH and cooled in ice Fifteen mmoles (1 5 ml) acetic anhydride was slowly added to 
the solution in ten fractions of 0.15 ml under continuous stirring After every addition 20 ml of 1N NaOH was 
added. The temperature of the mixture was allowed to rise to room temperature The pH was adjusted to 1.5 
and the water layer was extracted with ethyl acetate The extract was dried (Na,S04) and evaporated to 
afford a white crystallizing oil which was re crystallized from hexane/ethanol. The m.p ofthe compound was 
144-145° С (Clapp et al., 1970, reported 147° С). 
N-Acetyl S-(o-methylbenzyl)-L-cysteme was prepared by a reaction of n-bromo-o-xylene with N-
acetyl-L cysteine. Five mmoles (817 mg) N acetyl-L-cysteme, 5 mmoles (0 685 ml) d-bromo o-xylene and 
45 mmoles(6.18 ml) tnethylamine in the presence of a catalytic amount of Nal wererefluxed in 30 ml dioxane 
for 3 h. The compound that crystallized from the solution was filtered off The filtrate was collected m 170 ml 
ice cold water. The mixture was extracted several times with ether. Subsequently, the water layer was 
adjusted to pH 1 and extracted twice with one volume of ether. The ether layers were combined, dned 
(Na2S04) and evaporated to afford a residue which was crystallized and re-crystallized several times from 
hexane/ethanol. The m.p. ofthe crystalline white compound, which was identified as N-acety 1 S-(o methyl-
benzyl)-L-cysteine by NMR and GC-MS (Table 3, Fig. 2), was 153° С 
Results 
Depletion of Hepatic Glutathione 
The administration of toluene and the xylenes to rats resulted in a decrease in hepatic 
glutathione within 3 h after treatment. It is shown in Table 1 that, when these solvents 
are given in equal doses (4 mmoles/kg), o-xylene was most effective causing a decrease 
of about 75%, followed by m-xylene, p-xylene, and toluene. The effect of o-xylene on 
the hepatic glutathione concentration as a function ofthe dose is presented in Fig. 1. Al­
most maximal depletion was reached after 4 mmoles/kg. 
24 h after the administration ofthe highest dose of o-xylene the GSH level was found 
to be in the normal range again. 
Theoretically, conjugation of o-xylene with glutathione can take place by one or 
more ofthe following mechanisms: (1) spontaneously, by non-enzymatic conjugation; 
Table 1. Hepatic glutathione levels in the rat after the administration of toluene and xylenes 
Treatment* GSH concentration1· ^moles/g liver) 
Control 7.6 ± 0.3 
Toluene 5.5 + 0.3 
p-Xylene 4.6 ± 0.1 
m-Xylene 4.3 + 0.2 
o-Xylene 2.0 + 0.2 
' The compounds were administrated mtrapentoneally m arachis oil (4.0 mmoles/kg body weight) 
ь
 Liver glutathione concentrations were determined 3 h after the administration ofthe compounds (mean 
values ± SEM of four determinations) 
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* 6 
S4 
Fig. 1. EfTect of o-xylene on the 
hepatic glutathione concentration as 
a function of the dose. Concentrations 
were determined 3 h after the 
administration of o-xylene (2.00 p.m.). 
Values are means (+ SEM) of three 
rats 
2 4 6 
o-Xylene (mmoles/kg) 
Table 2. Incubation of o-xylene with glutathione in the presence of 105,000 g supernatant of rat liver 
homogenate; effect on the glutathione concentration in the incubation medium 
o-Xylene concentration (in mMolar) Glutathione concentration" 
Heat-denatured supernatantb Supernatant 
0 
0.5 
1.0 
2.0 
1367 ± 5 
1364 ± 18 
1363 + 2 
1362 ± 15 
1408 ± 4 
1399 ± 12 
1411 + 21 
1409 ± 6 
a
 Glutathione concentrations were expressed in 10"6 M (mean values ± SEM of three determina­
tions) 
b
 10 min at 100° С 
(2) enzymatic conjugation mediated by one of the GSH S-transferases; (3) bioac-
tivation by cellular enzymes, followed by enzymatic or non-enzymatic conjugation of a 
reactive metabolite with GSH. 
Table 2 illustrates that direct conjugation of o-xylene with GSH does not occur in 
vitro, neither spontaneously nor in the presence of 105,000 g supernatant of rat liver 
homogenate containing the GSH S-transferases. It is concluded, therefore, that o-
xylene is bio-activated by other cellular enzymes before it reacts with GSH. 
Increase in Urinary Thioether Concentration 
Conjugation products of xenobiotic compounds with GSH are often excreted as 
mercapturic acids or cysteine conjugates in urine. Accordingly, the excretion of 
thioethers in urine was determined 24 and 48 h after treatment of the rats with toluene 
and xylenes. The results are shown in Table 3. Administration of toluene and xylenes 
53 
Table 3. The excretion 
Treatment" 
Control 
Toluene 
o-Xylene 
m-Xylene 
p-Xylene 
Route 
oral 
¡.p. 
¡.p. 
i.p. 
i.p. 
οΓ toluene and 
Dose 
xylenei 
(mmoles/kg) 
-
1.0 
2.0 
3.0 
4.0 
1.0 
2.0 
3.0 
4.0 
0.5 
1.0 
1.5 
3.0 
3.0 
3.0 
as thioethcri m the rat 
Urinary thioether excretion11 
First day 
6 ± 2 
17± 1 
2 0 + 3 
26 ± 3 
37 ± 3 
2 1 + 2 
26 ± 3 
3 1 ± 4 
47 ± 8 
180 + 20 
270 ± 20 
330 ± 30 
420 ± 30 
69 ± 4 
34 ± 2 
-_ 
Second day 
7 ± 2 
7 ± 1 
8 + 1 
9 ± 3 
8 + 3 
7 ± 1 
7 ± 2 
10 ± 1 
10 ± 2 
10 ± 2 
17 ± 4 
34 ± 4 
96 + 5 
11 ± 1 
10 ± 1 
R. van Doorn et al. 
% of the dosec 
-
0.5 
0.4 
0.4 
0.5 
0.7 
0.5 
0.5 
0.5 
21 
16 
14 
10 
1.3 
0.6 
* The compounds were administered in 0.5 ml arachis oil 
ь
 Urinary thioether concentration is expressed as mmoles —SH/mole creatinine, using N-acetyl-L-cysteine 
as a standard in the SH-determination. Mean values ± SEM are presented (n = 3) 
c
 The percentage of the dose excreted as mercapturic acid was calculated using N-acetyl S-benzyl-
L-cy steine as a reference for toluene and N-acetyl-S4o-methyl-benzy l)-L-cy steine as a reference for the xy­
lenes (see Fig. 4) 
caused dose-dependent increases in the urinary thioether concentration. The enhanced 
excretion was almost completed within 24 h after administration of the compounds. 
The increase was most pronounced after treatment with o-xylene, the compound that 
was also most effective in hepatic GS H depletion. 
Identification of Urinary Thioethers 
Urine often rats was collected for 24 h after injection of o-xylene (200 mg/kg, i.p.). The 
urine samples were pooled, acidified to pH 2.0 with 4 N HCl, and extracted twice with 
two volumes of ethyl acetate. The combined ethyl acetate layers were evaporated to 
dryness and the residue was mixed vigourously by sonication in diethyl ether. After 
centrifugation at 3000 g for 5 min the solvent was separated and removed in vacuo. The 
residue was washed several times with hexane. A small volume of diethyl ether was 
added and the crystallizing compound was re-crystallized in hexane/ethanol. From the 
resulting white crystals mass- and NMR-spectra were obtained and the m.p. was 
determined. 
The white crystalline compound was shown to be identical to N-acetyl-S-(o-
methylbenzyl)-L-cysteine (Table 4, Fig. 2). The m.p. of the isolated compound was the 
same as the m.p. of the synthetized N-acetyl-S-(o-methylbenzyl)-L-cysteine. Hence, it 
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Fig. 2a and b. Mass spectra of thioethers. (a) The reference compound N-acetyl S-(o-methylbenzyl>L-cys-
teine; (b) thioether metabolite isolated from urine of rats after administration of о xylene 
is concluded that a mercaptunc acid that originates from side-chain metabolism, 
appears in the urine of rats dosed with o-xylene. 
Urine from four rats treated with toluene (4.0 mmoles/kg, i.p.) was collected for 24 
h, pooled and subjected to thin layer chromatography as described in the "Materials 
and Methods" section. The Rf-values of a thioether compound that was present in urine 
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Table 4. NMK data of a thioether isolated from the urine of rats treated with o-x> lene and of a synthetic 
mercaptunc acid 
Assignment 
- C O C H , 
- C , H 4 - C H , 
- S - C H -
- C ^ - C H j -
- C H ? - C H -
= C H - N H -
- c é H 4 -
Integral 
3 
3 
2 
2 
1 
Ie 
4 
Synthetic N-acetyl-S-
(o-methylbenzyl)cysteine 
(in CDC1,) 
(ppm)· 
2.01 (s) 
2.37 (s) 
2.95-3.01 (m) 
3.73 (s) 
4.78-4.85 (m) 
6.40 (d) 
7.16 (s) 
Isolated thioether 
(in CDjOD)" 
(ppm)' 
2.00 (s) 
2.38 (s) 
2.87-3.03 (m) 
3.78 (s) 
4.71-4.85 (mi 
exchanges with solvent 
7.14-7.16 (m) 
* NMR spectra were made with TMS at 0.00 ppm 
ь
 CDjOD; solvent signals at 3.32 and 4.85 ppm 
c
 No signal in 0 0 , 0 0 
Abbreviations: (s) singlet; (d) doublet, and (m) multiplet 
of toluene treated rats were found to be equal to the Rf-values of N-acetyl-S-benzyl-L-
cysteine in different solvent systems (Fig. 3). The Rf-values were calculated to be 0.35, 
0.69, and 0.63 with the solvent systems (a), (b), and (c), respectively. This indicates that 
benzylmercapturic acid appeared in rat urine as a metabolite of toluene. 
Quantification of Mercapturic Acid Excretion 
The reference compounds S-benzyl-L-cysteine, N-acetyl-S-benzyl-L-cysteine and N-
acetyl-S-(o-methylbenzyl)-L-cysteine were added to rat urine to reach concentrations 
ranging from 0.06 to 10.0 mM. According to the procedure described in the "Materials 
and Methods" section thioether-values were determined and plotted against the urinary 
concentration of the reference compounds (Fig. 4). A very low recovery (0.7%) was 
found for the cysteine conjugate as compared with those of the N-acetyl-cysteine 
conjugates (67 and 71%). Thus, the assay procedure is far more selective for mer-
capturates than for cysteine conjugates. 
As is shown in Table 3, it was calculated that only minor amounts of toluene, m-
and p-xylene were excreted as mercapturic acids in urine. o-Xylene, however, was ex­
creted as mercapturic acid for 10—21% of the dose. 
Discussion 
The results described here demonstrate that administration of toluene and xylenes to 
rats causes a decreased GSH concentration in the liver. This effect was most pro­
nounced after administration of o-xylene (Table 1). The decreases in GSH concentra­
tion after various doses of o-xylene are comparable with the degree of depletion found 
after administration of bromobenzene to rats (Jollow et al., 1974). 
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Fig. 3. Thin layer chromatography of rat urine extracts. Solvent systems: A: butanol-water-ammonia 
(25%)(3 : I : l,v/v);B:methylenechloride-methanol-aceticacid(10 :4 : l,v/v);С:butanol water-acetic 
acid ( 3 : 1 : 1 , v/v). Control refers to a urine extract obtained from rats given arachis oil only. Metabolite 
refers to an extract obtained from urine of rats treated with toluene (4.0 mmoles/kg), in arachis oil. The ref­
erence compound was benzylmercapturic acid 
The GS Η depletion was accompanied by an enhanced excretion of thioether 
compounds in the urine. The thioether excretion was highest after treatment of the ani­
mals with o-xylene. From the in vitro experiments on the conjugation of o-xylene with 
GSH (Table 2), it is evident that not o-xylene itself but a metabolite of o-xylene reacts 
with GSH. 
It has been reported that phenolic metabolites appear in the urine of rats exposed to 
toluene and xylenes (Bakke and Scheline, 1970), and that small amounts of o-cresol, 
which is not a normal constituent of urine, are found in urine of printing workers 
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Fig. 4. Recovery of o-methylbenzyl mercapturic acid, benzylmercapturic acid and S-benzyl-L-cysteine in 
the thioether determination. The compounds were solubilized in rat urine and subjected to the procedure 
described under "Determination of Urinary Thioether Excretion". The sulfhydryl concentration found 
was corrected for the attribution of thiols and thioethers normally present in rat urine 
exposed to toluene (Angerer, 1979). These findings suggest that aromatic epoxides are 
minor intermediary metabolites of toluene and xylenes. Therefore, one might suppose 
that the decrease in liver GSH and the concomittant thioether excretion in urine is due 
to detoxication of aromatic epoxides. 
However, the thioether compound that was excreted in the urine of rats treated with 
o-xylene, was identified as o-methylbenzyl mercapturic acid by means of NMR and 
GC-MS (Table 4, Fig. 2). This finding, and in addition, the chromatographic evidence 
for the presence of benzylmercapturic acid in the urine of rats treated with toluene, 
strongly suggest that an intermediate resulting from side-chain metabolism is involved 
in the depletion of liver GSH. 
Although side-chain metabolism leading to the urinary excretion of mercapturic 
acids appears to be a minor pathway in the biotransformation of toluene, m- and p-
xylene, a substantial fraction of o-xylene (10—20% of the dose) is eliminated as o-
methylbenzyl mercapturic acid. Bray et al. (1949), who studied the metabolism of the 
three xylenes in rabbits, found that about 60% of o-xylene, and 81 and 88% re­
spectively of m- and p-xylene were converted into toluic acids and their glycine 
conjugates. Our results showing that 10—20% of o-xylene is converted into mer­
capturic acid may explain this difference and clarify a thusfar unknown metabolic 
pathway of toluene and the xylenes. 
The formation of glutathione conjugates and the excretion of mercapturic acids 
can generally be considered as the result of detoxication of electrophiles in the organism 
(Arias and Jakoby, 1976; Chasseaud, 1979). Hence it may be doubted whether side-
chain oxidation is a warrant of "safe metabolism" in the biotransformation of methyl-
substituted benzenes. 
A decade ago it was shown that benzyl and menaphthyl esters afford mercapturic 
acids in the rat in vivo and that sulphate esters are converted in a relatively high yield 
5Θ 
Mercapturic Acid Formation from Toluene and Xylenes 
(Hyde and Young, 1968; Clapp and Young, 1970; Gillham et al., 1970). Menaphthyl 
and benzyl sulphate are substrates for a glutathione S-transferase, which converts these 
esters to thioethers (Gillham, 1971, 1973). Menaphthyl alcohol is not a substrate. The 
metabolism of toluene and xylenes to mercapturic acids might therefore involve 
sequential oxidation, sulphation and glutathione conjugation. 
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Summary 
Toluene, o-, m- and p-xylene, o-methylbenzylalcohol and o-methylbenzylsul-
fate were assayed for mutagenicity in the Ames assay. These compounds were 
unable to revert Salmonella typhimurium strains TA1535, TA1537, TA1538, 
TA98 and TA100, either with or without metabolic activation by S9 mix 
derived from livers of rats either untreated or induced with Aroclor 1254. 
Toluene and xylenes are major constituents of coal-tar naphtha and crude 
oil. Their use as solvents is very common. Recently we found that administra­
tion of toluene and xylenes to rats caused a decrease in the concentration of 
liver glutathione (van Doom et al., 1980a). The effect was most pronounced 
after the administration of o-xylene. A metabolite of this compound reacts 
with glutathione. These findings suggest that, during the metabolism of toluene 
and xylenes, alkylating intermediates are formed which react with glutathione. 
We now have circumstantial evidence that the metabolism of o-xylene leading 
to the formation of the glutathione conjugate proceeds via side-chain oxidation 
and sulfation (van Doom et al., 1980b). 
It is an important question whether, owing to their potential alkylating pro­
perties, one or more of the metabolic products of these methylated benzene 
derivatives are mutagenic. In the present study we tested toluene, o-, m- and 
p-xylene, o-methylbenzylalcohol and o-methylbenzylsulfate for mutagenicity 
in the Salmonella/microsome assay described by Ames et al. (1975). 
Materials and methods 
Chemicals 
Citric acid monohydrate and o-, m- and p-xylene were obtained from J.T. 
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TABLE 1 
RESULTS OF THE AMES ASSAY ON TOLUENE DERIVATIVES USING 5 Salmonella typhimuHum STRAINS WITHOUT ACTIVATION 
as Compound 
" tested 
Amount 
μΕ/plate 
Number of hi*'*' revertants per plate * 
Strain 
T A 1 6 3 5 TA1537 T A 1 5 3 8 TA98 T A 1 0 0 
7 0 ± 
8 3 ± 
7 3 ± 
65 ± 
5 6 ± 
7 2 t 
7 8 ± 
8 0 ± 
71 ± 
79 + 
7 0 ± 
69 ± 
7 0 ± 
8 4 ± 
7 3 ± 
7 1 ± 
8 
4 
8 
4 
5 
10 
7 
12 
5 
5 
5 
4 
2 
10 
4 
5 
Toluene 
o-Xylene 
/n-Xylene 
0 
100 
2 0 0 
5 0 0 
1 0 0 0 
2 0 0 0 
2 0 
5 0 
1 0 0 
2 0 0 
5 0 0 
2 0 
5 0 
1 0 0 
2 0 0 
5 0 0 
9 ± 
6 ± 
6 ± 
1 1 ± 
1 0 ± 
8 t 
9 ± 
β ± 
8 ± 
7 ± 
7 ± 
β ± 
9 ± 
7 ± 
9 ± 
7 ± 
2 
2 
1 
4 
3 
2 
2 
2 
1 
3 
4 
1 
2 
1 
2 
1 
4 ± 
3 ± 
5 ± 
4 ± 
4 ± 
6 ± 
8 t 
8 ± 
4 ± 
4 ± 
6 ± 
5 ± 
5 ± 
5 ± 
6 ± 
4 ± 
18 ± 1 
21 ± 2 
2 6 ± 8 
2 3 ± 3 
25 ± 4 
19 ± 3 
1 8 ± 3 
19 ± 3 
2 0 ± 1 
19 ± 3 
19 1 4 
2 3 ± 3 
21 ± 2 
21 ± 2 
25 ± 5 
2 8 ± 2 
25 ± 
18 ± 
21 ± 
21 ± 
19 ± 
2 2 ± 
29 ± 
2 3 ± 
25 ± 
21 ± 
19 ± 
2 6 ± 
28 ± 
21 ± 
28 ± 
20 ± 
5 
3 
2 
4 
1 
1 
3 
2 
3 
4 
3 
3 
1 
4 
6 
3 
p-Xylene 
o-Methylbenzyl alcohol 
o-Methylbenzyl sulfate 
Reference mutagen 
S odi um aride 
4-Nitloquinoline-l-oidde 
4-Nitto-o-phenylenedl amine 
9-Aminoaaddine 
Spontaneous 
2 0 
50 
100 
2 0 0 
5 0 0 
1 0 0 
2 0 0 
6 0 0 
1 0 0 0 
2 0 0 0 
Ob 
1 0 0 
2 0 0 
5 0 0 
1 0 0 0 
2 0 0 0 
5 
2 
1 0 
2 0 0 
6 ± 
10 ± 
12 ± 
9 ± 
10 ± 
7 ± 
10 ± 
11 ± 
8 ± 
9 ± 
7 ± 
7 ± 
β ± 
9 ± 
6 ± 
9 ± 
1 
2 
2 
2 
2 
3 
2 
2 
1 
2 
1 
3 
2 
2 
1 
2 
2 1 0 0 1 100 
35 ± 
17 + 
7 ± 
11 ± 
3 
1 
1 
3 
4 ± 
4 ± 
4 ± 
4 ± 
6 ± 
6 ± 
6 ± 
4 ± 
3 ± 
4 ± 
10 + 
6 ± 
4 ± 
6 ± 
7 ± 
β ± 
6 ± 
14 ± 
4 2 + 
2 
1 
1 
1 
1 
2 
1 
1 
1 
1 
2 
1 
1 
3 
4 
2 
1 
4 
1 
8 9 0 0 ± 2 0 0 
7 ± 1 
2 0 ± 
18 ± 
24 ± 
15 ± 
21 ± 
27 + 
21 ± 
2 2 ± 
2 2 ± 
20 ± 
20 ± 
19 ± 
19 ± 
24 ± 
20 ± 
26 ± 
2 4 ± 
175 + 
1 7 6 0 ± ; 
10 + 
24 ± 
2 
2 
2 
1 
5 
3 
2 
2 
3 
1 
3 
3 
4 
4 
3 
2 
2 
7 
36 
2 
2 
2 4 ± 
2 3 ± 
20 ± 
26 ± 
25 ± 
25 ± 
22 ± 
26 ± 
2 3 ± 
20 ± 
26 ± 
2 3 ± 
25 ± 
27 ± 
21 ± 
2 4 ± 
2 6 ± 
417 ± : 
1350 ± 1 
18 ± 
37 ± 
2 
5 
3 
1 
5 
1 
3 
3 
2 
4 
1 
2 
2 
1 
3 
2 
8 
12 
S3 
3 
3 
65 1 9 
6 3 ± 4 
6 2 + 5 
7 8 + 6 
7 6 + 8 
9 3 + 3 
7 2 ± 5 
65 ± 8 
6 4 + 1 
61 ± 1 
98 ± 4 
9 1 + 14 
85 ± 4 
9 3 ± 11 
8 2 ± 14 
1 0 0 t 7 
2 4 0 0 + 2 0 0 
4 1 0 0 1 120 
2 8 4 ± 2 3 
4 6 ± 16 
100 ± 5 
a
 Mean values ± S.E.M, of determinations in triplicate. 
b Unlike the other compounds, which were dissolved in DMSO, o-methylbenzyl sulfate was given in aqueous solution. 
Baker Chemicals (Deventer, The Netherlands). o-Methylbenzylalcohol, 9-ami-
noscridine hydrochloride monohydrate, 2-aminoanthracene, benzo[a]pyrene, 
4-nitro-o-phenylenediamine and 4-nitroquinoline-l-oxide were purchased from 
Aldrich Europe (Beerse, Belgium). Sodium azide and toluene were purchased 
from Merck (Darmstadt, FRG), D-biotin and L-histidine—HCl from Sigma (St. 
TABLE 2 
RESULTS OF THE AMES ASSAY ON TOLUENE DERIVATIVES 
б Salmonella typhimurium strains were used with activation by S9 mix from livers of untreated rats. 
Compound 
tested 
Toluene 
-
o-Xylene 
m-Xylene 
p-Xylene 
" 
o-Methylbenzyl alcohol 
o-Methylbenzyl sulfate 
Reference mutagen 
2-Arainoanthracene 
Benzo[a]pyrene 
9,10-DimethyIbenzanthracene 
Spontaneous 
Amount 
μβ/Plate 
0 
100 
2 0 0 
6 0 0 
1 0 0 0 
2 0 0 0 
2 0 
Б0 
100 
2 0 0 
0 0 0 
2 0 
5 0 
1 0 0 
2 0 0 
6 0 0 
2 0 
6 0 
1 0 0 
2 0 0 
500 
100 
2 0 0 
6 0 0 
1 0 0 0 
2 0 0 0 
0 b 
1 0 0 
2 0 0 
5 0 0 
1 0 0 0 
2 0 0 0 
1 
7.5 
2 0 
Number of his* revertants per plate 
Strain 
ТА15Э5 
β ± 
1 3 ± 
1 4 ± 
10 ± 
1 2 ± 
1 1 ± 
1 4 ± 
7 ± 
7 ± 
12 ± 
β ± 
1 3 ± 
1 0 ± 
В ± 
8 ± 
8 ± 
11 ± 
12 ± 
10 ± 
9 ± 
6 ± 
11 ± 
8 ± 
1 4 ± 
1 4 ± 
11 ± 
10 ± 
1 0 ± 
6 ± 
12 ± 
16 ± 
7 ± 
7 9 4 ± 
25 ± 
1 3 ± 
8 ± 
3 
3 
3 
3 
1 
1 
1 
1 
2 
3 
1 
1 
3 
2 
2 
3 
2 
3 
3 
1 
1 
A 
2 
1 
1 
1 
2 
2 
1 
1 
2 
1 
28 
9 
1 
3 
TA1537 
5 ± 1 
6 * 1 
4 ± 2 
3 ± 1 
6 * 1 
6 * 2 
4 * 1 
5 * 2 
3 * 1 
4 * 1 
9 * 4 
9 * 2 
6 * 1 
5 ± 1 
8 * 3 
6 * 1 
4 * 1 
4 * 1 
6 * 2 
5 * 2 
4 * 1 
6 * 1 
5 * 3 
5 * 1 
7 * 4 
3 * 1 
6 * 1 
4 * 1 
5 * 1 
5 * 2 
5 * 0 
10 ± 3 
1 7 6 ± 6 
5 * 2 
1 3 8 ± 6 
5 * 2 
T A 1 5 3 8 
2 2 
19 
1 4 
* 
* 
* 
2 4 * 
17 
19 
1 9 
1 1 
1 6 
1 3 
1 9 
16 
17 
2 3 
18 
2 0 
17 
17 
2 0 
1 6 
2 6 
21 
2 0 
2 4 
19 
17 
2 0 
1 4 
2 2 
2 4 
2 6 
18 
1 6 8 5 
39 
2 5 5 
2 0 
* 
* 
* 
* 
* 
* 
* 
* 
± 
± 
* 
* 
± 
* 
* 
* 
* 
± 
* 
± 
* 
* 
± 
± 
* 
* 
* 
* 
* 
* 
± 
± 
5 
2 
3 
1 
2 
1 
3 
1 
1 
2 
5 
2 
1 
4 
2 
3 
4 
2 
3 
2 
6 
3 
2 
2 
4 
1 
1 
1 
3 
5 
8 
2 
57 
3 
12 
3 
a 
TA98 
25 * 
13 * 
31 * 
29 * 
3 4 * 
3 5 * 
32 * 
26 * 
1 4 * 
26 * 
29 * 
3 3 * 
24 * 
26 * 
29 * 
24 * 
3 6 * 
30 * 
3 0 * 
29 * 
3 8 * 
1 6 * 
17 * 
22 * 
2 6 * 
29 * 
27 * 
21 * 
16 * 
20 * 
26 * 
30 * 
1 
3 
2 
3 
1 
3 
4 
6 
2 
2 
1 
3 
3 
3 
1 
5 
6 
1 
6 
2 
8 
1 
1 
4 
1 
3 
2 
4 
3 
4 
3 
2 
1345 * 7 1 
— 
68 * 
22 * 
3 
2 
TA100 
8 8 * 
9 8 * 
7 9 * 
81 * 
8 3 * 
7 4 * 
7 3 * 
8 0 * 
89 * 
8 2 * 
7 8 * 
8 4 * 
68 * 
78 * 
8 0 * 
101 * 
90 * 
8 8 * 
7 5 * 
7 8 * 
8 8 * 
8 2 * 
81 * 
8 3 * 
66 * 
8 8 * 
7 4 * 
9 0 * 
8 3 * 
79 * 
69 * 
82 * 
7 4 0 0 * 
3 3 9 * 
1 8 3 * 
91 * 
9 
4 
3 
6 
6 
6 
9 
8 
18 
1 
7 
3 
4 
2 
2 
6 
10 
2 
6 
6 
13 
7 
4 
6 
3 
6 
2 
8 
10 
8 
5 
3 
250 
17 
9 
3 
a
 Mean values * S.E.M. of determinations In triplicate. 
b Unlike the other compounds, which were all dissolved In DMSO, o-methylbenzyl sulfate was elven in 
aqueous solution. 
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Louis, U.S.A.). Nicotinamide adenine dinucleotide phosphate (NADP) disodi-
um salt and glucose 6-phosphate (G-6-P) disodium salt were purchased from 
Boehringer (Mannheim, F.R.G.). Purified agar was purchased from Difco Labo­
ratories (Detroit, U.S.A.), 9,10-dimethyl-l,2-benzanthracene from ICN Pharma­
ceuticals and nutrient broth No. 2 from Oxoid Ltd (Basingstoke, England). 
TABLE 3 
RESULTS OF THE AMES ASSAY ON TOLUENE DERIVATIVES 
5 Salmonella typhlmurlum strains were used with activation by S9 mix from livers of Aroclor-treated rats. 
C o m p o u n d 
tested 
Toluene 
o-Xylene 
m-Xylene 
p-Xylene 
o-Methylbenzyl alcohol 
o-Methylbenzyl sulfate 
Reference mutafen 
2-A mlnoant hracene 
Вепго[а]рутепе 
9,10-DimethyIbenzantbracene 
S p o n t a n e o u s 
A m o u n t 
MB /Plate 
0 
100 
200 
500 
1 0 0 0 
2 0 0 0 
20 
50 
100 
2 0 0 
500 
20 
50 
100 
200 
500 
20 
50 
100 
200 
5 0 0 
100 
200 
5 0 0 
1 0 0 0 
2 0 0 0 
0 b 
100 
2 0 0 
5 0 0 
1 0 0 0 
2 0 0 0 
1 
7.5 
20 
Numbers of his* revertants per plate a 
Strain 
T A 1 5 3 5 
11 ± 
7 ± 
1 1 ± 
11 ± 
8 ± 
7 ± 
12 ± 
8 ± 
18 ± 
14 ± 
14 ± 
12 ± 
10 ± 
7 ± 
10 ± 
12 ± 
9 ± 
10 ± 
1 1 ± 
7 ± 
10 ± 
8 ± 
7 ± 
7 ± 
12 ± 
7 ± 
8 ± 
10 ± 
1 3 ± 
1 3 ± 
11 ± 
7 ± 
4 
1 
4 
2 
1 
1 
4 
1 
3 
4 
1 
4 
3 
1 
1 
1 
2 
2 
4 
1 
3 
3 
1 
2 
0 
1 
3 
3 
1 
3 
3 
1 
1 3 2 ± 1 4 
19 ± : 
16 ± 
8 ± 
11 
2 
3 
T A 1 5 3 7 
7 ± 
8 * 
9 ± 
1 0 ± 
5 ± 
7 ± 
13 ± 
10 ± 
9 ± 
7 ± 
7 ± 
9 ± 
1 1 t 
5 ± 
7 ± 
8 ± 
11 ± 
1 2 ± 
9 ± 
8 ± 
10 ± 
8 ± 
7 ± 
4 ± 
1 0 ± 
6 ± 
8 ± 
6 ± 
7 ± 
1 0 ± 
6 ± 
11 ± 
5 4 ± 
2 2 2 ± 
1 2 6 ± 
9 ± 
3 
3 
2 
2 
2 
2 
1 
3 
4 
3 
3 
2 
2 
1 
1 
1 
2 
2 
1 
3 
3 
3 
1 
1 
2 
1 
1 
1 
1 
3 
1 
3 
5 
10 
3 
1 
T A 1 5 3 8 
2 4 ± 
24 ± 
26 ± 
18 ± 
2 1 ± 
21 ± 
28 ± 
2 5 ± 
22 ± 
2 3 ± 
2 4 ± 
2 8 ± 
19 ± 
24 ± 
21 ± 
2 2 ± 
17 ± 
19 ± 
22 ± 
2 1 ± 
22 ± 
19 ± 
2 4 ± 
22 ± 
17 ± 
2 5 ± 
26 ± 
2 3 ± 
2 5 ± 
2 5 ± 
2 1 ± 
22 ± 
538 ± 
381 ± 
57 ± 
2 0 ± 
5 
2 
7 
1 
4 
4 
1 
1 
4 
5 
4 
3 
1 
3 
3 
1 
2 
2 
2 
4 
3 
1 
1 
1 
2 
4 
8 
2 
5 
2 
5 
2 
22 
1 4 
4 
1 
T A 9 8 
24 ± 
32 t 
26 ± 
26 ± 
2 4 ± 
28 t 
28 ± 
2 4 ± 
3 3 ± 
21 ± 
31 ± 
32 ± 
31 ± 
26 ± 
29 ± 
29 ± 
29 ± 
27 ± 
26 ± 
32 ± 
2 4 ± 
24 ± 
26 ± 
3 1 ± 
1 8 ± 
3 5 ι 
31 ± 
27 ± 
2 3 ± 
26 ± 
20 ± 
28 ± 
281 ± 
3 
3 
4 
1 
3 
5 
2 
1 
6 
4 
2 
6 
1 
4 
1 
1 
1 
1 
4 
4 
2 
2 
1 
2 
1 
2 
3 
3 
2 
2 
2 
4 
8 
1 2 3 0 ι 6 0 
379 ± 
30 ± 
11 
2 
T A 1 0 0 
89 ± 1 5 
8 5 ± 6 
9 6 ± 9 
9 9 ± 5 
8 3 ± 1 1 
7 1 ± 3 
9 2 ± 3 
9 8 ± 8 
80 ± 6 
89 ± 7 
9 2 ± 6 
9 8 ± 6 
9 4 ± 9 
9 5 ± 4 
8 2 ± 4 
9 8 ± 7 
9 4 ± 1 3 
8 6 ± 7 
8 3 ± 5 
7 8 ± β 
9 4 ± 6 
9 3 ± 4 
8 0 ± 7 
8 1 ± 2 
8 4 ± 1 0 
8 3 ± Б 
9 3 ± 2 
1 0 8 ± 2 
8 3 ± 8 
1 0 7 ± 5 
1 0 5 ± 1 4 
1 1 2 ± 10 
6 5 0 ± 4 
8 7 0 ± 3 4 
4 9 1 ± 16 
1 0 4 ± 9 
a
 Mean values ± S.E.M. of determinations in triplicate. 
b Unlike the other compounds, which were dissolved in DMSO, o-methylbenzyl sulfate was given In aque­
ous solution. 
65 
o-Methylbenzylsulfate was synthesized from o-methylbenzylalcohol accord-
ing to Clapp and Young (1970). 
Mutagenicity testing 
The mutagenicity test was performed according to Ames et al. (1975) with 
Salmonella typhimurium strains TA1535, TA1337, TA1538, TA98 and 
TA100. We used Oxoid nutrient broth instead of Difco nutrient broth. 
Rat liver S9 (9000 £ supernatant) fractions were prepared from male Wistar 
rats either untreated or pretreated with Aroclor 1254. S9 mix contained C.l ml 
S9 per ml. 
Plates were counted after 48 h incubation at 37° С with a Biotran II auto­
mated colony counter. 
Results 
Table 1 shows that none of the tested toluene derivatives was directly muta­
genic to the Salmonella typhimurium strains. The mutability of the strains was 
verified with the directly acting mutagens: sodium azide, 4-nitroquinolme-l-
oxide, 4-nitro-o-phenylenediamine and 9-aimnoacridine. Tables 2 and 3 show 
that none of the toluene derivatives was mutagenic to Salmonella typhimurium 
after activation with liver S9 mix derived from either untreated or Aroclor-
1254-treated rats. To verify both mutability of the strains and efficiency of the 
metabolic activation system, we used the premutagens: 2-aminoanthracene, 
benzo[o]pyrene and 9,10-dimethyl-l,2-benzanthracene. 
Killing of the bacteria was only found to a low extent; at the highest concen­
trations 80—100% of the bacteria survived. 
Discussion 
In a previous study we obtained evidence that, during the metabolism of tolu­
ene and xylenes, reactive intermediates are formed, probably due to side-chain 
oxidation and sulfation. This in particular holds for o-xylene (van Doom et al., 
1980b). No mutagenicity could be detected for toluene, m-xylene orp-xylene; 
and o-xylene, o methylbenzylalcohol and o-methylbenzylsulfate were also 
found negative. We also investigated, using the method described by Brouns et 
al. (1979), whether these compounds are able to evoke DNA-excision repair in 
suspensions of freshly isolated rat hepatocytes. All these compounds, at con­
centrations ranging from 10"7 to IO"3 M, were negative. Gemer-Smidt and 
Friedrich (1978) studied the genotoxic effect of benzene, toluene and xylene 
by the SCE technique. They did not find any increase, either in the frequency 
of SCEs or in the number of structural chromosomal aberrations. Data about 
genotoxic effects of toluene were gathered by Dean (1978). He has been unable 
to trace any reference in the literature to microbial mutation testing of toluene. 
Reported animal experiments show that high concentrations of toluene are 
required to induce chromosomal aberrations. No significant increase could be 
detected in chromosomal aberrations in workers exposed to concentrations of 
toluene close to the maximal allowable concentration of 200 ppm for periods 
up to 15 years. 
ее 
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Summary 
The applicability of suspensions of rat hepatocytes as the metabolic factor in a 
bacterial mutagenicity test was studied. Therefore, mutagenicity of 4-aminobiphenyl 
and benzidine towards the Salmonella typhimurium strains TA 1538 and TA 100 in 
the presence of rat-hepatic microsomal preparations or intact liver cells was mea-
sured. The mutagenic potency of these compounds was also established in the 
intrasanguineous host-mediated assay. 
Comparison of the test results showed that the mutagenic activity of 4-
aminobiphenyl and benzidine after metabolism by intact rat hepatocytes resembled 
the mutagenic activity of these compounds after biotransformation in vivo more 
than after activation with a rat-liver S9 fraction. 
The Salmonella/microsome assay is widely used for the detection of mutagens [1]. 
Because many mutagens need metabolic conversion to generate their genotoxic 
properties, in this test in vitro mutagenic activation is mediated by the addition of a 
rat-liver S9 fraction. It is uncertain, however, to what extent the mutagenic activa-
tion by the enzymes present in the S9 fraction approximates the biotransformation 
in vivo, because during preparation of the S9 fraction, activating and deactivating 
enzymes are dissociated [5]. It may also be doubted whether the concentration of 
co-factors applied in the test in vitro reflects the situation in vivo [5]. For instance, 
the S9 fraction does not contain co-factors for the acetylation [10]. In general, the S9 
fraction catalyses phase-I reactions and contains little activity of phase-II reactions 
[8]. On the one hand, this could be the reason that the Salmonella/microsome assay 
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is inadequate for some classes of mutagen [5]. On the other hand, it could be 
possible to detect mutagens that are not detectable after activation in vivo. 
In the intrasanguineous host-mediated assay the indicator cells, in this case 
Salmonella bacteria, are injected into a lateral tail vein and are recovered mainly 
from the liver to be screened for the presence of mutants after treatment of the 
animals with a suspected compound [9,12]. Although the compound under test 
undergoes metabolism in vivo, this test system suffers from insensitivity. Probably 
because, in vivo, the systems are protected by urinary, biliary and respiratory 
excretion systems, high dose levels to the host are needed of certain compounds [5]. 
However, these levels are limited by the toxicity of the compounds to the host [11]. 
Because this system is biased to false negative responses, it should not be used as a 
primary mutagenic screen [11]. 
Because, in the total animal, metabolic activation is achieved mainly in the liver, 
we think that isolated rat hepatocytes deserve serious attention as a tool in 
mutagenicity studies. Mutagenic activation by intact hepatocytes may give a better 
approximation of the situation in vivo than does the rat-liver S9 fraction. Moreover, 
disturbing effects that occur in total animals owing to test compounds showing acute 
toxicity are eliminated. 
In this study we compared the mutagenicity of 2 structurally related carcinogenic 
aryl amines, 4-aminobiphenyl and benzidine, which are subject to a rather complex 
metabolism in vivo, in 3 different test methods: the Salmonella/microsome, the 
Salmonella/hepatocyte and the intrasanguineous host-mediated assays. 
Materials and methods 
Chemicals 
Benzidine was purchased from Merck (Darmstadt, F.R.G.). 4-Aminobiphenyl was 
from Aldrich Europe (Beerse, Belgium). D-Biotin, L-histidine-HCl and collagenase 
type I were obtained from Sigma (St. Louis, U.S.A.). Nicotinamide adenine di-
nucleotide phosphate (NADP) disodium salt and glucose-6-phosphate (G-6-P) di-
sodium salt were purchased from Boehringer (Mannheim, F.R.G.). Purified agar was 
from Difco Laboratories, nutrient broth No. 2 from Oxoid Ltd. (Basingstoke, 
England) and citric acid monohydrate from J.T. Baker Chemicals (Deventer, The 
Netherlands). 
Preparation of isolated hepatocytes 
The procedure was based on the methods described by Berry and Friend [3] and 
by Seglen [14], except for some modifications. All manipulations were performed 
under sterile conditions. Before the procedure, rats were anaesthetized by an i.p. 
injection of sodium pentobarbital (60 mg/ml distilled water, 0.35 ml). After 15 min 
of pre-perfusion of the liver with a Ca2+-free HEPES buffer, this buffer was 
replaced by a collagenase-containing HEPES buffer (0.06% w/v collagenase) for 
another 15 min. The perfusion rate was 25 ml/min. The crude cell suspension was 
treated according to the method of Seglen [14], and the final pellet was resuspended 
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in a Ca2"""-containing HEPES-TES buffer solution and diluted to a density of 
5 X 106 cells/ml. Trypan-blue exclusion showed the presence of about 95% viable 
cells. 
Salmonella /microsome mutagenicity assay 
The Salmonella/microsome assay was performed according to Ames et al. [1] 
with the Salmonella typhimunum strains TA 1538 and TA 100. We used Oxoid 
nutrient broth instead of Difco nutrient broth. Rat-liver S9 (9000 g supernatant) 
fractions were prepared from male Wistar rats either untreated or pretreated with 
phénobarbital. S9 mix contained 0.1 ml S9 per ml. 
Salmonella ¡ntrasanguineous assay 
The intrasanguineous assay was based on a method described by Mohn and 
Ellenberger [12]. Male Wistar rats weighing about 200 g were injected in the lateral 
tail vein with 1 ml of a saline suspension of Salmonella typhimunum. This suspension 
was prepared in the following way. 30 ml of an overnight-grown bacterial culture 
was inoculated into 100 ml of fresh nutrient broth and incubated in a shaker at 
370C. After 2.5 h, the bacterial suspension was centrifuged at 5000 g, and the pellet 
was resuspended in 1 ml of saline. A diluted suspension was plated for the estima-
tion of the number of bacteria present in the suspension. According to the method 
described by Bakshi and Brusick [2], 45 min after bacterial injection, each animal 
was injected intraperitoneally with 4-aminobiphenyl or benzidine dissolved in sterile 
tragacanth (2%) at a dose of 1.0 mmole/kg. The control animals were injected with 
the same amount of sterile tragacanth. 1 h after the administration of the test 
compound, the rats were anaesthetized by an i.p. injection of sodium pentobarbital 
(60 mg/ml distilled water, 0.35 ml) and the livers were removed aseptically. They 
were minced with scissors and suspended in 40 ml of sterile saline. This suspension 
was homogenized and centrifuged at 200 g. The supernatant was centrifuged twice 
for 20 min at 1200 g, then the ultimate pellet was suspended in 1.0 ml of saline. Of 
this suspension, 0.1 ml was plated in triplicate with a molten top agar containing 
only biotin (ño histidine) for the determination of the number of his + revertants. 
Another 0.1 ml of the suspension was diluted 10 _ 5 . Of this suspension, 0.1 ml was 
plated in triplicate with a molten top agar containing extra histidine for the 
determination of the total number of bacteria recovered. After incubation for 48 h at 
370C the number of colonies was counted, and the mutation frequency was 
calculated as the number of his+ revertants/108 bacteria recovered. 
Salmonella/hepatocyte mutagenicity assay 
The procedure of the Salmonella/hepatocyte assay was carried out as follows. In 
a shaking water-bath, closed sterile vials, each containing 3.1 ml of hepatocyte 
suspension (5 X 106 viable cells/ml), 0.8 ml of an overnight-grown suspension of 
Salmonella typhimunum (about 1.5 X 109 bact./ml) and 0.1 ml of a 4-aminobiphenyl 
or benzidine solution (in DMSO) were incubated at 370C for 1 h. Next, 0.5 ml of 
this mixture was plated in triplicate with a molten top agar containing only biotin 
(no histidine). The number of revertant colonies was counted after 48 h at 370C. 
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Results 
The mutagenicity of 4-ammobiphenyl and benzidine in the Salmonella /microsome 
assay 
In Fig. 1 the mutagenicities of 4-aminobiphenyl and benzidine are shown towards 
the Salmonella typhimunum strains TA1538 and TA100 in the Salmonella/micro-
some assay in the presence of S9 mix. 4-Aminobiphenyl was slightly more mutagenic 
than benzidine towards strain TA 1538. The mutagenicity of 4-aimnobiphenyl was 
very high towards the tester strain TA 100 as compared with benzidine (Fig. 1c, d). 
The mutagenic activity of both 4-aminobiphenyl and benzidine was increased when 
9000 g supernatant of livers derived from phenobarbital-trealed rats was used. 
Phénobarbital pretreatment strongly influenced the mutagenicity of 4-aminobiphenyl 
towards the tester strain TA 100. 
revèrtani cotomes per pote 
4
 °-\ TA 1538 
rever lam cototues per piate -
8O00-,
 T A 1 0 0 
.-"* 
. ir" 
4-AMINOBIPHENYL 
2 5 0 1 ТАНЮ 
¿О 8 0 130 160 
^ j m o l e s of c o m p o u n d per p i a t e 
4 0 ВО 120 1 6 0 
^ j m o l e · ot c o m p o u n d per p i a t e 
Fig I The mutagenicity of 4-aminobiphenyl and benzidine towards the Salmonella hphimurtum strains 
ТА 1538 and TAIOO in the plate assay in the presence of S9 mix S9 fractions were denved from untreated 
( ) or phenobarbital-pretreated rats ( ) Mean values±SEM of determinations in 
triplicate 
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Mutagenicity of 4-aminobiphenyl and benzidine in the intrasanguineous host-mediated 
assay 
The results of the host-mediated experiments are shown in Table 1. The recovery 
of the bacteria of both strains was low (0.4-2.4%). 
The mutagenicities of the compounds under test are given as reversions per IO" 
survivors. After treatment of the rat with benzidine, the number of reversions per 
108 survivors of strain TA1538 was very high in comparison with the number of 
reversions in the control rat. There was no significant increase in reversion rate after 
4-ammobiphenyl treatment with respect to the control treatment. Pretreatment of 
TABLE ι 
MUTAGENIC ACTIVITY OF 4-AMINOBIPHENYL AND BENZIDINE IN THE HOST-MEDIATED 
ASSAY 
Compound Phénobarbitala 
pretreatmcm 
Tester 
strain 
Recovery b Reversions 
per 108 
survivors 
Control 
Control 
4-Aminobiphenyl 
4-Aminobiphenyl 
Benzidine 
Benzidine 
Control 
Control 
4-Aminobiphenyl 
4-Aminobiphenyl 
Benzidine 
Benzidine 
Control 
Control 
4-Aminobiphenyl 
4-Aminobiphenyl 
Benzidine 
Benzidine 
Control 
Control 
4-Aminobiphcnyl 
4-Aminobiphenyl 
Benzidine 
Benzidine 
-
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
_ 
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
TA 1538 
TA 1538 
ΤΑ 1538 
ΤΑ 1538 
TA 1538 
ΤΑ 1538 
TA 1538 
TA 1538 
TA 1538 
TA 1538 
TA 1538 
TA 1538 
TAI00 
TA100 
TA100 
TA 100 
TA100 
TA100 
TA100 
TAI0O 
TAI00 
TA100 
TA 100 
TA100 
15 
09 
08 
24 
05 
18 
08 
10 
09 
12 
1 2 
16 
05 
04 
05 
08 
08 
08 
02 
10 
06 
14 
04 
1 3 
20 
43 
37 
50 
272 
377 
1 6 
42 
118 
104 
323 
267 
93 
287 
111 
174 
109 
95 
217 
127 
92 
102 
139 
153 
a
 Rats received 75 mg/kg per day for 4 days before the experiment 
ь
 Number of bactena recovered from the liver as a fraction of the number injected (ι ν ) 
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the rats with phénobarbital did not result in a significant difference in benzidine 
mutagenicity for TA 1538. Treatment with 4-aminobiphenyl, however, led to an 
increase of the reversion rate. 
With the Salmonella typhimurium strain TA 100, no increase of the reversion rate 
was detected after treatment of the rats, either with 4-aminobiphenyl, or with 
benzidine. Pretreatment of the rats with phénobarbital had no detectable influence 
on the reversion rates. 
The mutagenicity of 4-aminobiphenyl and benzidine in the Salmonella/hepatocyte assay 
In Fig. 2 the mutagenicities of 4-aminobiphenyl and benzidine are shown after 
metabolic activation by intact rat-liver cells towards the Salmonella typhimurium 
strains TA 1538 and TA 100. 
Benzidine was far more mutagenic than 4-aminobiphenyl when the tester strain 
revenant colonies per plate revertant colonies per plate 
140-
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100-
8 0 -
6 0 -
4 0 -
2 0 -
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Ï' z 1 / / / 
Í 
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• Г' 
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-
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/ 
Ь 
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200 300 400 
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Fig 2 The mutagenicity of 4-aminobiphenyl and benzidine towards the Salmonella i\phiniuriuni strains 
TAI538 and TAIOO after metabolic activation by rat-liver cells denved from untreated ( ) or 
phcnobarbital-pretreated rats ( ) Experimental details were as mentioned in Materials and 
Methods Mean values^ S Ε M of 3 separate expenments 
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TA 1538 was used and when metabolic activation was achieved by liver cells from 
untreated rats. When liver cells were used from phenobarbital-pretreated rats, we 
found a substantial increase in mutagenicity of both compounds, with benzidine still 
as the more active compound. 
The mutagenicity of 4-aminobiphenyl towards the Salmonella typhimunum strain 
TA 100 could hardly be measured after metabolic activation by rat-liver cells from 
untreated rats. However, when metabolic activation by rat-liver cells from pheno-
barbital-pretreated rats was achieved, the mutagenicity of 4-aminobiphenyl was well 
detectable to the Salmonella typhimunum strain TA 100. 
There was hardly any observable mutagenicity of benzidine to the Salmonella 
typhimunum strain TA100 when liver cells from untreated rats were used. Mutagenic 
activation to this strain was achieved to a low extent with liver cells that were 
isolated from phenobarbital-pretreated rats. 
Discussion 
Many mutagenic chemicals do not exert their genotoxic actions until they have 
been metabolized by the organism. Thereto, most mutagenicity tests in vitro, such as 
the frequently used Ames assay, must be supplied with an activating enzyme system, 
commonly a liver microsomal preparation. One has to realize that, in vivo, the 
mutagenic potency of the chemicals is determined by the balance between mutagenic 
activation and inactivation reactions. 
Fig. 1 shows that, after activation with an S9 fraction, 4-aminobiphenyl was more 
mutagenic than benzidine. This particularly holds for the mutagenicity towards 
strain TA 100. On the other hand, no mutagenicity of 4-aminobiphenyl was observed 
after metabolic activation in vivo (i.e. in the host-mediated assay, Table 1), whereas 
the mutagenicity of benzidine was well observable in this assay. 
Considering the great discrepancy between the mutagenicity after incubation of 
benzidine and 4-aminobiphenyl in vitro or in vivo, it was interesting to compare the 
mutagenicity" of 4-aminobiphenyl and benzidine with isolated intact hepatocytes as 
the metabolizing system (Fig. 2). The results are summarized in Table 2, which also 
shows the ratios between mutagenicity of 4-aminobiphenyl and benzidine, measured 
in the presence of various activating systems. These values are derived from the 
mutagenicity data on the highest concentrations tested. It is obvious that, with tester 
strain TA 1538, benzidine was more mutagenic than 4-aminobiphenyl, both in the 
host-mediated assay and in the Salmonella/hepatocyte assay. This is in contrast 
with the results obtained by activation with the S9 liver fraction. 
With tester strain TA 100 we found no mutagenic activity of 4-aminobiphenyl or 
benzidine in the host-mediated assay and a low mutagenic response in the 
Salmonella/hepatocyte assay. 
No marked changes in the ratios were observed after pretreatment of the rats with 
phénobarbital. 
There is no doubt that the structural and functional organization of the enzymes 
involved in biotransformation is considerably disturbed in the rat-liver S9 fraction. 
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TABLE 2 
MUTAGENICITY RATIO OF 4-AMINOBIPHENYL/BENZIDINE IN TA 1538 
Pretreatment Activation system 
None 
Phénobarbital 
in TA 100 
None 
Phénobarbital 
S9 mix 
1 8 
1 3 
21 
37 
Hepatocytes 
0 20 
0 43 
1 14 
14 
Host-mediated 
0013 
0 038 
a 
a 
^ 4-Aminobiphenyl and benzidine were both non-mutageme towards TA 100 in the host-mediated assay 
Differences in cellular integrity may be the reason for a quantitative as well as 
qualitative difference between mutagenic metabolites formed in S9 mix and those 
released from hepatocytes both in vitro and in vivo. 
The question arises whether the low sensitivity of the host-mediated assay, when 
compared with hepatocyte-mediated tests, is also due to the very low recovery of 
bacteria from rat livers and, therefore, to the low absolute numbers of induced his + 
mutant cells. 
It is known that phénobarbital is capable of inducing several drug-metabolizing 
enzymes of the liver. Phénobarbital might influence in particular the activation of 
carcinogenic aryl amines, because these compounds are metabolized by a complex 
series of sequential steps to gain their toxic properties [16]. The increase in mutagen-
icity of 4-aminobiphenyl and benzidine after activation with a liver S9 fraction or 
with hepatocytes from phenobarbital-treated rats is in agreement with this. However, 
in the host-mediated assay, we only found a weak mutagenic response with 4-
aminobiphenyl towards TA 1538 after pretreatment of the rats with phénobarbital. 
This could mean that, for the dose applied, the capacity of the enzymes is not 
rate-limiting for the mutagenic activation in vivo. It was not possible to increase the 
dose because of the acute toxicity, particularly of 4-aminobiphenyl, to the rats. 
Several investigators, including ourselves, have used isolated hepatocytes as a 
metabolic system in short-term mutagenicity testing [4,6,7,13,15]. From these studies 
it was suggested that the overall metabolism in the hepatocyte is fairly representative 
of the biotransformation in vivo. Policy et al. [13] concluded that intact hepatocytes 
may more efficiently produce mutagenic metabolites than do disrupted cell fractions. 
Other investigators found a better correlation between bacterial mutagenicity and 
carcinogenicity of benzo[a]pyrene and 4 of its major metabolites by using activation 
with intact liver cells instead of a cell homogenate [6]. 
The results of the present study show that, with the Salmonella/hepatocyte assay, 
mutagenic activities of 4-aminobiphenyl and benzidine are found that obviously 
differ from those measured in the Salmonella/microsome assay and resemble more 
closely the mutagenic activities observed with the host-mediated assay. 
7Θ 
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Summary 
The applicability of isolated intact hepatocytes as a metabolic factor in bacterial 
mutagenicity screening was studied. Mutagenic activities of 12 known premutagenic 
compounds were determined in a Salmonella typhimurium test system comprising 
hepatocytes and were compared with mutagenicity data obtained with the commonly 
used Salmonella/ microsome plate assay. In a qualitative sense the results obtained 
with the two systems were, in general, equivalent. However, some specific differences 
were found depending on the bacterial strain used. For instance, dimethylnitrosa-
mine was only mutagenic for Salmonella strain TA1S3S in the hepatocyte suspension 
system. On the other hand, benzo[a]pyrene was hardly mutagenic towards TA100 
with hepatocytes in contrast with thedear-cut effects in the microsome plate assay. 
In a quantitative respect, for benzidine, 2-acetylaminofluorene, 2-aminoanthra-
cene and dimethylnitrosamine, obviously divergent mutagenic values were recorded 
with the different procedures. These differences were found to be connected with the 
presence of intact hepatocytes. This appeared by a comparison between mutagenici-
ties with intact hepatocytes and with S9 prepared from disrupted hepatocytes. The • 
results support previous recommendations that tests with intact cell metabolism 
should be included in a battery for screening of carcinogens in vitro. 
The Salmonella/microsome assay is widely used for the detection of genotoxic 
agents, including carcinogens and mutagens. Because many mutagens need meta-
bolic conversion to generate their genotoxic properties, in this test mutagenic 
activation in vitro is mediated by the addition of a 9000 X g supernatant from rat 
0 
liver (S9 fraction). It is uncertain, however, to what extent the mutagenic activation 
by the enzymes present in the S9 fraction approximates the biotransformation in 
vivo [6]. 
Recently we showed, for the mutagenic activation of 4-aminobiphenyl and 
benzidine, that metabolism by intact rat hepatocytes resembles more the biotransfor-
mation in vivo than the metabolism with a rat-hver S9 fraction [3]. It might be an 
interesting question in this respect whether a mutagenicity test system with intact rat 
hepatocytes as the metabolic factor has some value as a tool in the screening of 
chemicals. 
In the present study, efforts were made to compare mutagenicities of some known 
genotoxic compounds, in the common microsome plate assay and in a test system 
with hepatocytes in suspension. 
Materials and methods 
Chemicals 
Dimethylnitrosamine, benzo[a]pyrene, 2-acetylaminofluorene (2-AAF) and 2-
aminoanthracene were purchased from Aldrich Europe (Beerse, Belgium). D-Biotin, 
L-histidine-HCl, collagenase type 1, nicotinamide adenine dinucleotide phosphate 
(NADP) disodium salt and glucose 6-phosphate (G-6-P) disodium salt were obtained 
from Sigma (St. Louis, MO, U.S.A.). Purified agar was from Difco Laboratories, 
nutrient broth No. 2 from Oxoid Ltd. (Basingstoke, U.K.). Di-N-butylnitrosamine 
and 7,12-dimethylbenzanthracene were purchased from the Eastman Kodak Com-
pany. 3-Methylcholanthrene was from Koch-Light Laboratories Ltd. 3'-Methyl-4-di-
methylaminoazobenzene and 3,2'-dimethyl-4-aminobiphenyl were obtained from 
ICN Pharmaceuticals Inc. Benzidine and citric acid monohydrate were from Merck 
(Darmstadt, F.R.G.), diethylnitrosamine was from ABC (Div. of Aldrich Chemical 
Co. Inc., Milwaukee, U.S-A.). 2-Hydroxyethylhydrazine and cyclophosphamide were 
purchased from Asta (Brackwede, F.R.G.). All other chemicals used were of highest 
purity obtainable. 
Preparation of isolated hepatocytes 
The procedure was based on the methods described by Berry and Friend [2] and 
by Seglen [12], except for some modifications. All manipulations were performed 
under sterile conditions. Before the procedure, male Wistar rats were anaesthetized 
by an i.p. injection of 0.35 ml sodium pentobarbital (60 mg/ml distilled water). 
After 15 min of pre-perfusion of the liver with a Ca2+-free HEPES buffer (pH 7.4), 
this buffer was replaced by a collagenase-containing HEPES buffer (0.06% w / v 
collagenase; pH 7.6) and pre-perfusion was continued for another 15 min. The 
perfusion rate was 40 ml/min The crude cell suspension was treated according to 
the method of Seglen [12], and the final pellet was resuspended in a Ca2'''-containing 
HEPES-TES buffer solution (pH 7.6) and diluted to a density of 10 X 106 cells/ml. 
Trypan-blue exclusion showed the presence of about 95% viable cells. 
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Preparation of S9 mix from isolated hepatocytes 
10 ml of a suspension of 10 X 10' liver cells/ml was centrifuged for 2 min at 
1600 x g. The pellet was suspended in 5 ml of HEPES-TES buffer containing 2% 
albumin, glucose 6-phosphate (5 μ moles/ml) and NADP (4 μ moles/ml). This 
suspension was sonicated twice for 20 sec, with an interval of 30 sec in an MSE 
Ultrasonic Disintegrator (100 W) at maximal energy. During this step the suspension 
was cooled on ice. (After a microscopical check it turned out that all cells were 
broken.) Next, the sonicated suspension was centrifuged for 20 min at 9000 X g. To 
the supernatant, S ml of the HEPES-TES buffer containing albumin, glucose 
6-phosphate and NADP was added. All manipulations were performed at 4 0 C and 
under sterile conditions. 
Salmonella / hepatocyte suspension assay 
The Salmonella/hepatocyte suspension assay was carried out as follows. In a 
shaking waterbath (210 r.p.m.), closed sterile vials (inner diameter 24 mm, height 55 
mm), each containing 387.5 μΐ of hepatocyte suspension (10 Χ 106 viable cells/ml), 
0.1 ml of an overnight-grown suspension of Salmonella typhimurium (about 1.5 X 109 
bact./ml) and 12.5 μΐ of a solution (in DMSO) of the compound under test, were 
incubated at 370C for 2 h. Next, each mixture was plated with a molten top agar 
containing only biotin (no histidine). 
The number of revenant colonies was counted after 48 h at 37° C. 
Salmonella / microsome mutagenicity plate assay 
The Salmonella/microsome plate assay was performed according to Ames et al. 
[1] with Salmonella typhimurium strains hisG46, TA1535, TA1538 and TA100. We 
used Oxoid nutrient broth instead of Difco nutrient broth [8]. Rat-liver S9 (9000 X g 
supernatant) fractions were prepared from untreated male Wistar rats according to 
Ames et al. [1]. S9 mix contained 0.1 ml S9 per ml. 
Salmonella/-disrupted hepatocyte suspension assay 
In this assay. Salmonella typhimurium and the compound under test were in­
cubated as described for the Salmonella/hepatocyte assay. However, instead of a 
suspension of hepatocytes, we added 387.5 μΐ of S9 mix prepared from an equal 
amount of isolated hepatocytes used in the parallel Salmonella/hepatocyte assay. In 
those experiments, hepatocytes and 39 were derived from the same rat liver. Molten 
top agars contained only biotin (no histidine). 
Results 
Influence of incubation time on the mutagenicity of benzidine 
In Fig. 1 the number of his^ revenant colonies of TA1538 is shown as a function 
of the incubation time of benzidine with rat hepatocytes. After about 2 h of 
incubation, the number of revenant colonies is maximal at the lowest concentration 
of benzidine tested (10 μΜ). There is only a slow increase in the number of his+ 
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Fig. 1. Effect of incubation tune on the mutagenicity of benzidine towards Salmonella lyphimunum 
TAI 538 in the presence of inuct hepatocytes Experimental details were as mentioned in Materials and 
methods. Mean values ±S.E.M. of deierannations m triplicate. 
revenant colonies after 2 h of incubation when benzidine is tested at a concentration 
of SO μΜ. At a benzidine concentration of 100 μΜ a linear correlation is found 
between the number of revertant colonies and the time of incubation. 
These results and our findings that the viability of the rat hepatocytes ranged 
between 69 and 79% after 2 h of incubation and between 42 and 68% after 4 h of 
incubation, led us to perform the incubations during 2-h periods. 
Revenants measured with the Salmonella/hepatocyte suspension and Salmonella/ 
microsome plate assay 
Aromatic amines 
The mutagenicities of benzidine. 2-acetylaminofluorene and 3,2'-dimethyl-4-
aminobiphenyl determined with Salmonella typhimurium TA1538 and TA100 are 
shown in Fig. 2a. No results are shown with Salmonella typhimurium TA1535, 
because none of these compounds was mutagenic towards this strain, either in the 
Salmonella/hepatocyte or in the Salmonella/ microsome assay. Mutagenicities of 
2-aniinoanthracene are plotted in Fig. 2b. 
These results indicate that the mutagenic properties of 2-AAF, benzidine and 
3,2'-dimethyl-4-aminobiphenyl towards strains TA1538 and TA100 can be detected 
in the Salmonella/microsome assay as well as in the Salmonella/hepatocyte assay. 
The same holds true for 2-aminoanthracene, as shown in Fig. 2b. 
Polycyclic aromatic hydrocarbons 
Mutagenicities of benzo(a]pyrene, 3-methylcholanthrene and 7,12-dim.ethylbe-
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Fig. 2. (a) Mutagenicities of 2-AAF, benzidine and S^'-dunethyM-aimnobiphenyl towards Sabnonella 
ryphimunum'TAlSìi and TAI00 in the Salmonella/bepatocyle suspension assay ( ) and in the 
SalmoneUa/microsome plate assay ( ). (b) Mutageniaties of 2-aniinoanthracene towards Salmonella 
lyphtmunum TA1535, TA1S38 and TAI00 in the Salmonella/bepatocyte suspension assay ( ) and 
in the Salmonella/miCTOSome plate assay ( ). Expenmental details were as menuoned in Materials 
and methods. Mean values of determinations in triplicate. 
nzanthracene in the Salmonella/bepatocyte and SalmoneUa/microsome assays are 
shown ш Fig. 3. The mutagenicities were determined with Salmonella typhimurium 
strains TA1535, TA1538 and TA100. Because of the limited solubility of 3-methyl-
cholanthrene, this compound was tested up to a concentration of only 25 μΜ in the 
Salmonella/bepatocyte assay and to an amount of 12S nmoles/plate in the 
SalmoneUa/microsome assay. 
The only compound that shows a clear mutagenic effect towards Salmonella 
typhimunum TA1S35 in the hepatocyte assay is 7,12-dimethylbenzanthracene, 
whereas none of these compounds is mutagenic towards this strain in the microsome 
assay (Fig. 3). Benzo[a]pyrene is the only compound that is mutagenic in the 
Salmonella/bepatocyte assay towards Salmonella typhimurium TA1538, while 3-
methylcholanthrene and 7,12-dimethylbenzanthracene are also mutagenic towards 
Salmonella typhimunum TA1S38 in the SalmoneUa/microsome assay. Fig. 3 also 
shows that benzot a ]pyrene, 3-methylcholanthrene and 7,12-dimethylbenzanthracene 
are mutagenic in both assays towards Salmonella typhimurium TAI 00. 7,12-Dimeth-
ylbenzanthracene appeared to be weakly mutagenic towards Salmonella typhimurium 
TAI S3 S in the hepatocyte but not mutagenic in the microsome assay. 
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N-Nitrosoanunes 
The mutagenicities of dimethylnitrosamine and diethylnitrosamine in the 
Salmonella/hepatocyte and SalmoneUa/microsome assays are shown in Fig. 4. 
Dimethylnitrosamine is mutagenic in the hepatocyte assay towards Salmonella 
typhimurium.strains hisG46, TA1S3S and TA100. In the SalmoneUa/microsome 
assay it is only mutagenic to a low extent towards Samonella typhimurium strain 
hisG46. Diethylnitrosamine is mutagenic only towards Salmonella typhimurium 
hisG46 in both assays.lt is mutagenic in both tests to a low extent 
We also tested the weakly carcinogenic dibutylnitrosamine in both assays. Be-
cause of its toxicity towards the bacteria it was tested up to 10 mM and 12.5 
μ moles/plate in the hepatocyte and in the microsome assay, respectively. No 
mutagenicity of dibutylnitrosamine was detected in strains hisG46, TA1S35 and 
TA100 in either assay. 
Other compounds 
Cyclophosphamide. The mutagenicity of cyclophosphamide in both the 
Salmonella/hepatocyte and the SalmoneUa/microsome assays towards Salmonella 
typhimurium TA1535 and TA100 is represented in Fig. 5. Cyclophosphamide is very 
mutagenic, towards Salmonella typhimurium TA1S35 and TA100 in both assays. The 
numbers of induced revenants are about the same. Cyclophosphamide was negative 
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Θ6 
in Salmonella typhimurium TA1538 in both assays. 
Hydroxyethylhydrcume. Clear mutagenic responses were obtained with 2-hy-
droxyethylhydrazine in the two test systems with either strain TA1535 or TA100 
(Fig. 5). Salmonella typhimurium TA1538 appeared to be insensitive for the muta­
genic activity of this compound. 
3'-Methyl-4-dimethylaminoazobenzene. 3'-Methy]-4-diinethylaminoazobenzene 
was weakly mutagenic towards Salmonella typhimurium TAI 00 in both assays. No 
mutagenicity of this compound was detected towards Salmonella typhimurium strains 
TA1535 andTA153^ in either assay. 
Comparison of mutagenicities with intact or disrupted hepatocytes 
Fig. 6 shows the mutagenicities of dimethylnitrosamine, benzidine and 2-
aminoanthracene towards Salmonella typhimurium strains hisG46, TA1S38 and 
TA1538, respectively. As the activating system, we used either a suspension of 
isolated rat hepatocytes or S9 derived from disrupted hepatocytes. All other experi­
mental conditions in both assays were the same, except for the addition of an 
NADPH-generating system to the S9 preparation. 
It was observed that dimethylnitrosamine and benzidine are much more muta­
genic after activation by intact hepatocytes than after activation by the S9 mix 
towards strains hisG46 and TA1538, respectively. 2-Aminoanthxacene was much 
more mutagenic towards TA1538 after activation with the S9 mix than after 
activation with intact hepatocytes. 
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Discussion 
Previous investigations have shown that isolated hepatocytes can be considered as 
valuable experimental models for the study of bioactivation of premutagenic com­
pounds, in particular those compounds that undergo complex reaction sequences 
[4,5]. The aim of the present study was to investigate whether a hepatocyte-mediated 
assay with Salmonella typhimunum is also useful for screening purposes. 
The present results show that, in a qualitative sense, there is a conformity between 
the responses to most compounds tested in the Salmonella/hepatocyte and 
Salmonella/microsome assays. On the other hand, for some compounds qualitative 
differences are observed. For instance benzidine and 2-AAF are mutagenic in the 
Salmonella/ hepatocyte but not in the Salmonella/microsome plate assay towards 
TAI00 (Fig. 2a). Further, dimethylnitrosamine, although not mutagenic towards 
TAI S 35 in the standard plate assay, shows an obvious mutagenic effect in the 
hepatocyte assay towards this strain (Fig. 4). Although one is apt to believe that 
these differences can be explained by the intactness of intracellular relationships, it 
must be excluded that other differences, inherent to the assay protocol, are also 
responsible. In the Salmonella/hepatocyte suspension assay, mutagenic activation 
b; rat-liver cells mainly occurs in a liquid medium. Otherwise, mutagenic activation 
in the Salmonella/microsome plate assay occurs in the agar medium. 
To be sure that the qualitative differences observed in mutagenicity are not due to 
different experimental conditions but are the result of different forms of the 
activating system, we compared the mutagenicities of dimethylnitrosamine, be­
nzidine and 2-aminoanthracene in the Salmonella/hepatocyte suspension assay and 
a Salmonella/ disrupted hepatocyte suspension assay. These compounds were chosen 
because they showed substantial differences when tested in the Salmonella/ 
hepatocyte suspension or Salmonella/microsome plate assay. The S9 mix used in 
these experiments was prepared from an equal amount of isolated hepatocytes from 
the same rat as used in the parallel Salmonella/hepatocyte assay. In this way we 
were able to.study solely the effect of cellular integrity. The results indicate that the 
higher mutagenicity values of dimethylnitrosamine and benzidine in the Salmonella/ 
hepatocyte assay can be ascribed to the application of intact rat hepatocytes as the 
metabolic factor (Fig. 6). On the other hand, the higher mutagenicity of 2-
aminoanthracene as found in the Salmonella/microsome plate assay is the conse­
quence of the use of S9 mix. 
The present results of this comparative study suggest that the Salmonella/ 
hepatocyte assay may be useful in routine testing of mutagens. This is strongly 
supported by the relatively high mutagenic activity of dimethylnitrosamine after 
metabolism by the intact hepatocytes. Although this compound is weakly mutagenic 
in the Salmonella/microsome assay [10], several investigators have described its 
substantial mutagenicity in assays in vivo [7,11]. On the basis of our previous 
comparison of mutagenicities of 4-aminobiphenyl and benzidine in assays in vitro 
with either hepatocytes or microsomal preparations, and in the intrasanguineous 
host-mediated assay, it is suggested that the metabolic activation by intact hepato­
cytes reflects the complex biotransformation in vivo [3]. Many false-positive and 
ΘΘ 
false-negative results in carcinogenicity tests in vitro are bebeved to be explainable 
by inadequacies of the metabolic activation system applied in vitro [9]. Therefore, we 
support the recommendation that tests with intact cell metabolism, as described 
above, should be included in a battery for screening of carcinogens in vitro [13]. 
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SUMMARY 
The mutagenicity of urine from rats treated with benzidine or 5 other 
arylamines (0.25 mmol/kg; i.p.) was studied using the Ames-assay. It was 
found that samples of urine collected for 24 h after the administration of 
the carcinogens, benzidine, 4-aminobiphenyl and 2-ammonaphthalene, 
showed significantly mutagenic activity, whereas no mutagenicity was ob-
served in urine after treatment with 3,3'-5,5'-tetramethylbenzidine, 2-amino-
biphenyl and 1-aminonaphthalene. 
Mutagenic activities were dependent on the use of either hepatic S-9 Mix 
or cytosol as the activating enzyme preparation. The addition of /3-glucuroni-
dase enhanced mutagenicity, except for 2-ammonaphthalene. 
The appearance of mutagens in urine was studied at varying doses of 
benzidine and at different time-intervals after the administration. The 
different excretion patterns found after the activation either with S-9 Mix 
or with cytosolic enzyme(s) suggest the presence in urine of different types 
of mutagenic products. 
INTRODUCTION 
Durston and Ames [1] described a simple method for the detection of 
mutagens in urine. They demonstrated mutagenic activity in urine of rats 
that were treated with relatively low doses of 2-acetylaminofluorene. Inde-
pendently, Commoner et al. [2] have also shown the presence of mutagenic 
metabolites in urine of rats fed on diets containing the carcinogens 2-acetyl-
aminofluorene and dimethylaminoazobenzene. It was proposed that this 
method may have great potential for the screening of human urine to detect 
exposure to environmental carcinogenic agents. 
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In recent studies the presence of mutagens was found in urine from 
cigarette smokers [3,4]. Mutagens were also demonstrated in urine of 
patients having received therapeutic doses of the trichomonacide metroni­
dazole or cytostatics like cyclophosphamide [5—7]. It is remarkable that 
nurses handling several cytostatic drugs in oncological units also exhibited 
mutagenicity in concentrates of their urine [8] . These mutagenic activities, 
however, were much lower than those found in the urine of patients treated 
with these drugs. 
In the present study an effort has been made to further validate the urine 
mutagenicity test. We investigated the appearance of mutagens in the urine 
of rats treated with aromatic amines, some of which are carcinogenic [9,10]. 
It is known that a great number of metabolites of the carcinogenic ary lamines 
appear in the urine of treated animals [11,12]. Since it is unlikely that these 
metabolites are excreted at the same rate, attention was paid to procedural 
aspects, like the time of urine sampling. In addition, the need for metabolic 
activation of the urinary mutagens was studied. 
MATERIALS AND METHODS 
Chemicals 
Benzidine, 1-aminonaphthalene and D-glucose were purchased from Merck 
(Darmstadt, F.R.G.); 4-aminobiphenyl and 2-aminobiphenyl from Aldrich 
Europe (Beerse, Belgium). Bacterial ^-glucuronidase, 3,3'-5,5'-tetramethyl-
benzidine, D-biotin and L-histidine-HCl were obtained from Sigma (St. Louis, 
U.S.A.); amberlite, type XAD-2 from Serva (Heidelberg, F.R.G.) and nicoti­
namide adenine dinucleotide phosphate (NADP) disodium salt and glucose 
6-phosphate G-6-P disodium salt from Boehringer (Mannheim, F.R.G.). 
Purified agar and nutrient broth were purchased from Difco Laboratories 
(Detroit, U.S.A.)." 2-Aminonaphthalene was purchased from Fluka (Buchs, 
Switzerland), saccharo-l,4-lactone from Calbiochem (Los Angeles, U.S.A.) 
and citric acid monohydrate from J.T. Baker Chemicals (Deventer, The 
Netherlands). All other chemicals used were of highest purity obtainable. 
Animals 
Male Wistar rats weighing about 200 g were purchased from TNO (Rijswijk, 
The Netherlands). The animals were housed individually in stainless steel 
metabolism cages, designed for the separate collection of urine and feces. 
The rats had free access to water and food (Hope Farms, V/oerden, The 
Netherlands). Aromatic amines, dissolved or suspended in olive oil (under 
nitrogen to prevent oxidation) were injected intraperitoneally. 
Urine samples were collected for 24 h, unless stated otherwise, and 
stored at — 20oC until assayed. Before they were assayed, the individual 
samples were completed to 15 ml and sterilized by filtration through 0.2 μ m 
membrane filters. 
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Mutagenicity testing 
Mutagenicity of the urine samples was determined using the Salmonella 
typhimurium strains TA 1538 and TA 100 [13]. 0.1 ml of a nearly full-
grown suspension of the bacteria (2 X 10' bact./ml) was added to the 
topagar, containing 0.3 ml of diluted urine, and was supplied with varying 
volumes of an activating enzyme system. As indicated elsewhere, the acti­
vating enzyme system consisted of one or more of the following components: 
(a) 0.5 ml S-9 Mix, prepared according to Ames et al. [13], containing 
50 μΐ hepatic 9000 g supernatant from phénobarbital induced rats and a 
NADPH-generating system. 
(b) 0.4 ml liver cytosol, equivalent to 100 mg fresh liver, derived from 
non-induced rats. 
(c) 0.1 ml of a sterile β-glucuronidase solution (6500 U/ml). 
In one experiment urine samples were collected every 5 h during a 50 h 
period, they were stored at — 20oC until assayed. Each 5-h sample was put 
through a column with a 4-cm3 bed volume of amberlite XAD-2, washed 
with 1.5 ml of water to remove histidine [3] and the adsorbed material was 
eluted with 10 ml of aceton. The eluate was evaporated to dryness under 
nitrogen at 60oC and the residue was dissolved in 0.85 ml of dimethyl-
sulphoxide. 0.1 ml of this solution was added per plate and assayed for 
mutagenicity with the Salmonella typhimurium tester strain TA 1538 in 
the presence of an activating enzyme system. 
RESULTS 
Effect of various activating systems. 
Several combinations of activating enzymes were studied to detect muta­
genic activity in urine of rats treated with benzidine. The results are sum­
marized in Table I. It can be seen that in the absence of an activating system 
no substantial mutagenicity was found. The addition of the conventionally 
used microsomal oxidizing, S-9 Mix, resulted in the appearance of a great 
number of revertant colonies. Further, addition of β -glucuronidase in com­
bination with S-9 Mix gave an increase of about 40%. This may indicate the 
presence in urine of glucuronidated benzidine metabolites, which after 
hydrolysis, can be activated through microsomal oxidation to the proximate 
mutagens. Addition of saccharo-l,4-lactone, a specific inhibitor of the 
^-glucuronidase activity [14], completely counteracted the enhancement of 
mutagenicity in the presence of ^-glucuronidase but did not significantly 
influence the activation by the S-9 Mix alone. 
On the other hand, as is shown in Table I, addition of a hepatic cytosol 
fraction resulted in the appearance of a considerable number of revertant 
colonies, which increased about 10-fold by the action of /3-glucuronidase. 
Addition of saccharo-l,4-lactone had no influence on the activating capacity 
of the cytosol fraction. Further, it is shown that the action of (3-glucuroni­
dase alone was insufficient to form the proximate mutagens. 
When the NADPH-generating system (which delivers the essential cofactor 
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TABLE I 
EFFECT OF DIFFERENT ACTIVATING SYSTEMS ON MUTAGENICITY OF URINE 
FROM BENZIDINE-TREATED RATS" DETECTED WITH S. TYPHIMURIUM TA 1538 
Additions0 ReverUnte/plateb 
None 0-glucuron- Saccharo-1,4- |3-glucuronidase + 
idase lactone saccharo-l ,4-lactone 
S-9 Mix 4430 ± 340 6200 ± 510 4760 ± 140 3730 ± 515 
S-9 Mix 112 ± 4 524 ± 22 
without 
NADP/G-6-P 
Cytosol 595 ± 33 6500 ± 220 744 ± 48 
None 59 ± 3 76 t 2 
Spontaneous 42 ± 5 
aRats received 250 дтоі/ке i.p., 24-h urine was diluted to 15 ml. Samples of 0.3 ml were 
plated in the presence of 0.1 ml TA 1538 suspension (2X 10' bact./ml). 
bMean values (±S.E.M.) of 3 measurements of the same urine. 
'Additions to the topagar (per plate): S-9 Mix, 0.5 ml; Cytosol, 0.4 ml of 105 000 g 
supernatant from 25% rat liver homogenate; β-glucuronidase, 650 units dissolved in 0.1 ml 
water; saccharo-l ,4-lactone, final cone. 3 mM. 
for the monooxygenase activity) was left out of the S-9 mixture, the acti­
vating capacity disappeared almost totally. It is therefore excluded that the 
activation which is brought about by liver cytosol, represents an artifact due 
to contamination by microsomal particles. 
Influence of the dose of benzidine 
Rats were injected intraperitoneally with increasing amounts of benzidine. 
Twenty-four-hour urine samples were collected and tested for mutagenicity 
with S-9 Mix or liver cytosol, either with or without the addition of 0-gluc-
uronidase. The number of revertant colonies/plate was plotted as a function 
of the dose of benzidine (Fig. la,b). It can be seen in Fig. l a that the relative 
increase in mutagenicity caused by the action of ^-glucuronidase is highest 
at low doses of benzidine. This may indicate that at the lower doses a greater 
fraction is excreted as glucuronides that, after being hydrolysed, need an 
oxidative activation to become proximate mutagens. Possibly, at increasing 
benzidine concentrations the glucuronyl transferases or the mechanisms in­
volved in the transport of the glucuronides become saturated. At higher doses 
(above 0.1 mmol/kg) the graphs of Fig. la show a reasonably linear relation­
ship between urinary mutagenicity and dosage. In contrast, the urinary muta­
genicity that results from a combined activation with ^-glucuronidase and 
cytosol enzymes, is independent of the dose at high doses of benzidine 
(Fig. lb) . 
Time course of the appearance of mutagens in urine 
The excretion of mutagenic products in urine of rats after the adminis-
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Fig. 1. (a,b) Influence of the dose of benzidine on the urinary mutagenicity, as detected 
with different activating enzyme preparations. Experimental details were as mentioned in 
Materials and Methods. 
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Fig. 2. (a,b,c) Time course of the appearance of mutagens in urine, as detected with 
different activating enzyme preparations. Experimental details were as mentioned in 
Materials and Methods. 
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TABLE II (a) 
MUTAGENIC ACTIVITY IN URINE OF RATS TREATED WITH SEVERAL ARYLAMINES 
о 
о 
Treatmentb 
Benzidine 
3,3'-5,5'-Tetra-
methylbenzidine 
4-Aminobiphenyl 
2-Aininobiphenyl 
2 - Aminonaphthalene 
1 -Aminonaphthalene 
Number oí his' μ revertants/plate" 
Urine and tester strain ТА 1538 added to the topagar with:c 
— 
66 t 6 
46 t 8 
47 ± 2 
42 t 2 
46 t 3 
44 ± 2 
β -glucuron­
idase 
86 ± 7 
47 ± 9 
49 ± 3 
51 ± 10 
45 * 8 
47 ± 2 
S-9 Mix 
4200 ± 1 2 0 
47 ± 4 
100 ± 10 
51 t 5 
85 ± 6 
61 ± 4 
S-9 Mix + 
|3-glucuron­
idase 
6200 ± 100 
46 ± 3 
189 ± 14 
58 ± 7 
80 ± 7 
50 ± 6 
Cytosol 
480 ± 31 
35 ± 4 
55 ± 6 
48 ± 6 
42 ± 6 
43 ± 2 
Cytosol + 
β -glucuron­
idase 
7200 ± 320 
32 ± 1 
277 ± 8 
49 ± 5 
36 ± 3 
45 ± 4 
aMean values (± S.E.M.) of 3 measurements of the same urine. 
bRats received 250 Mmol/kg i.p., 24-h urine was diluted to 15 ml. Samples of 0.3 ml were plated in the presence of 0.1 ml ТА 1538 
suspension (2x10* bact./ml). 
cAdditions to the topagar (per plate): S-9 Mix, 0.5 ml; cytosol, 0.4 ml of 105 000 g supernatant from 25% rat liver homogenate; (3-
glucuronidase, 650 units dissolved in 0.1 ml water. 
TABLE Π (b) 
MUTAGENIC ACTIVITY IN URINE OF RATS TREATED WITH SEVERAL ARYLAMINES 
Treatmentb 
Benzidine 
3,3'-5,5'-Tetra-
methylbenzidine 
4-Aimnobiphenyl 
2-Aminobiphenyl 
2 -Aminonaphthalene 
1 -Aminonaphthalene 
Number of his1 > revertants/plate" 
Urine and tester strain TA 100 added to the topagai with:0 
— 
212 ± 12 
188 ± 2 
199 ± 14 
220 ± 11 
181 ± 14 
222 ± 4 
β -glucuron­
idase 
281 ± 10 
240 ± 11 
260 ± 23 
239 ± 10 
230 ± 4 
234 ± 4 
S-9 Mix 
7040 ± 200 
210 ± 14 
444 ι 13 
248 i 16 
782 ± 14 
230 ± 16 
S-9 Mix + 
β -glucuron­
idase 
7300 ± 630 
208 ± 7 
1210 ± 45 
293 ± 17 
850 ± 47 
234 ± 14 
Cytosol 
424 ± 27 
204 ± 5 
201 ± 5 
192 ± 7 
199 ± 17 
213 ± 16 
Cytosol + 
β -glucuron­
idase 
7400 ± 320 
241 ± 16 
822 ± 27 
216 ± 9 
219 ± 31 
252 ± 9 
BMean values (± S.E.M.) of 3 measurements of the same urine. 
bRats received 250 Mmol/kg i.p., 24-h urine was diluted to 15 ml. Samples of 0.3 ml were plated in the presence of 0.1 ml TA 100 
suspension (2x10' bact./ml). 
cAdditions to the topagar (per {date): S-9 Mix, 0.5 ml; cytosol, 0.4 ml of 105 000 g supernatant from 25% rat liver homogenate; β-
glucuronidase, 650 units dissolved in 0.1 ml water. 
tration of benzidine was studied as a function of the time. Thus benzidine, 
0.25 mmol/kg, was injected i.p. and urine samples were collected at intervals 
of 5 h. The urine samples were concentrated on a XAD-2 column and tested 
for mutagenicity as mentioned above. 
Comparison of the graphs in Figs. 2a and b reveals that the mutagenic pro­
ducts, which can be activated with S-9 Mix, appeared earlier in the urine 
than those which exert their mutagenicity after activation with liver cytosol 
or combined β -glucuronidase and liver cytosol. 
The volumes of the urine portions consecutively produced during the 5-h 
periods are depicted in Fig. 2c. It is apparent that the excretion patterns of 
the urinary mutagens are independent of the quantities of urine produced in 
each period. 
Comparison of six aromatic amines 
The mutagenic activity in urine of rats that were treated with equal doses 
of different aromatic amines (0.25 mmol/kg; i.p.) was assayed in 24 h urine 
samples, using the bacterial strains TA 1538 and TA 100. Three pairs of 
structurally related arylamines were studied. Both S-9 Mix and hepatic 
с tosol, either with or without the addition of ^-glucuronidase, were used 
for the activation of mutagenic compounds. The results are given in Table II. 
No mutagenic activity was detected with ТА 100 and ТА 1538 in the urine 
of rats treated with the compounds: 3,3'-5,5'-tetramethylbenzicime, 2-amino-
biphenyl and 1-aminonaphthalene. However, urine of rats treated with the 
carcinogenic structure analogues, benzidine, 4-aminobiphenyl and 2-amino-
naphthalene, showed significant mutagenic values. The urine of animals 
given 4-aminobiphenyl or 2-ammonaphthalene was much less mutagenic than 
the urine from the benzidine-treated rats. Further, it was found that, in con­
trast with benzidine and 4-aminobiphenyl, administration of 2-ammonaph­
thalene did not lead to urinary excretion of product(s) that can be converted 
to active mutagenes) by the action of cytosolic enzymes. 
DISCUSSION 
These results clearly demonstrate that the administration to rats of benzi­
dine or some other carcinogenic amines results in the excretion of certain pro­
ducts in the urine that are not directly mutagenic to Salmonella typhimurium, 
but become mutagenic after the addition of activating enzymes. Although 
the excretion products following the administration of benzidine to rats have 
not been identified in the present study, there are good reasons to assume 
that these are for the most part metabolic products of benzidine and not 
benzidine itself. For instance, the total mutagenic activity of rat urine col­
lected for 2 days after the injection of a certain dose of benzidine, greatly 
surpasses the mutagenic potential of the same amount of benzidine when 
tested with the same bacterial strains in vitro, using metabolic activation 
with S-9 Mix. 
It was further shown that different enzymes can be used for the metabolic 
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activation of the urinary products, namely microsomal monooxygenase or 
cytoplasmic enzyme(s), either with or without the concomitant application 
of ^-glucuronidase. 
The increase in mutagenicity by the presence of β -glucuronidase indicates 
that part of the mutagenic metabolites appear in the urine as glucuronides. 
This is in accordance with the findings of Durston and Ames [1] and Com­
moner et al. [2] who detected mutagens in the urine of rats fed 2-AAF. 
Durston and Ames [1] detected most mutagenicity when urine was incubated 
with S-9 Mix in the presence of ^-glucuronidase. Commoner et al. [2] detec­
ted most mutagenicity with S-9 Mix in an ether extract of urine preincubated 
with β -glucuronidase and Taka-diastase. 
We now present evidence that not only the action of the oxidative enzymes 
present in the S-9 Mix can lead to the formation of mutagenic products, but 
the cytosolic liver fraction also appears to contain enzyme(s) capable of 
converting certain urinary products of benzidine into proximate mutagens. 
The data depicted in Figs, la and b suggest that the dose-dependency of 
the urinary mutagenicity resulting from an activation with β -glucuronidase 
and S-9 Mix differs from that found after treatment of the urine samples 
with ^-glucuronidase and liver cytosol. 
From Fig. 2 it may be concluded that the metabolites that were activated 
with S-9 Mix appeared in urine earlier after application of benzidine than 
those activated with cytosol. Almost all detectable mutagens in urine were 
excreted within 24 h elfter application. Kellner et al. [15] found that after 
intravenous administration of 0.2 mg [14C]benzidine/kg body wt to male 
Wistar rats 17% of the radioactivity appeared in urine. The urinary excretion 
was almost completed within 1 day. This is in good agreement with our 
results. 
From the results shown in Figs. 1 and 2 it may be concluded that treat­
ment of rats with benzidine results in the appearance in urine of different 
classes of compounds, some of which require oxidative, and others non-
oxidative metabolism to produce mutagenic activity. 
One of the enzymes present in rat liver cytosol that could be responsible 
for the activation of urinary metabolites is Λ/,Ο-acyltransferase. N-Hydroxydi-
acetylbenzidine that has weak mutagenic properties by itself, was found to 
be activated by the action of iV.O-acyltransferase [16]. This gives rise to the 
presumption that the mutagens we detected with the aid of cytosol are 
N-hydroxyacetylderivatives of benzidine and 4-aminobiphenyl, which are 
mainly excreted in urine as glucuronides. ΛΓ-Hydroxyacetylderivatives of 
benzidine were found in the urine of people fed benzidine [17]. The urinary 
metabolite of 4-aminobiphenyl detected as mutagen after activation with 
cytosol in the presence of β -glucuronidase might be the glucuronide of N-
hydroxy-4-acetylaminobiphenyl, which was identified by Miller et al. [11] 
to be a metabolite in rat urine after treatment with 4-aminobiphenyl. 
From a comparison of mutagenic activities in urine of rats treated with 
different aromatic amines (Table II), it appears that only those compounds 
which have obvious carcinogenic potencies give rise to the excretion of muta-
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gens in urine. The mutagenic activity of urine from rats given benzidine was 
much higher than that in the urine from 4-aminobiphenyl treated rats. This 
is remarkable because 4-aminobiphenyl appeared to be more mutagenic 
when tested in vitro with TA 1538 and TA 100 using rat liver S-9 Mix as the 
activating system. Further studies are in progress now to explain this discre-
pancy. 
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SUMMARY 
Urinary metabolites of rats treated with benzidine and some other 
genotoxic aromatic amines became mutagenic in the Ames assay after 
activation with liver cytosol from rat, mouse and guinea pig. Most of the 
mutagenic metabolites appeared in urine as glucuronides. Strong evidence 
was found that N, O-acyltransferase is responsible for the mutagenic 
activation by rat liver cytosol. The inhibitory effect of paraoxon and 
sodium fluoride indicates that the activation by mouse liver cytosol is 
due to the action of deacetylase. Mutagenic activation by guinea pig liver 
cytosol seemed to be mediated in part by deacetylase. The metabolite 
activated by these enzymes most likely is a glucuro ni dated, N-acetylated, 
N-hydroxylated product. 
INTRODUCTION 
In our previous work it was shown that after treatment of adult male 
Wistar rats with some aromatic amines, mutagens could be detected in 
their urine, using various activating systems in the Ames assay [1]. It was 
remarkable that the use of rat liver cytosol as an activating system in testing 
urine of benzidine treated rats, caused a considerable number of revertant 
colonies. In the presence of /3-glucuronidase the mutagenic activation was 
enhanced, whereas the action of ^-glucuronidase alone was insufficient to 
Abbreviations: G-6-P, glucose 6-phosphate; NADPH, nicotinamide adenine dinucleotide 
phosphate;TLC, thin-layer chromatography. 
105 
form the proximate mutagens. This activation was suggested to be non-
oxidative. 
Two possibilities of non-oxidative enzymatic conversion of metabolites of 
aromatic amines which enhance mutagenicity for Salmonella typhimurium 
have been described. First there is an enzymatic deacetylation reaction 
which can be inhibited by paraoxon and sodium fluoride [2]. For example 
yV-hydroxy-2-acetamidofluorene has been shown to be many times less 
mutagenic than its deacetylated product iV-hydroxy-2-aminofluorene [3,4]. 
The second enzymatic reaction that gives rise to an increase in mutagenicity 
of metabolites of aromatic amines is a reaction mediated by ΛΓ,Ο-acyltrans-
ferase. This enzyme is able to transfer an 7V-acetyl group from an N-acetyi-N-
arylhydroxylamine to the oxygen to form the O-acetyl derivative of the 
JV-arylhydroxylamine. Due to the action of this enzyme in the presence of 
7V-hydroxy-2-acetamidofluorene or ЛГ-hydroxy-diacetylbenzidine an increased 
mutagenicity to Salmonella typhimurium was detected [5,6]. In the 
investigation presented in this paper we studied the nature of the mutagenic 
activation of rat urinary benzidine metabolites by liver cytosol from rats, 
mice and guinea pigs. In addition we present data about some other aromatic 
am nes which can be detected as mutagens in urine from rats after activation 
by liver cytosol. 
MATERIALS AND METHODS 
Chemicals 
Benzidine, sodium fluoride and ammoniumsulfate were purchased from 
Merck (Darmstadt, F.R.G.). 2-Acetamidofluorene, 2-aminofluorene, 2-
aminoanthracene, 4-aminobiphenyl and diethyl-p-nitrophenylphosphate 
(paraoxon) were from Aldrich Europe (Beerse, Belgium). 2,7-Diaminonaph-
thalene was obtained from ICN Pharmaceuticals, Inc., Sephadex G-100 from 
Pharmacia (Uppsala, Sweden). Bacterial β -glucuronidase, D-biotin and 
L-histidine-HCl, were obtained from Sigma (St. Louis, U.S.A.). Amberlite, 
type XAD-2 was purchased from Serva (Heidelberg, F.R.G.). Nicotinamide 
adenine dinucleotide phosphate (NADP) disodium salt and glucose 6-phos-
phate (G-6-P) disodium salt were purchased from Boehringer (Mannheim, 
F.R.G.). Purified agar was from Difco Laboratories, nutrient broth No. 2 
from Oxoid Ltd. (Basingstoke, England) and citric acid mono hydrate from 
J.T. Baker Chemicals (Deventer, The Netherlands). All other chemicals 
used were of highest purity obtainable. 
Animals 
Male Wistar rats weighing about 200 g were purchased from TNO 
(Rijswijk, The Netherlands). The animals were housed individually in 
stainless steel metabolism cages, designed for the separate collection of 
urine and feces. The rats had free access to water and food (Hope Farms, 
Woerden, The Netherlands). Aromatic amines, dissolved or suspended in 
olive oil (under nitrogen to prevent oxidation) were injected intraperi-
toneally (250 Mmol/kg). 
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Urine samples were collected for 24 h and stored at — 20oC until assayed. 
Before testing, the individual samples were completed to 15 ml and 
sterilized by filtration through 0.2-дт membrane filters. 
Mutagenicity testing 
Mutagenicity of the urine samples was determined using the Salmonella 
typhimurium strains TAI538 and TA100 [7]. 0.1 ml of an overnight grown 
suspension of the bacteria (±1.5 X 109 bact./ml) was added to the topagar, 
containing 0.1 ml of diluted urine, and was supplied with an enzyme system. 
Unless otherwise indicated, this enzyme system consisted of 0.4 ml liver 
cytosol, equivalent to 100 mg fresh liver, derived from non-induced male 
Wistar rats, male Swiss mice or male albino guinea pigs, and/or 0.1 ml of a 
sterile j3-glucuronidase solution (1500 U/ml). 
Effect of paraoxon and sodium fluoride 
In the study of the effects of paraoxon and sodium fluoride on the 
mutagenic activation of urine of benzidine treated rats by liver cytosol from 
rats, mice and guinea pigs, we used the method described by Okuno et al. 
[8] with some modifications: 0.4 ml liver cytosol was 15 min preincubated 
at 370C with various paraoxon/sodium fluoride concentrations and then 
mixed with 0.1 ml of urine of a benzidine treated rat, 0.1 ml of a bacteria 
suspension (TA1538) and 0.1 ml of a ^-glucuronidase solution (1500 Units/ 
ml). This mixture was further incubated at 37°C for 20 min. After addition 
of 2 ml of topagar the mixture was plated. 
Identification of the activating enzyme in rat liver cytosol 
Partial purification of the activating enzyme was applied to 4 g of wet rat 
liver material following the method described by King [9] with some slight 
modifications. We used a column of Sephadex G-100 (3 X100 cm) and a 
flowrate of 3.7 ml/h. 0.7 ml fractions were collected. The UV-absorbance of 
the eluate was monitored continuously at 254 nm. 
Activating capacity was determined in the Ames assay by adding 0.1 ml of 
the filter sterilized fractions to 0.1 ml of urine of benzidine treated rats, 
0.1 ml of a bacterial suspension (TAI 538) and 0.1 ml of a 0-glucuronidase 
solution (1500 U/ml). 
Mutagenicity testing of benzidine metabolites separated by thin-layer 
chromatography (TLC) 
A 24-h urine sample of a benzidine treated rat was applied to a column 
with a 4 cm3 bed volume of Amberlite XAD-2. Next the adsorbed material 
was eluted with 10 ml of acetone. The eluate was evaporated to dryness 
under nitrogen at 60oC and the residue was dissolved in 0.6 ml of ethanol. 
Eighteen samples of 12 μΐ of this solution were applied to TLC-plates. Glass 
plates (5 X 20 cm) coated with a 0.25-mm thick layer of silicagel 60 F254 
obtained from Merck (Darmstadt, F.R.G.) were employed. Butanol/acetic 
acid/water ( 4 : 1 : 1 ; v/v) was used as solvent system. Metabolites on TLC-
plates were visualized under UV-light of 254 nm. Separated metabolites were 
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scraped off. Eighteen corresponding metabolite fractions were combined and 
dissolved in 2.4 ml of dunethylsulphoxide. Sihcagel rests were removed by 
centnfligation. 0.1 ml of this solution was added per plate and assayed for 
mutagenicity with the Salmonella typhimunum tester strain TA1538 in the 
presence of an activating system. 
RESULTS 
Mutagenic activation of urine of benzidine treated rats with liver cytosol 
from rats, mice or guinea pigs 
The effect of liver cytosol from rats, mice or guinea pigs on the mutagenic 
activity in unne of rats treated with benzidine was studied. The results are 
shown in Table I. It can be seen that in the absence of cytosol no substantial 
mutagenicity was found. Addition of hepatic cytosol from rats or guinea pigs 
resulted in an enhancement in the number of revertant colonies. A number 
that increased many times by the addition of ^-glucuronidase. Mutagenicity 
was hardly detectable in the presence of mouse liver cytosol, whereas after 
the addition of /^-glucuronidase an obvious mutagenic activity was observed. 
β-Γ lucuronidase alone did not result m a remarkable number of revertants. 
Effect of paraoxon and sodium fluoride on the deacetylatmg enzymes in 
liver cytosol f ют rat, mouse or guinea pig 
Figure 1 shows the effect of paraoxon and sodium fluoride on the muta­
genic activation of urinary benzidine metabolites by liver cytosol from rats, 
mice or guinea pigs. It is shown that the activation by rat liver cytosol was 
not counteracted by paraoxon or sodium fluoride, whereas the activation by 
TABLE I 
EFFECT OF LIVER CYTOSOL FROM RAT, MOUSE AND GUINEA PIG ON MUTA­
GENICITY OF URINE FROM BENZIDINE TREATED RATS" DETECTED WITH 
SALMONELLA TYPHIMURlUMTAlbSB 
Additions0 Revertants/plateb 
None β Glucuronidase 
None 7 ± 1 18 ± 1 
Rat liver cytosol 80 ± 7 854 ± 9 
Mouse liver cytosol 1 6 ± 1 139 ± 5 
Guinea pig liver cytosol 39 ± 6 7 0 1 ± 1 6 
Background 7 ± 1 
a
 Rats received 250 /umol/kg ι ρ , 24 h unne was diluted to 15 ml Samples of 0.1 ml were 
plated in the presence of 0 1 ml TA1538 suspension (1 5 X 10' bact /ml) 
ь
 Mean values (±S Ε M ) of 3 measurements of the same urine 
c
 Additions to the topagar (per plate) cytosol, 0 4 ml of 105 000 g supernatant from 
2o% liver homogenate, (3 glucuronidase, 150 units dissolved in 0 1 ml water 
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concentrat ion of paraoxon ( m M ) 
concentrat ion of Na F ( M ) 
Fig. 1. Influence of paraoxon and sodium fluoride (broken line) on the cytosol mediated 
mutagenicity of urine of benzidine treated rats. liver cytosol from rats (Λ), mice (B) and 
guinea pigs (C) was used in the presence of ^-glucuronidase. Experimental details were as 
mentioned in Materials and Methods. 
mouse liver cytosol almost completely disappeared in the presence of 
paraoxon or sodium fluoride. The inhibition of the activation by guinea pig 
liver cytosol seems to have an intermediate character. 
The activating rat liver cytosolic enzyme 
A deacetylation reaction that can be inhibited by paraoxon and sodium 
fluoride did not seem to play a role in mutagenic activation of urinary 
benzidine metabolites by rat liver cytosol. The question arises whether an 
activation by N,O-acyltransferase is involved. In order to clarify this question 
we subjected the rat liver cytosol to gel filtration chromatography by using 
the same method as King applied for purification of N,O-acyltransferase 
[9]. We did not measure N,O-acyltransferase activity directly, but tested the 
fractions only on their mutagenic activating capabilities. It was interesting 
to see that the fractions having the highest acyltransferase activity as 
measured by King corresponded with those fractions in our study having the 
highest mutagenic activating capability. It is tempting therefore to conclude 
that the mutagenic activation is due to the action of N, O-acyltransferase 
(Fig. 2). 
Cytosolic activation of urinary benzidine metabolites separated by thin-layer 
chromatography (TLC) 
Results of the cytosolic activation of benzidine metabolites, separated by 
TLC, into mutagens are shown in Table II. Although the activation by rat 
liver cytosol and mouse liver cytosol is different, as can be seen from Fig. 1, 
the metabolite they activate is the same. 
It was noted that no mutagenic effects were detected with liver cytosol 
without further addition of ^-glucuronidase. Presumably, the (pre)mutagenic 
metabolite excreted into the urine is a glucuronide. 
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TABLE II 
MUTAGENIC ACTIVATION OF BENZIDINE METABOLITES SEPARATED BY 
THIN-LAYER CHROMATOGRAPHY 
RF value 
0 (origin) 
0.32 
0.37 
0.41 
0.49 
0.54 
0.63 
Background 
Number of Лі revertants/plate" 
TLC-fractionsb and tester strain 
Rat liver Rat liver 
cytosol cytosol + 
^•glucuronidase 
3± 1 3 ± 1 
4 ± 1 25± 8 
6± 3 310 ± 28 
14 ± 3 23 ± 2 
21 ± 4 23 ± 5 
20 ± 3 20 ± 5 
11 ± 4 12 ± 4 
5 ± 1 
1 
TAI538 added to the topagar with:c 
mouse liver 
cytosol + 
^-glucuronidase 
4± 1 
4 * 1 
188 ± 20 
13 ± 2 
18 ± 4 
15± 1 
11 ± 2 
Guinea pig liver 
cytosol + 
^-glucuronidase 
7 ± 1 
19 ± 1 
256 ± 38 
20 ± 2 
22 ± 2 
31 * 4 
20 ± 2 
a
 Mean values (±S.E.M.) of 3 measurements of the same urine. 
b
 Details about preparation of different TLC-fractions are mentioned in Materials and 
Methods. 
c
 Additions to the topagar (per plate): cytosol, 0.4 ml of 105 000 g supernatant from 
25% liver homogenate; ^ -glucuronidase, 150 units dissolved in 0.1 ml water. 
Comparison of benzidine with some other aromatic amines 
Five other aromatic amines besides benzidine, given to rats at a dose of 
0.25 mmol/kg, were found to result in the appearance of mutagens 
detectable after addition of liver cytosol. Mutagenic activities of urine of 
treated rats after addition of liver cytosol from rats, mice or guinea pigs 
are given in Table Ilia and Illb for the tester strain TAI 538 and TA100, 
respectively. In accordance with the findings shown in Fig. 1 these results 
suggest that cytosol liver fractions from rats, mice and guinea pigs contain 
different activating enzyme systems. Mutagenic urinary metabolites from 
rats given benzidine are well detectable after activation with liver cytosol 
from rats or guinea pigs in the presence of j3-glucuronidase, whereas they 
also might be detected with liver cytosol from mice in the presence of 
j3-glucuronidase. Mutagenic activity in the urine of 4-aminobiphenyl treated 
rats was poorly detectable whatever liver cytosol was used for the activation. 
Treatment of rats with 2-aminofluorene or 2-acetamidofluorene resulted in 
the appearance of urinary mutagens which were detectable after activation 
with liver cytosol in the presence of /^-glucuronidase. In this respect liver 
cytosol from guinea pig was more active than that from rat or mouse. In 
the case of 2-aminoanthracene detection of mutagenic activity is possible 
after activation with liver cytosol from guinea pigs in the presence of 
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TABLE III (a) 
MUTAGENIC ACTIVATION OF URINE OF RATS TREATED WITH ARYLAMINES BY LIVER CYTOSOL FROM RAT, MOUSE OR 
GUINEA PIG 
Treatment1» Number of his* revertants/platea 
Urine and tester strain TA1538 added to the topagar with:c 
4-Aminobiphenyl 
2-Aminofluorene 
2-Acetamidofluorene 
2-Aminoanthracene 
2,7-Diaminonaphthalene 
— 
8± 1 
37 * 4 
37 ± 4 
8 ± 2 
7 ± 1 
0-Glucuron-
idase 
7 ± 1 
36 ± 7 
35 ± 5 
9 ± 2 
7 ± 1 
Rat liver 
cytosol 
11 ± 4 
29 ± 2 
35 ± 4 
19 ± 3 
39 ± 2 
Rat liver 
cytosol + 
0-glucuron-
idase 
25 ± 1 
548 ± 19 
493 ± 23 
90 ± 10 
13 i 1 
Mouse liver 
cytosol 
11 ± 2 
27 ± 2 
35 ± 3 
12 ± 2 
61 ± 8 
Mouse liver 
cytosol + 
β -glucuron­
idase 
1 3 * 1 
431± 18 
360 ± 21 
28 * 3 
15 ± 4 
Guinea 
liver 
cytosol 
8 ± 
142 ± 
128 ± 
67 ± 
893 ± 
pie 
1 
3 
7 
1 
27 
Guinea pig 
liver 
cytosol + 
0-glucuron-
idase 
26 ± 2 
1000 ± 40 
718 t 28 
150 ± 11 
689 ± 13 
a
 Mean values (±S.E.M.) of 3 measurements of the same urine. 
b
 Rats received 250 Mmol/kg i.p., 24-h urine was diluted to 15 ml. Samples of 0.1 ml were plated in the presence of 0.1 ml TA1538 sus­
pension (1.5 X 10' bact./ml). 
c
 Additions to the topagar (per plate) : cytosol, 0.4 ml of 105 000 g supernatant from 25% liver homogenate; ^ -glucuronidase 150 units 
dissolved in 0.1 ml water. 
TABLE III (b) 
MUTAGENIC ACTIVATION OF URINE OF RATS TREATED WITH ARYLAMINES BY LIVER CYTOSOL FROM RAT, MOUSE OR 
GUINEA PIG 
Treatment1» 
Benzidine 
4- Aminob ¡phenyl 
2-Aminofluorene 
2-Acetamidofluorene 
2-Aminoanthracene 
2,7-Diaminonaphthalene 
Number of ftis* revertants/platea 
Urine 
_ 
162 ± 
153 ± 
145* 
139 ± 
145 ± 
155 ± 
and tester strain TAI00 added to the topagar with:0 
7 
2 
6 
14 
13 
6 
0-Glucuron-
idase 
145 ± 14 
155 ± 14 
152 ± 6 
136± 11 
189 ± 14 
138 ± 7 
Rat liver 
cytosol 
165± 16 
145 t 5 
99 ± 20 
91 ± 8 
209 ± 12 
105 ± 9 
Rat liver 
cytosol + 
0-glucuron-
idase 
915 ± 90 
141 ± 7 
436 ± 35 
453 t 27 
781 * 30 
123 ± 1 
Mouse liver 
cytosol 
146 ± 7 
127 t 12 
117 ± 8 
107 ± 2 
137 ± 6 
114± 2 
Mouse liver 
cytosol + 
/3-glucuron-
idase 
366 t 9 
178 ± 9 
725 ± 22 
481 ± 21 
263 ± 34 
114 ± 11 
Guinea pig 
liver 
cytosol 
204 ± 13 
197 * 8 
303 ± 26 
135 ± 12 
796 ± 41 
303 ι 18 
Guinea pig 
liver 
cytosol + 
0-glucuron-
idase 
1030 ± 20 
298 ± 23 
1370± 40 
1100 ± 50 
1470 ± 160 
249 ± 7 
a
 Mean values (tS.E.M.) of 3 measurements of the same urine. 
b
 Rats received 250 Mmol/kg i.p., 24-h urine was diluted to 15 ml. Samples of 0.1 ml were plated in the presence of 0.1 ml TA100 sus­
pension (1.5 x 10* bact./ml). 
c
 Additions to the topagar (per plate): cytosol, 0.4 ml of 105 000 g supernatant from 25% liver homogenate^-glucuronidase 150 units 
dissolved in 0.1 ml water. 
¿(-glucuronidase, to a lesser extent after activation with rat liver cytosol in 
the presence of ^-glucuronidase and only poorly after activation with liver 
cytosol from mice in the presence of /3-glucuronidase. In contrast, mutagens 
in urine of rats treated with 2,7-dianiinonaphthalene were found in the 
absence of /3-glucuronidase; guinea pig liver cytosol is the most suitable 
activating system in this case. 
The use of Salmonella typhimurium strain TA100 as detection organism 
for the activated mutagens led to similar results. 
DISCUSSION 
Urinary mutagenic metabolites of some genotoxic aromatic amines were 
detected by application of the Ames assay using liver cytosol from rat, 
mouse or guinea pig as the activating system. The considerable increase in 
mutagenicity by the presence of /3-glucuronidase might indicate that a major 
part of the mutagenic metabolites appear in urine as glucuronides except 
for the metabolites of 2,7-diaminonaphthalene. 
It is interesting that treatment with the bifunctional aromatic amines, 
benzidine and 2,7-diaminonaphthalene leads to the production of urine with 
higher mutagenic potency than when the rats were treated with 4-amino-
biphenyl or 2-aminonaphthalene. Treatment of rats with a dose up to 
2 mmol/kg of 2-aminonaphthalene did not result in the appearance of 
mutagens in urine that are detectable after activation by liver cytosol in 
the presence or absence of /3-glucuronidase. 
With respect to the mutagenic activation by the enzymes present in liver 
cytosol, an obvious species difference in the sensitivity for the deacetylase 
inhibitors, paraoxon and sodium fluoride, was observed (Fig. 1). The 
activating capacity in mouse liver cytosol can be inhibited almost com-
pletely by paraoxon (10~4 M) or sodium fluoride (IO -1 M). It is known 
that paraoxon does not affect the ΛΓ,Ο-acyltransferase catalyzed mutations 
in Salmonella [5,10]. Nor does sodium fluoride inhibit the enzymatic 
transacetylation [11]. This may suggest that in the case of mouse liver 
cytosol a deacetylation rather than a transacetylation is responsible for 
the activation of the mutagens. On the other hand, mutagenic activation 
of the urinary benzidine metabolites by liver cytosol from the rat can not 
be inhibited by paraoxon or sodium fluoride (Fig. 1). King [9] con­
clusively demonstrated the presence of N,O-acyltransferase in rat liver 
cytosol and emphasized the role of this enzyme in the generation of 
genotoxic products from .W-hydroxy-2-acetamidofluorene. The data of 
- Fig. 2 shows that the enzyme in rat liver cytosol responsible for the 
mutagenic activation of urinary benzidine metabolite(s), probably is the 
same as characterized by King [9] being N, O-acyltransf erase. Activation of 
the urinary benzidine metabolites by guinea pig liver cytosol seemed to be, 
at least in part, the result of the action of deacetylase (Fig. 1). These results 
also correspond with data from other investigators. Schut and Thorgeirsson 
[12] did not find JV-hydroxy-2-acetamidofluorene deacetylase activity in rat 
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Fi'. 2. Gel nitration chromatography of the activating enzyme present in rat liver cytosol. 
A partially purified fraction of rat liver cytosol was chromatographed on Sephadex 
G-100. The mutagenic activating capacity of the fractions is expressed as the number of 
revertants. Experimental details were as mentioned in Materials and Methods. 
liver cytosol. Irving [2,13] detected some deacetylating capacity in liver 
cytosol from guinea pig. Bartsch et al. [14] reported a substantial trans-
acetylating activity in rat liver cytosol whereas little or no activity was 
observed in liver cytosol from guinea pig or mouse [11,15,16]. 
From the foregoing it may be concluded that the mutagenic activity of 
the urine of benzidine treated rats can be achieved by different enzymes. 
However, as is suggested by the data of Table II, only 1 premutagenic 
urinary metabolite was found. Therefore, one may speculate about the 
nature of this metabolite. The mutagenic product from this metabolite 
formed through the action of either Af.O-acyltransferase (rat liver cytosol) 
or deacetylase (mouse liver cytosol) presumably contains a hydroxylated 
amino function. Such metabolites are known mutagenic substances for 
Salmonella typhimurium [17]. Studies are in progress now to identify the 
premutagenic urinary benzidine metabolite. Most likely this is a N-acetylated, 
N-hydroxylated and glucuronidated derivative. Trol et al. [18] and Belman 
et al. [19] found ЛГ-hydroxyacetyl derivatives of benzidine in the urine of 
people given benzidine, thereby showing the ability of humans to produce 
this kind of urinary metabolites. 
The Ames assay on urine samples is suggested to be useful in the detection 
of human exposure to genotoxic substances [20,21]. We propose that when 
exposure to arylamines is involved, urinary mutagenicity tests should be 
carried out using an activating system containing cytosol and ^-glucuronidase. 
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METABOLISM OF BENZIDINE-BASED DYES AND THE APPEARANCE OF MUTAGENIC 
METABOLITES IN URINE OF RATS AFTER ORAL OR INTRAPERITONEAL ADMINISTRATION 
R.P. Bos, M.A.M. Groenen, J.L.G. Theuws, Ch.-M. Leijdekkers and 
P.Th. Henderson 
Institute of Pharmacology, Toxicology Unit, University of Nijmegen, 
Nijmegen, The Netherlands 
SUMMARY 
The azo reduction and acetylation in vitro and the mutagenic activation 
in vivo of three azo dyes were studied. In the presence of rat-liver 9000 g 
supernatant benzidine was released from direct black 38 and direct brown 95, 
whereas hardly any benzidine was produced during incubation of direct blue 6. 
Incubation of benzidine with isolated rat. hepatocytes resulted in the 
appearance of diacetylbenzidine. No diacetylbenzidine was formed during 
incubation of benzidine with rat-liver 9000 g supernatant, unless the 
cofactor for the acetylation reaction, acetyl coenzyme A, was added to the 
incubation medium. Isolated rat hepatocytes were capable to produce 
diacetylbenzidine from direct black Э , direct blue 6 or direct brown 95 
without supplementation with acetyl coenzyme A. 
Administration of benzidine, direct black 38 or direct brown 95 to rats 
resulted in the appearance of mutagenicity in urine. For direct black 38 
significantly higher mutagenicity values were found in urine after oral 
administration than after intraperitoneal treatment. Such differences were 
not observed for benzidine and direct brown 95. 
The results demonstrate that rat liver has a considerable capacity to 
reduce azo compounds. Nevertheless, for some compounds, like direct black 38, 
extrahepatic enzymes, most likely present in the intestinal flora, may also 
play a substantial role in the azo cleavage. 
Submitted to Toxicology 
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INTRODUCTION 
Benzidine-based dyes are widely used in dyeing of textiles such as cotton, 
silk, wool and nylon (1). They are also used in plastics, paper and leather, 
in aquous printing inks and in wood stains. Some case-control mortality 
studies indicate an increased risk of developing bladder-cancer after 
occupational exposure to benzidine-based dyes via inhalation, ingestion or 
skin absorption (2,3). The carcinogenic potential of these dyes has been 
attributed on one hand to the presence of residual benzidine in the dyes (4), 
on the other hand to benzidine that has been formed metabolically as a result 
of reduction in V'ivo of the azo bonds. Studies in animals given these 
benzidine-based dyes showed the appearance of benzidine and benzidine 
metabolites in urine (1,5,6). Tanaka et al. (7) demonstrated that oral 
administration of the benzidine-based dyes congo red or direct black 38 to 
rats resulted in mutagenicity of the urine extracts, when tested in the 
Salmonella/microsome assay. This mutagenicity was ascribed to the presence 
of benzidine metabolites in urine. 
In a review concerning the metabolism of azo compounds. Walker (8) 
suggested that it" may be concluded that the intestinal azo-reducing systems 
were considerabLy more active and non-specific than the hepatic azo reductase 
in animals. For a benzidine-based dye like direct black 38 it was suggested 
by Cerniglia et al. (9) that anaerobic intestinal bacteria may play a 
significant role in the metabolism. The data presented by Martin and Kennelly 
(10) suggest that mammalian liver may play only a minor or negligible role 
in the azo reduction of dyes derived from benzidine. This conclusion was 
drawn from experiments in vitro. Liver preparations, like microsomes, 
generally differ in activity of enzymes involved in the biotransformation 
and concentrations of cofactors from the intact liver in vivo. 
In the present investigation we studied the metabolism of some benzidine-
based dyes (Fig. 1) and measured the mutagenicity of rat urine after either 
intraperitoneal or oral administration of these compounds. Since several 
studies suggest that the overall metabolism in the hepatocyte is fairly 
representative for the biotransformation in vivo (11,12,13), we have 
investigated azo reduction by intact hepatocytes. 
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HATERIALS AND METHODS 
Chemicals 
Direct black 38, direct blue 6 and direct brovm 95 were obtained from 
Pechiney Ugine Kuhlmann (Amsterdam, The Netherlands). It was ascertained 
that no residual benzidine was present in the samples of the dyes. 
Benzidine (BD) was purchased from Merck (Darmstadt, F.R.G.). D-Biotin, 
L-histidine-HCl, collagenase type I, nicotinamide adenine dinucleotide 
phosphate (NADP) disodium salt and glucose-6-phosphate (G-6-P) disodium 
salt were purchased from Sigma (St. Louis, U.S.A.). Acetyl coenzyme A was 
obtained from Boehringer (Mannheim, F.R.G.). Purified agar was from Difco 
Laboratories, nutrient broth No. 2 from Oxoid Ltd. (Basingstoke, England), 
and amberlite type XAD-2 from Serva (Heidelberg, F.R.G.). 
Monoacetylbenzidine (МЛВ) was purchased from ICN Pharmaceuticals, Inc. 
I^N'-diacetylbenzidine (DAB) was synthetized according to Johnson et al. 
(14). All other chemicals used were of highest purity obtainable. 
11Θ 
Anima Is 
SPF Wistar rats weighing about 200 g had free access to water and WIK 
food (Hope Farms, Woerden, The Netherlands). 
Colleation of urine samples 
The SPF rats were housed individually in stainless steel metabolism 
cages, designed for the separate collection of urine and feces. 
Solutions of benzidine, direct black 38 and direct brown 95 in 
tragacanth (2%) (under nitrogen to prevent oxidation) were injected 
intraperitoneally or given per os (250 umol/kg). 
Urine samples were collected for 24 h and stored at -20 С until 
assayed. Before they were assayed the individual samples were completed 
to 15 ml and sterilized by filtration through 0.2 μπι membrane filters. 
Preparation of isolated hepatoautes 
The procedure was based on the methods described by Berry and Friend 
(15) and by Seqlen (16), except for some modifications. Before the 
procedure, male Wistar rats were anaesthetized by an i.p. injection of 
0.35 ml sodium pentobarbital (60 mg/ml distilled water). After 15 min of 
2+ pre-perfusion of the liver with a Ca -free HEPES buffer, this buffer 
was replaced by a collagenase-containing HEPES buffer (0,06% w/v 
collagenase) and pre-perfusion was continued for another 15 min. The 
perfusion rate was 25 ml/min. The crude cell suspension was treated 
according to the method of Seglen (16), and the final pellet was 
2+ 
resuspended in a Ca -containing HEPES-TES buffer solution and diluted to 
a density of 5 χ 10 cells/ml. Trypan-blue exclusion showed the presence 
of about 95% viable cells. 
Incubation of the dyes and isolation of the metabolites 
200 μΐ of a solution of the testcompound, was incubated for 4 hrs at 
370C (210 r.p.m.) in the presence of either 10 ml of rat-liver 9000 g 
8 
supernatant, prepared as S9 mix according to Maron and Ames (17) or 10 
hepatocytes in 10 ml of HEPES-TES buffer solution. The incubation was 
stopped on ice. Next, the cells were sonicated twice for 15 seconds and 
the suspension was centrifuged for 10 min at 4000 g. The supernatant was 
put through a column with a 4 cm bed volume of amerlite XAD-2, washed 
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with plenty of water and the adsorbed material was eluted with 10 ml of 
acetone. The eluate was evaporated to dryness under nitrogen at 60 С and the 
residue was dissolved in 100 μΐ of solvent B. 
High-performance liquid chromatography (HPLC) 
Aliquots of the solubilized residue were injected into the 0.02 ml sample 
loop of a Pye Unicam HPIXZ equipped with a 3 XP pump, a variable wavelength 
detector and a 10 mV Kipp recorder. The stainless steel column was 150 mm 
long i.d. 4.6 mm and filled with Lichrosorb RP 1Θ. The flow rate was 1 ml/mln 
and the wavelength was adjusted to 280 run. Simultaneously with sample 
injection, the following solvent programme was commenced: 
10 min linear gradient from 100% solvent A (80% aquapur, 10% 5M HAc/NaAc 
(pH = 5.0), 10% methanol) to 80% solvent A/20% solvent В (90% methanol, 10% 
rM HAc/NaAc (pH = 5.0)). 25 min linear gradient from 80% A/20% В to 55% A/45% 
B. 5 min linear gradient from 55% A/45% В to 100% B. Finally 5 min solvent В 
and return to A. 
Mutagenicity testing 
Mutagenicity of the urine samples was determined using the Salmonella 
typhimurium strain TA1538 (17). 0.1 ml of an overnight grown suspension 
9 
of the bacteria (+_ 1.5 χ 10 bact./ml) was added to the topagar, containing 
0.3 ml of diluted urine, and was supplied with an enzyme system. The 
activating enzyme system consisted of either 0.5 ml S9 mix, prepared 
according to Maron and Ames (17), containing 50 μ1 hepatic 9000 g supernatant 
from phénobarbital induced rats and a NADPH-generating system, in the 
presence of 0.1 ml of a sterile 0-glucuronidase solution (1500 U/ml), or 
0.4 ml liver cytosol, equivalent to 100 mg fresh liver, derived from non-
induced rats, in the presence of 0.1 ml of a sterile B-glucuronidase 
solution 1500 U/ml (18,19). 
RESULTS 
Azo reduction of direct black Z8, direct blue 6 and direct braun 95 by rat-
liver 9000 g supernatant 
The incubation of direct black 38, direct blue 6 and direct brown 95 with 
rat-liver 9000 g supernatant resulted in the appearance of benzidine. Neither 
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monoacetylbenzidine nor diacetylbenzidine was detected. Fig. 2 shows the 
amounts of benzidine that were released after incubation of the dyes at 
various concentrations at 37 С for 4 hrs. Incubations of direct black 38 and 
direct brown 95 at concentrations over approximately 5 шМ resulted in a 
decreased product formation. Hardly any benzidine was produced during 
incubation of direct blue 6. 
b«nzidine I nmole» ) 
30 
TO"» TO'* IO - 3 VX* 
concentratici oí the dye ( M , log scale) 
Fig. 2 The amount of benzidine measured after a 4 h incubation at 37 С of 
10.2 ml of a solution of direct blaak 38 (и m)t direct blue 6 
(Δ bjj or direct broim 95 (o o) with rat-liver 9000 g supernatant. 
Experimental details were as mentioned in Materials and Methods. 
Pretreatment of rats with phénobarbital (75 mg/kg per day for 4 days) 
resulted in an increase of hepatic cytochrome P450 of about 200 per cent. No 
enhancement of the formation of benzidine was observed when 9000 g liver 
supernatant from induced animals was incubated with direct brown 95. Further 
fractionation of the hepatic 9000 g supernatant by centrifugation at 105000 g 
revealed that the reducing enzyme activity was present in the 105000 g 
supernatant. 
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In vitro acetylation of benzidine by isolated rat hepatooytee and 9000 g 
supernatant 
Incubations of low concentrations of benzidine with isolated rat 
hepatocytes resulted in the appearance of considerable amounts of 
diacetylbenzidine (table 1). The amount of monoacetylbenzidine formed after 
Table 1 
METABOLISM OF BENZIDINE INTO MONOACETYLBENZIDINE AND DIACETYLBENZIDINE BY 
_a 
ISOLATED RAT HEPATOCYTES 
Concentration (μΜ) 
Before incubation 
Hepatocytes/ml BD 
0 • 540 
IO7 540 
IO7 110 
IO7 '27 
After incubation 
BD 
540 
440 + 75 
n.d. 
n.d. 
MAB 
n.d. 
150 + 23 
4 + 0.6 
n.d. 
DAB 
n.d. 
2 2 + 4 
100 + 17 
2 5 + 4 
Incubation was at 37 С for 2 hours. Further experimental conditions were 
as described in Materials and Methods. 
Mean values (+ S.E.M.); n.d. not detectable. 
incubation of benzidine with rat-liver 9000 g supernatant was negligible, 
whereas diacetylbenzidine was not detected. When, however, the incubation 
medium was supplemented with the cofactor for the acetylation reaction, 
acetyl coenzynE A, enzymes of the rat-liver 9000 g supernatant were capable 
to convert benzidine into monoacetylbenzidine and diacetylbenzidine (table 
2). 
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Table 2 
METABOLISM OF BENZIDINE INTO MONOACETYLBENZIDINE AND DIACETYLBENZIDINE BY 
RAT-LIVER 9000 g SUPERNATANT IN THE PRESENCE OF ACETYL COENZYME A 3 
b 
Concentration (μΜ) 
Before incubation After incubation 
BD Acetyl coenzyme A BD MAB DAB 
5.4 0 5 + 0 . 9 0.08 + 0.02 n . d . 
5.4 37 n . d . 0.7 + 0 . 1 2 3 . 6 + 0 . 6 
5.4 124 n . d . 0 . 1 1 + 0 . 0 2 5 . 0 + 0 . 9 
5.4 370 n . d . n . d . 5.0 + 0.9 
Incubation was at 37 С for 4 hours. 10.2 ml incubation mixture contained 
1 ml 9000 g supernatant equivalent to 250 mg rat liver. Experimental 
details were as mentioned in Materials and Methods. 
b 
Mean values (+ S.E.M.); n.d. not detectable. 
Metabolism of diveat blaak 38, direct blue 6 and direot brown 95 by isolated 
rat hepatoaytes 
After incubation of direct black 38, direct blue б or direct brown 95 with 
isolated rat hepatocytes, we found diacetylbenzidine. Neither benzidine nor 
monoacetylbenzidine was detected. Apparently, by the azo-bond reduction in 
these dyes, benzidine was released and immediately acetylated by the 
hepatocytes. 
Fig. 3 shows the production of diacetylbenzidine that was formed during 
incubation of direct black 38, direct blue 6 and direct brown 95 with rat 
hepatocytes at 37 С for 4 hrs. The substrate concentrations at which 
diacetylbenzidine formation is optimal, are rather different for the 3 dyes. 
This suggests different affinities of the dyes for the metabolizing systems 
involved. At increasing concentrations of the dyes the metabolism was 
inhibited. 
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fig. 3 The amount of diacetylbenzidine measured after a 4 h incubation at 
37 С of 10.2 ml of a solution of direct black 38 (· »), direct blue 
6 (à à), or direct broum 95 (o o^  with isolated rat hepatocytes. 
Experimental details were as mentioned in Materials and Methods. 
Excretion of mutagenic metabolites in urine of rats 
In animal studies it was investigated whether administration in vivo of 
the benzidine-based dyes leads to formation and excretion of acetylated 
benzidine metabolites, which are known to be mutagenic towards Salmonella 
typhimurium ТАІ5Э after appropriate activation. Table 3 shows mutagenic 
activities in urine from rats having received benzidine, direct black 38 or 
direct brown 95, either intraperitoneally or per os. Mutagenic activation 
of the urinary metabolites was carried out by two different systems; S9 mix 
in the presence of ß-glucuronidase, or rat liver cytosol in the presence of 
ß-glucuronidase (18,19). Highest mutagenicity values were found after 
treatment of the rats with benzidine. For this compound and for direct brown 
95 no remarkable differences in the appearance of urinary mutagens after 
administration via different routes were observed. On the other hand, for 
direct black 38 relatively high mutagenicity values were found in urine of 
rats after oral administration. This difference is most pronounced after 
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Table 3 
MUTAGENICITY OF URINE FROM RATS AFTER ADMINISTRATION OF BENZIDINE DIRECT 
BLACK 38 OR DIRECT BROWN 95, EITHER INTRAPERITONEALLY OR PER OS 
Number of his revertants/plate 
Urine and tester strain TA1538 added to the topagar 
with 
S9 mix + 3-glucuronidase 
Treatment 
r a t l i v e r cy toso l + 
(¡-glucuronidase 
benzidine i . p . 
experiment 1 
experiment 2 
experiment 3 
benzidine p.p. 
experiment 1 
experiment 2 
experiment 3 
direct black 38 i.p. 
experiment 1 
experiment 2 
experiment 3 
direct black 38 p.p. 
experiment 1 
experiment 2 
experiment 3 
direct brown 95 i.p. 
experiment 1 
experiment 2 
experiment 3 
direct brown 95 p.p. 
experiment 1 
experiment 2 
experiment 3 
untreated 
6980 + 50 
8730 + 280 
9230 + 300 
6010 + 380 
9110 + 120 
8740 + 350 
346 + 20 
327 + 4 
243 + 4 
930 + 61 
647 + 15 
763 + 8 
450 + 33 
215 + 27 
126 + 20 
133 + 23 
210 + 23 
131 + 12 
23 + 3 
9390 + 590 
6150 + 600 
11000 + 330 
7290 + 530 
9460 + 280 
10300 + 1070 
748 + 30 
113 + 3 
141 + 5 
5670 + 510 
4790 +_ 190 
3770 + 460 
1230 + 20 
1020 + 60 
637 + 25 
527 + 36 
1050 + 70 
714 + 3 
30 + 5 
Mean values (+_ S.E.M.) pf 3 measurements of the same urine. 
Additions to the topagar (per plate): S9 mix, 0.5 ml; rat liver cytosol, 
0.4 ml of 105000 g supernatant from 25% rat liver homogenate; 
fj-glucurpmdase, 150 Units dissolved in 0.1 ml water. 
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metabolic activation with rat liver cytosol. 
DISCUSSION 
The detection of benzidine after incubation of direct black 3Θ or direct 
brown 95 with hepatic 9000 g supernatant, indicates that enzymes capable of 
azo dye reduction are present in this liver preparation (Fig. 2). After 
incubation of direct blue 6 hardly any benzidine was detected. Further 
findings suggested that cytochrome P-450 is not rate-limiting in the 
reduction of these dyes into benzidine. In addition, it was observed that 
the enzymes involved in the reduction of direct brown 95 were present in 
the 105000 g supernatant fraction of rat liver. Therefore, most likely the 
enzyme responsible for the reduction of direct brown 95 is the cytosolic 
azoreductase described by Huang et al. (20). This is not in agreement with 
the findings of Martin and Kennelly (10), who found rat liver microsomes, 
from phenobarbital-pretreated animals, capable to reduce the azo groups of 
a number of dyes, among which the benzidine-based dyes direct black 38 and 
congo red. 
In table 1 we showed that intact hepatocytes - in contrast with 9000 g 
supernatant - were able to convert benzidine into acetylated derivatives. 
The inability of the 9000 g supernatant fraction to acetylate benzidine, can 
be explained by the absence of acetyl coenzyme A (table 2). 
Lazear et al. (21) and Tanaka et al. (7) showed that monoacetylbenzidine 
and diacetylbenzidine are much more mutagenic them the parent compound 
benzidine. In a previous study (22) we demonstrated that benzidine was much 
more mutagenic after activation with isolated rat hepatocytes than after 
activation with rat liver 9000 g supernatant. On the basis of the present 
results, this is most likely attributable to the capability of rat 
hepatocytes to acetylate benzidine. 
In the animal experiments (table 3) it is shown that after administration 
of benzidine (250 pmoles/kg) much more mutagenicity appeared in rat urine 
than after the administration of equal doses of direct black 3Θ or direct 
brown 95. Tanaka et al. (7) suggested that urinary mutagenicity after 
administration of such azo dyes is caused by urinary metabolites of 
benzidine that is released by azo reduction. 
Another mutagenic product that is formed during reduction of direct black 
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38, is 1,2,4-triaminoben2ene. Administration to rats of 1,2,4-triaminobenzene 
resulted in the appearance of mutagenicity in urine. However, after metabolic 
activation with S9 mix in the presence of S-glucuronidase higher values v/ere 
observed than after activation with rat liver cytosol in the presence of 
S-glucuronidase (data not shown). The number of revertants obtained with 
1,2,4-triaminobenzene amounted only about one per cent of that after an equal 
dose of benzidine. This finding supports the concept that the urinary 
mutagenicity is caused by the presence of metabolites of benzidine. 
In regard of genotoxic activation of azo dye compounds, much emphasis has 
been led on the role of intestinal metabolism (2,9). It is generally thought 
that after oral exposure these substances are rapidly reduced with the aid 
of azo-cleaving enzymes of the bacterial flora. The benzidine released 
after azo reduction will be absorbed and subsequently be activated by 
enzymes of the liver. If the liver only has a poor reducing capacity, this 
concept includes that genotoxic metabolites are formed in a less degree if 
the azo compounds enter the organism parenterally, thereby avoiding the 
metabolism of the gut. 
From a comparrson of mutagenicities found in urine after either 
intraperitoneal or oral administration of direct black 38, it is obvious 
that indeed most mutagens appeared in urine after oral administration of 
this dye (table 3). After intraperitoneal administration, urinary 
mutagenicity may be considered as the result of azo reduction, mainly 
occurring in the liver. Intestinal metabolism seems to result in an extra 
contribution to the urinary mutagenicity due to this dye. This is in 
accordance with the results of Cerniglia et al. (9), who showed that 
anaerobic incubations гп vitro of direct black 38 with rat intestinal 
microorganisms leads to an effective reduction of the azo bonds. On the 
other hand, for direct brown 95 we did not find a significant difference 
between the urinary mutagenicities after either intraperitoneal or oral 
administration. It can be noticed that direct brown 95 was reduced more 
rapidly by liver 9000 g supernatant than direct black 38. 
Further studies are necessary to answer the question which factors 
determine whether the first step in the toxification process of azo 
compounds takes place in the gut or in the liver. Undoubtedly, the rate of 
intestinal absorbtion which depends on physico-chemical properties (such as 
lipophilicity) plays an important role. The results described in this paper 
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demonstrate that the l iver has a substantial capacity to reduce azo 
compounds. 
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Summary. Urinary thioether compounds, such as mercapturic acids, can be 
considered as nontoxic end products of potentially alkylating agents. On the 
other hand, urinary mutagenicity may represent thé excretion of potential 
mutagens that have not definitively been detoxified by the organism. It is 
suggested that a combined urinary thioether and mutagenicity test may be 
useful in monitoring people occupationally exposed to potentially alkylating 
compounds, in particular to mixtures of these chemicals. Exposure to cigarette 
smoke, containing several known mutagens and carcinogens, is expected to 
interfere with the test results. 
The excretion of mutagens and thioethers was determined in urine of 
smokers and nonsmokers. Smokers excrete more mutagens and thioether 
compounds than nonsmokers. Further, it was found that the urinary muta-
genicity and thioether level are significantly related to the amount of 
cigarettes smoked. 
Key words: Urinary thioethers - Mercapturic acids - Mutagenicity of urine -
Cigarette smoking - Potentially alkylating agents - Exposure test 
Many studies have emphasized the role of endogenous sulfhydryl-containing 
compounds, particularly glutathione (GSH), in the detoxication of chemicals 
such as mutagens and carcinogens that act through the covalent binding of 
reactive metabolites (Jollow et al., 1974; Jaeger et al., 1974; Mitchell et al., 1976; 
van Doorn et al., 1978). The conjugates that are formed by the reaction of the 
electrophilic metabolites with the nucleophilic GSH, are subsequently excreted 
through the bile or in the urine, commonly as mercapturic acids (N-acetylcysteine 
derivatives) (Chasseaud, 1973, 1976). 
Previously, we suggested that the appearance of mercapturic acids or other 
thioether compounds in urine might be a useful indication of exposure to 
potentially alkylating agents (Seutter-Berlage et al., 1977). Accordingly, it was 
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found that employees of chemical plants, exposed to complex mixtures of 
chemicals, excreted more thioether compounds than their colleagues working in 
administrative departments. Recently, Vainio et al. (1978) also reported raised 
concentrations of thioethers in the urine of rubber workers. Although the urinary 
thioether assay appears useful in assessing the exposure of large numbers of 
people, the relatively high background-values which were found in both studies, 
limit its possibilities as a method for biological monitoring. Undoubtedly, 
cigarette smoking greatly attributes to the basic exposure of people to potentially 
alkylating chemicals. Cigarette smoke contains more than two thousand different 
compounds, including several known carcinogens and mutagens. There are many 
reports dealing with the carcinogenicity of cigarette smoking (Wynder, 1968; van 
Duuren, 1968, 1971; Bock, 1971). Recently, Yamasaki and Ames (1977) devel­
oped a method for concentrating mutagens from urine and demonstrated that 
smokers have mutagenic urine while nonsmokers do not. They proposed that this 
procedure be used in monitoring the urine of people or animals in toxicological 
studies. 
In the present study mutagenicity and thioether excretions in urine of smokers 
and nonsmokers have been compared. An improved analytical procedure for the 
estimation of thioethers enabled us to evaluate the interference of cigarette 
smoking in the thioether test. 
Materials and Methods 
Chemicals 
Amberlite, type XAD-2, was obtained from Serva (Heidelberg, FRG). Nicotinamide adenine 
dinucleotide phosphate (NADP) disodium salt, glucose-6-phosphate disodium salt and 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB) were obtained from Boehringer (Mannheim, FRG), D-
biotin and L-histidine-HCl from Sigma (St. Louis, USA) and citric acid monohydrate from J. T. 
Baker Chemicals (Deventer, the Netherlands). Purified agar, nutrient broth and yeast extract 
were purchased from Difco Laboratories (Detroit, USA), D-glucose, metaphosphoric acid 
[(НРОэ)п], sodium borohydride (NaBFL) and N-acetyl-L-cystein from Merck (Darmstadt, 
FRG). 
Bacterial Strain 
Salmonella typhimurium ТА 1538 was used throughout this investigation. This strain was a gift 
from Dr. B. N. Ames. 
Microsomal Enzymes 
Nine thousand g supernatant derived from liver homogenates of rats pretreated with 
Aroclor 1254 was purchased from Bionetics (Kensington, USA). 
Urine Samples 
Samples of urine from male smokers and nonsmokers being on normal diets and not receiving 
any medication were collected from 2.00—6.00 p. m. The subjects were classified in four groups 
136 
Thioethers and Mutagens in Urine from Cigarette Smokers 
as follows: nonsmokers, persons smoking 1—10, 11—20, and 20 or more cigarettes a day (n = 5 
for each group). 
In a separate experiment urine samples of one of the subjects were collected daily from 
10.00 a.m. until 6.00 p.m. for several days. During this period he smoked a number of cigarettes 
varying for 0—20 daily. Urine samples were frozen immediately and stored without preserva­
tives at -20° С until experimental assay. 
Assay of Creatinine 
The creatinine concentration of each urine sample was determined as described by Goiter and 
De Graaff (1955). 
Mutagenicity Testing 
The method for concentrating mutagens and determining mutagenicity in urine samples has 
been described by Yamasaki and Ames (1977). We modified this method by using urine 
concentrates obtained from a volume of urine corresponding to an amount of 1.0 mmol 
creatinine instead of urine concentrates from 100 ml portions. The urine was put through a 
column with a 4 cm1 bed volume of Amberlite XAD-2 and the adsorbed material was e fu ted 
with 10 ml acetone. The eluate was evaporated to dryness and the residue was dissolved in 0.4 ml 
dimethyl sulfoxide. 0.1 ml of this solution was added per plate and assayed for mutagenicity 
with the S. typhimurium tester strain TA 1538 in the presence of the microsomal enzymes as 
mentioned above. Urinary mutagenicity was expressed as the number of revertants per mmol 
creatinine per 106 bacteria. About 10a bacteria were plated in each experiment. It was found that 
in no case more than 15% of the bacteria were killed by the urine concentrate. 
Assay of Urinary Thioether Concentration 
The general procedure for the determination of urinary thioethers has been described previously 
(Seutter-Berlage et al., 1977). In the present study improved results were obtained by applying 
acid extraction and reduction of the samples prior to alkaline hydrolysis. 
To a 5.0 ml sample of urine in a glass-stoppered tube 0.125 ml of 4 N HCl was added. Then 
10 ml ethyl acetate was added and the urine was extracted by shaking vigourously several times 
and allowing the layers to separate. The extraction was repeated with 10 ml ethyl acetate. The 
ethyl acetate layers were collected, evaporated to dryness and subsequently dissolved in 2.5 ml 
water. 
A 1.0 ml aliquot of this solution was pipetted in a test tube (brown glass, stoppered) and 
0.10 ml anti-foam reagent, consisting of 90% ethanol and 10% octanol, was added, followed by 
the addition of 1.0 ml 5% NaBbh. The tube was incubated unstoppered in a waterbath of 60° С for 
15 min in order to reduce all disulfide compounds to mercaptans. Immediately after incubation 
the solution was neutralized with 0.50 ml 2.7 N HCl. After 10 min 0.20 ml of a metaphosphoric 
acid solution (10 mg/ml) was added. Five min later the sulfhydryl concentration of the mixture 
was determined according to Ellman (1959) as follows. 
A 0.25 ml aliquot of the incubation mixture was added to 2.3 ml of a freshly prepared mixture 
consisting of 2.0 ml 0.5 M Sörensen-phosphate buffer (pH 7.1) and 0.3 ml DTNB solution (0.4 mg 
DTNB per ml 1% sodium citrate solution). Absorbances were read at 412 nm. Corrections were 
made for the attribution to the absorbance by the colour of the urine extract and of the DTNB 
solution. N-acetyl-L-cystein was used as a reference standard. 
1.0 ml 4N NaOH was added to the rest of the incubation mixture. The solution was saturated 
with N2, the tubes were closed and alkaline hydrolysis was performed at 100° С for 50 min in order 
to hydrolyze the thioether compounds. After incubation the tubes were cooled in ince for 10 min 
and neutralized with 1.0 ml 4N HCl. The sulfhydryl concentration was determined as described 
above. 
137 
R. van Doorn et al. 
URINARY THIOETHER 
цтоі /mmole creatinine 
Зг 
1 -
MUTATION FREQUENCY 
„..no bact mmol creatinine 
Τ 
JL 
b 
τ 
--
- -
•ΞΓ^" 
•Ю It -20 > 20 
cigarettes per day 
Ξ 
Τ 
τ 
~ 
--- _ 
ίΓ_. 
l-Ю tl-20 >20 
cigarettes per day 
Fig. 1. a Thioether concentrations of urine samples from smokers and nonsmokers. Thioethers 
were assayed as described in the Materials and Methods section and are expressed as μιηοΐ 
SH-/mmol creatinine. Values are presented as means ± S.E.M. Each group consisted of five 
subjects, b Mutagenicity of urine from smokers and nonsmokers. The mutagenic activity was 
determined as described in the Materials and Methods section and expressed as the number of 
revertant colonies of S. typhimurium TA 1538 per mmol creatinine per 106 bacteria. Mean 
values + S.E.M. are presented. Each group consisted of five persons, a Significantly different 
from the preceeding group at P<0.05 (Wilcoxon, two-sample test), b Significantly different 
from the preceding group at P<0.01 (Wilcoxon, two-sample test) 
The differences in absorbance that were measured before and after alkaline hydrolysis 
represent the concentration of thioether compounds. The urinary levels of thioether compounds 
were expressed as μπιοί SH-Zmmol creatinine. 
Results 
Urinary Concentrations of Thioether 
As a consequence of the improved analytical procedure, which allowed us to 
differentiate between disulfides and thioether compounds, substantially lower 
normal thioether levels in human urine were found, as compared with those in 
previous studies (Seutter-Berlage et al., 1977; Vainio et al., 1978). As is 
demonstrated in Fig. 1, it was possible to distinguish between nonsmokers and 
the different categories of smokers at the significance level even with a small 
group of subjects. An increase in the number of cigarettes smoked a day was 
reflected by an increased urinary thioether excretion. 
Excretion of Mutagens in Urine 
The concentration of mutagenic agents in the urine of cigarette smokers was 
expressed as mutation frequency, i.e., the number of revertant colonies per 
million bacteria, per mmol urinary creatinine. 
In Fig. 1 b the mutation frequencies in urines from the different smoking 
groups are compared. Persons smoking up to 10 cigarettes a day did not show a 
significant increase in the mutation frequency when compared with nonsmokers. 
Urine mutagenicity in the group of persons smoking 11—20 cigarettes a day and 
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Fig. 2. Comparison between the urinary thioether excretion and mutagenicity of urine from the 
different smokers and nonsmokers. O: nonsmokers; Q:1—10 cigarettes/day; β: 11—20 ciga­
rettes/day; · · more than 20 cigarettes/day 
in the group of persons smoking more than 20 cigarettes daily significantly 
increased when compared with the preceding group. 
Relation Between the Excretion of Thioethers and Mutagens 
In Fig. 2 the urinary thioether excretion is plotted as a function of the occur­
rence of potentially mutagenic agents in urine. It can be seen that smokers 
excrete more thioether compounds and show a higher mutation frequency in the 
urine when compared with nonsmokers. 
Smoking up to about 10 cigarettes a day caused no statistically significant 
change in the mutation frequency whereas the urinary thioether excretion shows a 
remarkable increase. On the other hand, for the heavy smokers it appeared that 
the urinary mutation frequency increased strongly, while there was hardly any 
increase in the urinary thioether excretion. 
Kinetics of Urinary Excretion of Mutagens and Thioethers 
The time-dependent course of the urinary excretion of thioethers and mutagens, 
due to cigarette smoking, was studied by monitoring one single subject during a 
period of 20 days. The daily amount of cigarettes gradually increased from 0 to 20 
cigarettes. The experiment ended with a non-smoking period of four days. The 
results are shown in Fig. 3. It can be seen that the appearance in the urine of 
the mutagens thai are inhaled during smoking and excreted unchanged or as 
metabolites, is fairly well related to the number of cigarettes smoked during that 
day. This is demonstrated, e.g., at the end of the smoking period where no 
smoking immediately resulted in a rapid decrease in urinary mutagenicity. On the 
other hand, the excretion of thioethers responded more slowly to a change in the 
number of cigarettes smoked. 
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Fig.3. Mutagenic activity detected with S.typhimurium TA 1538 and thioether concentrations 
of urine samples from one single subject during a period of 20 days. Mutagenicity and thioether 
concentration are expressed as revertants per 10' bacteria per mmol creatinine, and μπιοΙ 
SH-/mmol creatinine, respectively. Note that the urinary mutagenicity and thioether concen­
trations follow the variations in smoking pattern 
Discussion 
The analytical procedure for the assay of urinary thioether concentrations used in 
this study, showed much lower background values than those found in previous 
studies (Seutter-Berlage et al., 1977; Pentz, 1978; Vainio et al., 1978). This is 
mainly due to the reduction of the urine samples with NaBH4 before the alkaline 
hydrolysis of the thioethers, which enabled us to make corrections for the 
contribution of urinary disulfides to the amount of sulfhydryl groups finally 
measured. This is in particular important for the elimination of the interference 
by the disulfide cystine, which normally is present in urine at an average 
concentration of 49μιηο1 SH-Zmmol creatinine (ranging from 21 to 131) (Diem, 
1960). In addition, the present thioether test has been made more selective by the 
extraction of acidified urine samples with ethyl acetate. The values obtained 
represent the excretion of acidic, sulfur-containing compounds, most probably 
detoxication products such as mercapturic acids, and thus may reflect the 
exposure to potentially alkylating agents. 
In applying this method, we were able to differentiate between the urinary 
thioether values of smokers and nonsmokers, and even between those of light, 
moderate and heavy smokers (Fig. la). 
Another technique that has 'been proposed to be useful in monitoring people 
for exposure to high risk substances, is the detection of mutagenicity in the urine 
(Durston and Ames, 1974; Legator et al., 1975; Yamasaki and Ames, 1977). We 
think that mutagenic testing of urine might be particularly valuable in diagnosing 
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exposures, in which the hazardous compounds are inadequately detoxified by the 
organism, or, otherwise, can be re-activated after jnitial detoxication. This test 
could therefore be complementary to the thioether test, because the value of the 
latter mainly depends on an effective detoxication, namely through the conjuga-
tion of reactive metabolites with SH-groups. 
We found mutagens in the urine of smokers, especially in the urine of heavy 
smokers. Most of the excreted mutagens need metabolic activation, since 
mutation frequencies were much lower in the absence of microsomal enzymes. 
These findings are in accordance with the results reported by Yamasakiand Ames 
(1977). We suggest, however, that more accurate quantification of the urinary 
mutagenicity can be made by taking into account the creatinine concentration of 
urine. The variance in the values of both urinary thioether and mutagenicity, as 
clearly shown in Fig. 2, may be partly the result of individual differences in 
smoking habits (depth of inhalation, filter cigarettes, length of the discarded butt, 
etc.). 
The absence of a significant increase in mutagenicity of the afternoon urine of 
persons smoking up to 10 cigarettes a day (Fig. 1 b), might be due to the fact that 
these light smokers generally smoked during the evening of the day before. 
Possibly, the greater part of the potential mutagens that were inhaled during 
smoking had already been eliminated. This is supported by the data of Fig. 3 
showing that after cigarette smoking mutagens appear much faster in the urine 
than the thioether products. This phenomenon also excludes the possibility that 
the thioethers excreted in the urine have mutagenic properties. 
The combination of the thioether and mutagenicity tests as presented here 
may be valuable in monitoring people who are exposed to occupational levels of 
potentially alkylating agents. The present data indicate that cigarette smoking 
may interfere with the test results. 
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SUMMARY 
Eight non-smokers were experimentally exposed to cigarette smoke by 
staying in a poorly ventilated room together with heavy smokers for 6 h. Air 
samples were taken and the extract appeared to contain mutagenic substances. 
This is in accordance with the presence of carcinogens in tobacco smoke. 
Inhalation of the contaminated air by the passive smokers resulted in an 
increase in the urinary excretion of products mutagenic in the Salmonella/ 
microsome assay. This observation suggests that there is a causality in the 
association between increased cancer risk and passive smoking, as was found 
by other investigators. 
INTRODUCTION 
It is a question of far-reaching significance, whether passive inhalation of 
tobacco smoke has only annoying, reversible effects like irritation of the 
eyes and the respiratory tract, or can cause permanent injury to health. Does 
passive smoking on the long run lead for example to an increased risk of 
cancer? 
In 1981 Trichopoulos et al. [13] reported results from a case-control 
study demonstrating a statistically significant association between husbands 
smoking and women's cancer risk. About the same time, Hirayama [8] came 
to the same conclusion on the basis of a more extensive epidemiological 
investigation. He stated that passive and involuntary exposure to cigarette 
smoke markedly increases the risk of lung cancer. Contrary to these reports 
Garfinkel [7] failed to show such a statistically significant relationship. 
Recently, the discrepancies between the results of these epidemiological 
studies have been discussed at length [10,11]. In particular, objections were 
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made to the quantitative interpretations with respect to the increased risk of 
lung cancer in passively smoking women. 
In the present investigation an attempt was made to study the causality 
of an increased cancer risk due to passive smoking. Thereto, urine samples of 
passive smokers staying in a smoky room for 6 h were screened for the 
presence of mutagens. Measurement of urinary mutagenicity has been used 
successfully to establish environmental exposure to mutagenic or carcino­
genic agents. In previous studies it was shown that active cigarette-smoking 
leads to the appearance of mutagens in the urine [4,17]. Other investigations 
are dealing with urinary mutagenicity after occupational or therapeutic 
exposure to carcinogenic substances [2,5,12]. 
MATERIALS AND METHODS 
Collection of urine samples 
Urine samples were collected from 8 male non-smokers and 10 smokers 
of either sex. The age of the subjects ranged from 25 to 35 years. It was 
assured that the non-smokers did not use any drugs. The non-smokers together 
.vith the heavy smokers stayed in a room (110 m3) with poor ventilation 
for 6 h. During this period 157 cigarettes were smoked by the smokers. Just 
before the exposure was started, urine was collected and discarded. There­
upon urine was collected for a 12-h period. In addition urine of non-smokers 
was collected for the same period the day before and the day after the ex­
posure to cigarette smoke. After collection, the urine samples were stored at 
—20°С until assayed. All samples were handled at one go to avoid negative 
influences of variations in the assay on the final result. 
Method for concentrating mutagens present in urine 
Thirty percent of a 12-h urine sample was loaded on an amberlite XAD-2 
column with a 4-cm3 bed volume. The column was washed 3 times with 5 ml 
of aqua dest. The adsorbed material was eluted with 10 ml of acetone. The 
eluate was evaporated to dryness under nitrogen at 60oC and the residue was 
dissolved in 0.45 ml of dimethylsulphoxide. 
Air sampling 
During the stay of persons in the room filled with smoke, a total of about 
500 С of smoky air was bubbled (1.3 i/min) through 2 cylinders (in series) 
filled with ice-cold hexane. The same was done 1 day before and 1 day after 
the experiment, when no smokers were present in this room. The hexane 
portions were combined and evaporated to dryness, using a rotary evapo­
rator. The final residue was taken up in 1 ml of dimethylsulphoxide. 
Salmonella/microsome assay 
Urine and air concentrates (0.1 ml per plate) were assayed f or mutagenicity 
with the Salmonella typhimurium tester strain TAI538 in the presence of 
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S9 mix [1]. Every determination was done in triplicate. After incubation of 
the plates for 48 h at 37°С the number of revertant colonies was counted. 
S9mix 
The S9 mix was prepared according to Ames et al. [1] and contained per 
ml, 100 μ 1 of a hepatic 9000 X g supernatant from Aroclor 1254 induced rats 
and a NADPH-generating system. 
Statistical analysis 
The experimental data (8 cases (i = 1,2,.. ,8); 3 observations x ·^ (ƒ = 
1,2,3)) were handled as follows. In our particular case we formulated the 
nullhypothesis: H0: per case there is no preference for the highest value in 
any of the 3 observations; and the alternative hypothesis, Hi : per case there 
is a preference for the highest value in the second observation. This results 
in a binomial test with probability of success 0.33 if Яо is true. "Success" is 
defined as "the value of the second observation being the highest". 
RESULTS 
Mutagenicity in urine 
Urine samples of 8 non-smoking persons were collected before, during 
and after the passive exposure to cigarette smoke and mutagenicities were 
measured. The results are shown in Table 1. For 6 out of 8 persons highest 
TABLE 1 
MUTAGENICITY OF URINE FROM PASSIVE SMOKERS 
Non-smoker RTIRS -value' 
Collection of urine samples1* 
Day before Day of Day after 
passive passive passive 
smoking smoking smoking 
a 1.8 5.5 3.1 
b 3.4 4.2 2.3 
с 2.9 3.4 2.3 
d 3.1 3.0 2.4 
e 3.8 2.7 2.2 
f 3.1 4.2 3.2 
g 2.4 3.1 1.8 
h 4.0 5.1 2.9 
а
Д
т
/ Д
я
 = Mean no. of revertante found with urine/Mean no. of revertante found with 
aqua dest. 
bDetailed information is given in Materials and Methods. 
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values were observed at the day of passive smoking. Statistical analysis of the 
data revealed a significant enhancement of urinary mutagenicity during 
passive smoking (P = 0.02). 
Urine of the 10 smokers was collected the day of the experiment and 
handled in the same way as the urine of the passive smokers. Relative urinary 
mutagenicity values (RT/Rs) ranged from 9.0 to 42.0 with a median value of 
23.0. 
Mutagenicity in the air 
During the passive smoking experiment tha ambient air in the room, 
gradually contaminated with cigarette smoke, was tested for the presence 
of mutagens. A concentrate equivalent to 50 Í of air, containing the cigarette 
smoke, revealed 155 revertant colonies per plate. Testing a concentrate of an 
equal volume of air from the same room the day before or the day after, 
when no smokers were present, revealed 12 and 16 revertant colonies per 
plate, respectively. 
DISCUSSION 
These results clearly indicate that during experimental conditions, simula-
ting passive smoking, compounds are inhaled that lead to urinary excretion 
of products which are mutagenic in the Sa/moneWa/microsome assay. This 
finding is in good agreement with the observation that the ambient air in the 
smoky room contained a substantial amount of mutagenic substances as 
compared with the background as measured the day before and the day after 
the experiment. The mutagenicity in the air sample is in conformity with the 
data about the presence of carcinogens in tobacco smoke. In 1964 
Galuskinova [6] reported the presence of benzo[a]pyrene in the smoky 
atmosphere of .social meeting rooms and restaurants. Other investigators 
found that the amount of some carcinogens, e.g. /3-naphthylamine, in side-
stream smoke is many times that in mainstream smoke [14]. 
Since it is generally acknowledged that most of the genotoxic carcinogens 
can be detected by in vitro mutagenicity tests, our results about the muta-
genicity in urine of passive smokers can be considered as an indication of 
carcinogenic exposure. This is in support of the reports of Hirayama [ 8] and 
of Trichopoulos et al. [13], who suggested a statistically significant associa-
tion between husbands smoking and women's cancer risk. Nevertheless it can 
be doubted whether the estimations of the relative risks due to passive 
smoking, as made by these authors, are realistic [11]. 
It is known that the incidence of lung cancer is well-correlated with the 
smoking habits of the people concerned [3,16]. In a previous paper we 
showed that there exists a relationship between the mutagenicity in urine 
and the number of cigarettes smoked [4]. It is an interesting question, 
whether urinary mutagenicity might give in some way a reflection of the 
relative cancer risk of smoking. 
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In the urine of 8 non-smokers we found a median urinary mutagenicity 
value (RT/RS) of 3.7 during the experimental passive smoking. The median 
urinary mutagenicity value of these persons on the day before and after the 
passive-smoking experiment was 2.8. In urine of the 10 heavy smokers 
(> 20 cigarettes/day) we found urinary mutagenicity values ranging from 9.0 
to 4 2 with a median value of 23.0. Thus the increase in urinary muta-
genicity due to the passive exposure to cigarette smoke is about 4% of the 
increase observed with the active smokers during the experiment. Judging 
from these data, it is very tempting, though speculative, to suppose that the 
increased risk of cancer for passive smokers under comparable circumstances 
is of the same order of magnitude. 
During the last decade society has become very concerned about the 
environmental cancer risk. Inhalation of air-pollutants, like PAHs produced 
in the combustion of, for instance, coal and oil, has been considered as a 
major cause of the increased pulmonary cancer [15]. For smokers the risk is 
multiplied, because the presence of many other carcinogenic substances in 
the cigarette smoke. It is important to note that the benzo[a]pyrene concen-
tration of cigarette smoke is 500—1000 times higher than the average value 
in the city air [15]. In addition, cigarette smoke may contain inducers of 
microsomal oxidation by which other pre-carcinogenic substances are con-
verted into their active forms [2,9]. 
The experimental results of the present study and the available epidemi-
ological data suggest that non-smokers involuntarily inhale potential carcin-
ogens. Strategies to control the environmental cancer problem can be only 
successful if the health-hazards of passive smoking are sufficiently acknowl-
edged. 
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Mutagenicity of urine from nurses handling cytostatic drugs, 
Influence of smoking 
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Mutagenicity of Urine from Nurses Handling Cytostatic 
Drugs, Influence of Smoking* 
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Summary. Mutagenicity towards Salmonella typhimunum ТА 100 of urine from 
smoking nurses, who were occupationally involved in the treatment of patients 
with cytostatic drugs, was significantly increased in comparison with that of 
smoking control subjects Mutagenicity towards Salmonella typhimunum 
ТА 100 was not increased in exposed non-smokers when compared to control 
non-smokers. In smoking subjects urinary mutagenicity appeared increased 
towards Salmonella typhimunum ТА 1538 in the presence of S-9 mix. 
Rats pretreated with Aroclor 1254 showed higher mutagenicity in their 
urine than untreated rats after cyclophosphamide administration. Therefore, 
the synergistic effect of smoking might be due in part to induction of enzymes 
involved in the mutagenic activation of cytostatic drugs Further, the animal 
experiments showed that cyclophosphamide (the most frequently used muta­
genic cytostatic drug) can be absorbed after oral or percutaneous administra­
tion. Therefore, it is not excluded that differences in working hygiene between 
smokers and non-smokers also play a role. 
Key words: Mutagens/urme - Salmonella typhimunum - Antineoplastic agents 
- Cyclophosphamide - Smoking - Environmental exposure 
Introduction 
Many cytostatic drugs used in anti-cancer therapy have been shown to be genotoxic 
m short-term assays (Benedict et al. 1977; Scino et al. 1978; Matheson et al. 1978). 
This genotoxicity in vitro is in most cases paralleled by carcinogenicity in animals 
(Harris 1976; Leopold et al 1979) For this reason these substances bring about a 
potential hazard to persons who are occupationally involved in the synthesis, 
formulation and administration of these drugs, e.g. during nursing of cancer 
patients. This risk has already been studied by some investigators, who showed an 
increase in sister chromatid exchanges and in chromosomal gaps in lymphocytes of 
nurses handling cytostatic drugs (Norppa et al. 1980; Waksvik et al. 1981). 
* Support by the General Directorate of Labour, Dutch Ministry of Social Affairs 
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Treatment of patients or animals with these drugs resulted in the appearance of 
mutagens in their urine (Minnich et al. 1976; Pak et al. 1979; Balbinder et al. 1981). 
These mutagens can be detected for instance with the aid of the Salmonella 
typhmunum strains selected by Ames et al. (1975). Falck et al. (1979) detected 
mutagenicity m urine of non-smoking nurses working in oncology departments. 
The mutagenicity was reduced when special safety measures were applied (Falck et 
al. 1981). 
It has been reported by Yamasaki and Ames (1977) and van D o o m et al. (1979) 
that smoking of cigarettes results in the excretion of mutagens in urine. In 1980 
Falck et al. showed that u n n e from smoking rubber industry workers was much 
more mutagenic than urine from either non-smoking workers or smoking non-
workers. This might be either a simple additional effect or an indication for a 
potentiating effect of smoking on urinary mutagenicity. The latter possibility is 
supported by the recent finding of co-mutagenic properties of urine concentrates 
from smoking people (Hannan et al. 1981). In the present study we investigated the 
combined effect of smoking and exposure to cytostatic drugs on the mutagenicity 
of urine from hospital workers involved in the preparation and administration of 
cytostatic drugs. 
Materials and Methods 
Chemicals 
Amberlite, type XAD-2, was obtained from Serva (Heidelberg, FRG). Nicotinamide adenine 
dinucleotide phosphate (NADP) disodium salt, glucose-6-phosphate (G-6-P) disodium salt, 
D-biotin and L-histidine-HCl were obtained from Sigma (St. Louis, USA). Glucose and citnc 
acid monohydrate were from Merck (Darmstadt, FRG) Purified agar was from Difco 
Laboratories (Detroit, USA), nutrient broth No. 2 from Oxoid Ltd. (Basingstoke, England) and 
cyclophosphamide from Asta (Brackwede, FRG). All other chemicals used were of highest punty 
obtainable. 
Media 
Media used in the bacterial mutagenicity experiments were prepared as described by Ames et al. 
(1975) We used Oxoid nutrient broth instead of Difco nutrient broth as suggested by Ames in a 
supplementary writing. 
Cytostatic Drugs 
Cytostatic drugs arnved at the wards in ampoules, vials or capsules, as dragées or as tablets. 
A 3-month survey of cytostatic drugs shows several substances that are mutagenic to Salmonella 
typhimunum, including doxorubicin, melphalan, lomustine, daunorubicin, cyclophosphamide, 
cis-platinum and mercaptopunne. During this period 114 g cyclophosphamide (252 dragées or 
flasks) and 38 5 g of the other mutagenic cytostatics (1138 ampoules, tablets, capsules or vials) 
were used. 
Collection of Urine Samples 
Urine samples were collected for 24 h from nurses (л = 29) and other people (n = 3) involved in the 
administration and preparation of cytostatics and from control persons (л = 29), mainly 
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secretaries, play leaders and receptionists, working on the same hospital wards. Falck et al. ( 1979) 
stated that urine should be collected after some working days. We started collection of the unne 
samples at the beginning of the third working day, mostly Wednesday. In this way the urine 
samples could be tested soon after collection. During sampling they were coded and stored at low 
temperatures After the collection of the unne samples they were stored at - 20oC until assayed. 
As soon as possible the urine samples were tested by persons unacquainted with the origins of the 
urine samples. 
In the animal experiments male Wistar rats, weighing about 250 g were used. The rats, having 
free access to water and food, were housed individually m stainless steel metabolism cages 
designed for the separate collection of urine and feces After administration of cyclophosphamide 
or doxorubicine, urine samples were collected for 24 h 
Method for Concentrating Mutagens Present m Unne 
Ten per cent of a 24-h urine sample was loaded on an amberlite X AD-2 column with a 4-cm3 bed 
volume The column was washed three times with S ml of aqua dest. The adsorbed material was 
eluted with 10 ml of acetone The eluate was evaporated to dryness under nitrogen at 60° С and the 
residue was dissolved in 0.3 ml of dimethylsulphoxide (DMSO). 
In one experiment 5% of a 24-h unne sample from a patient was loaded on an amberlite 
XAD-2 column The ultimate residue was dissolved in 0 3 ml of DMSO. 
The total 24-h unne sample was loaded on a XAD-2 column in order to concentrate mutagens 
present in rat unne, the final residue was dissolved m 0 35 ml of DMSO 
Solvent values (S) were obtained by using 11 of aqua dest. instead of a 24-h unne sample 
Salmonella Microsome Plate Incorporation Assay 
Urine concentrate was added (0.1 ml per plate) and assayed for mutagenicity with the Salmonella 
typhtmunum tester strain TA 100, and in a number of cases with the Salmonella typhimunum tester 
strain TA 1538 in the presence of S-9 mix Every determination was done at least in tnphcate. 
After incubation of the plates for 48 h at 37° С the number of revenant colonies was counted. 
S-9 Mix 
The S-9 mix was prepared according to Ames et al. ( 1975) and contained per ml 100 μΐ of a hepatic 
9000 £ supernatant from Aroclor 1254 induced rats and a NADPH-generating system. 
Results and Discussion 
Mutagenicity m Urine from Patients and Rats Receiving Cytostatic Drugs 
In Table 1 it is shown that rats treated with cyclophosphamide or doxorubicine 
have mutagenic urine. The urinary mutagenicity was detectable with the tester 
strain TA 100 without addition of S-9 mix. 
Patients receiving cyclophosphamide also had urine which was mutagenic to 
the tester strain TA 100 without addition of S-9 mix (Table 2). It should be noted 
that urine from the patient receiving 400 mg a day appeared to be toxic to the 
bacteria after the concentration procedure mentioned in the materials and methods 
section. In this case only 5% instead of 10% of the 24-h urine volume was used. 
The direct mutagenic properties of urine from the patients and rats that 
received cytostatic drugs are in accordance with the findings of several investi­
gators, who demonstrated that many of these drugs have mutagenic properties per 
se or appear as direct mutagenic metabolites in urine, detectable with the 
Salmonella typhimurium strain TA 100 (Matheson et al. 1978; Pak et al. 1979). 
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Table 1. Mutagenicity of urine from rats treated with cytostatics 
Mutagenicity towards TA 100 (his* revenants per plate) 
Urine* from rats treatedb with 
Cyclo­
phosphamide 
Doxo-
rubicine 
Unne* from 
untreated rat 
(control) 
79 
71 
75 
75 
Aqua 
dest 
81 
78 
81 
80 Mean 
648 
637 
650 
645 
246 
213 
273 
244 
Ry/Rs-ratio' 
81 31 0 94 
* A 24-h urine sample was put through a X AD-2 column The eluate was evaporated and the final 
residue was dissolved in 0 35 ml of DMSO, 0 1 ml of this solution was added per plate and 
assayed for mutagenicity with the Salmonella typhmunum strain TA 100 in the absence of 
S-9 mix 
ь
 Male Wistar rats weighing about 200 g were injected intrapentoneally with cyclophosphamide 
(100mg/kg) or doxorubicme (15mg/kg) 
Rr/Rs 
Mean number of revertants found with urine 
Mean number of revertants found with aqua dest 
Mutagenicity towards TA 100 (his* revertants per plate) 
Unne' from patients receiving cyclophosphamide at a 
dose of 
100mg/day 400mg/day,, 
Table 2. Mutagenicity of urine 
from patients receiving cyclo­
phosphamide 
RT (mean) 
Rs (mean) 
316 
321 
300 
312 
66 
329 
354 
340 
342 
341 
50 
RT/RS 4 7 68 
* Ten per cent of a 24-h urine sample was put through a 
XAD-2 column The eluate was evaporated and the 
final residue was dissolved in 0 3 ml of DMSO, 0 1 ml 
of this solution was added per plate and assayed for 
mutagenicity with the Salmonella typhmunum strain 
TA 100 in the absence of S-9 mix 
b
 In this case only 5% of a 24-h unne sample was used 
RT/RS = 
Mean number of revertants found with unne 
Mean number of revertants found with aqua dest 
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Fig. 1. Effect of exposure to cytostatics on urinary mutagenicity. The mutagenicity of urine 
samples from control subjects (non-smokers, smokers) and exposed subjects (non-smokers, 
smokers) as detected in the plate incorporation assay with the tester strain TA 100 in the absence 
of S-9 mix is expressed in RT/Rs values. Median values are 1.23,1.27, 1.34 and 1.55, respectively 
Mean number of revenants found with urine 
RT/RS = Mean number of revertants found with aquadest. 
Mutagenicity in Urine from Nurses and the Influence of Smoking 
In Fig. 1 the mutagenicities of urine samples of exposed and control subjects are 
shown. Mutagenicity was determined with the aid of the Salmonella typhimurium 
strain TA 100 in the plate incorporation assay and given in RT/RS values. Both 
groups (exposed and control) are subdivided into smokers and non-smokers. The 
mutagenicity of urine from exposed smokers was significantly higher than that of 
the control smokers (Wilcoxon test: Ρ = 0.028). In this respect exposed non-
smokers did not differ from control non-smokers. 
As has been reported earlier, smoking of cigarettes gives rise to the appearance 
of mutagens in urine. Testing of urine samples with the aid of the Salmonella 
typhimurium strain TA 1538 in the presence of S-9 mix is the method commonly 
used for detection of urinary mutagens as a consequence of smoking (Yamasaki 
and Ames 1977; van Doom et al. 1979). The mutagenicity of urine from smoking 
subjects tested in this way is shown in Fig. 2. Mutagenicity of urine from smokers 
was significantly increased (Wilcoxon test: Ρ < 0.0001). 
The finding that urinary mutagenicity of exposed smokers as detected with 
TA 100 is higher than that of control smokers (Fig. 1) cannot be due to a difference 
in smoking behaviour. First, there is a good correlation between the number of 
cigarettes smoked and the urinary mutagenicity as detected with the strain TA 1538 
in the presence of S-9 mix (van Doom et al. 1979). From this and from Fig. 2 we 
may conclude that the group of control smokers did not consist of people smoking 
less than people of the group of exposed smokers. On the basis of the data obtained 
with TA 1538 it might be concluded that the group of control smokers even 
contains more heavy smokers. Second, a comparison of urinary mutagenicity of 
control smokers with that of the control non-smokers as detected with TA 100 
(Fig. 1) did not give a statistically significant difference between the two groups 
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Fig. 2. Effect of smoking on urinary mutagenicity. The mutagenicity of urine samples from 
control subjects (non-smokers, smokers) and exposed subjects (non-smokers, smokers) as 
detected in the plate incorporation assay with the tester strain TA 1538 in the presence of S-9 mix 
is expressed in Rr/R
s
 values. Median values are 3.4, 12.5, 3.1 and 9.0, respectively 
R-r/Rs = Mean number of revenants found with urine Mean number of revenants found with aqua dest. 
(Wilcoxon test: P>0.05). Mutagens in urine as a consequence of smoking could 
not be detected with TA 100. 
Synergistic Effect of Smoking 
The increase in mutagenicity of urine from smokers exposed to cytostatics in 
comparison with the mutagenicity of urine from control smokers as detected with 
the strain TA 100 suggests a synergistic effect. Synergistic effects of smoking on the 
urinary mutagenicity have been observed by other investigators. Falck et al. (1980) 
showed a much higher mutagenicity in the urine from smokers working in the 
rubber industry than in urine from non-smoking workers or in urine from control 
smokers. Recently Wheeler et al. (1981) reported that smoking may have a 
synergistic effect on the appearance of mutagens in urine of coal-tar-treated 
psoriatic patients. It was found by Hannan et al. (1981) that cigarette smoke 
condensate and urine concentrate from smokers exhibit a co-mutagenic action on 
the mutagenicity of 2-aminoanthracene. The co-mutagenic factor was absent in 
urine concentrates from non-smokers. 
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Table 3. Mutagenicity of urine 
from a cyclophosphamide-
treated patient mixed with urine 
from smokers and non-smokers 
Urine concentrate* 
added to the topagar 
Patient 
Patient + smoker 1 
Patient + smoker 2 
Patient + non-smoker 
Smoker 1 
Smoker 2 
Non-smoker 
Number of his* 
revertants/plate" 
(strain TA 100) 
341 ± 5 
170 ±17 
248 + 16 
194± 3 
142 ± 6 
156 ±13 
137 ± 3 
Five per cent of 24-h urine samples from a patient, a 
smoker or from a non-smoker alone or combined was 
loaded on a X AD-2 column. The eluate was evaporated 
and the final residue was dissolved in 0.3 ml of DMSO; 
0.1 ml of this solution was added per plate in quadru­
plicate and assayed for mutagenicity with the Salmo­
nella typhimurium strain TA 100 in the absence of S-9 
mix 
Mean values (± SEM) of four measurements of the same 
urine 
revenant colonies per plate 
800 
6 0 0 
A00 
200 
1000 
cyeloptiosphamide ( >jg/plate) 
Fig. 3. Influence of urine concentrate on mutagenicity of cyclophosphamide. The mutagenicity 
of cyclophosphamide was determined in the plate incorporation assay, using the Salmonella 
typhimurium strain TA 100 in the presence of S-9 mix; 0.1 ml of urine concentrate from non-
smokers or smokers, norharman (400 ц&/р1аІе) or the vehicle (DMSO), respectively, was added 
to the topagar 
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Treatment" 
Cyclophosphamide 
Mutagenicity towards TA 100 
(his* revertants/plate)" 
Urine' from 
Unpretreated Aroclor 1254 
rats pretreated ratsd 
Experiment 1 228 ± 9 338 ± 6 
Experiment 2 245 ± 14 419 ± 13 
Experiment 3 2 5 0 + 7 424 ± 2 
Saline 106 ± 8 91 ± 7 
" Male Wistar rats weighing about 250 g were injected 
intraperitoneally with cyclophosphamide (20mg/kg) 
or saline 
'' Mean values (± SEM) of three measurements of the 
same urine 
c
 A 24-h urine sample was put through a XAD-2 column. 
The eluate was evaporated and the final residue was 
dissolved in 0.35 ml of DMSO; 0.1 ml of this solution 
was added per plate and assayed for mutagenicity with 
the Salmonella typhimunum strain TA 100 in the 
absence of S-9 mix 
d
 Rats received a single dose of Aroclor 1254 (500 mg/kg) 
5 days before the administration of cyclophosphamide 
Because we only found an increased mutagenicity in urine from subjects 
exposed simultaneously to cigarette smoke and cytostatic drugs, the question arose 
whether in this case a co-mutagenic action of smoking was involved. To study a co-
mutagenic effect of smoking on the urinary mutagenicity after exposure to 
cyclophosphamide, we combined the urine of a cyclophosphamide-treated patient 
with urine from smokers and a non-smoker and compared the urinary mutageni-
city. The data presented in Table 3 show that neither urine from a non-smoker nor 
urine from a smoker increases the mutagenicity of urine from a patient receiving 
cyclophosphamide. It may be concluded from this that no direct co-mutagenic 
action is involved. 
Another possibility is that the co-mutagenic effect takes place at the level of the 
mutagenic activation of cyclophosphamide. We studied the influence of urine 
concentrates from smokers and non-smokers and of the known co-mutagen 
norharman on the in vitro mutagenicity of cyclophosphamide tested with TA 100 
in the presence of S-9 mix. The results are shown in Fig. 3. There was no difference 
in the increase in mutagenicity of cyclophosphamide caused by urine concentrate 
from smokers or non-smokers. This increase might be explained partly by the 
presence in urine concentrate of certain factors promoting bacterial growth, and 
not by the presence of specific co-mutagenic factors. Figure 3 even shows a 
decreasing effect of norharman, a known co-mutagenic substance present in 
cigarette smoke (Nagao et al. 1977). 
Several compounds (3-methylcholanthrene, Aroclor 1254, and phénobarbital) 
are known to induce enzymes of the microsomal mono-oxygenase system. Jusko 
Table 4. Influence of Aroclor 
1254 on the urinary mutageni-
city of rats given cyclo-
phosphamide 
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Treatment 
Cyclophosphamide 
Mutagenicity towards TA 100 
(his* revertants per plate)" 
Administration1' 
On the Orally 
skin 
Experiment 1 198 ± 6 490 ±16 
Experiment 2 282 ± 8 532 ±25 
Experiments 304+15 555± 8 
Olive oil 117± 8 
* A 24-h unne sample was put through a XAD-2 column. 
After evaporation of the eluate, the final residue was 
dissolved in 0.35 ml of DMSO; 0.1 ml of this solution 
was added per plate and assayed for mutagenicity with 
the Salmonella lyphimunum strain TA 100 in the ab­
sence of S-9 mix. Mean values (±SEM) of three 
measurements of the same urine 
ь
 Male Wis ta г rats weighing about 250 g were given 
10 mg of cyclophosphamide in suspension in olive oil 
(0.1 ml), either on the close-shaven skin in the neck or 
per os 
(1979)and Boobis et al. (1979) found that cigarette smoking significantly increased 
mono-oxygenase activity and cytochrome P-448 content· in human liver. An 
increased mono-oxygenase activity can also be held responsible for the increase in 
urinary mutagenicity after exposure of smokers to (pre) mutagenic cytostatics. The 
data from Table 4 clearly show that pretreatment of rats with Aroclor 1254 results 
in a twofold increase in urinary mutagenicity after exposure of rats to cyclo­
phosphamide. This finding supports the concept that the higher urinary muta­
genicity in exposed smokers in comparison with exposed non-smokers is due to 
induction of activating enzymes as a consequence of smoking. 
On the other hand, it cannot be excluded that the synergistic effect of smoking is 
partly caused by differences in working hygiene between smokers and non-
smokers. In this respect, although the nurses do not smoke during work periods, a 
finger-shunt effect might play a role. 
Possibility of Exposure to Cytostatic Drugs 
Most probably, absorption of the cytostatic drugs by the nurses handling these 
substances may occur via: 
1 ) Skin contact with the drug in solution or as dust, or skin contact with urine from 
patients treated with these substances 
2) Inhalation of the dust of the drug or aerosolized drug particles 
This means that the manner in which the preparations are unpacked when they 
arrive from the pharmacy department, the way the nurses handle these prepara­
tions and the urine from treated patients, and the waste and spilling of the 
preparations are all very important factors in regard to their exposure. 
159 
Table 5. Mutagenicity of unne 
from rats after administration 
percutaneously or orally of 
cyclophosphamide 
R Ρ Bos et al. 
It is known that many polar and non-polar toxicants can easily penetrate the 
skin. Because most genotoxic cytostatic preparations are water-soluble, we were 
interested in absorption of these drugs through the skin, because this could be very 
important with respect to the route of intake. Therefore, experiments were done in 
which the urinary mutagenicity was compared between rats having received 
cyclophosphamide percutaneously or orally (Table 5). At 24 h after application, 
urine from percutaneously treated rats showed about 50% of the mutagenicity of 
the urine from rats having received cyclophosphamide per os. 
Conclusion 
It has been emphasized by several authors that smoking may potentiate or add to 
the health effects of workplace exposures (NIOSH 1979; WHO 1981; Joosting 
1981). In the present study it was found that smoking increased urinary 
mutagenicity detectable with TA 1538 (Fig. 2). On the other hand, with TA 100 it 
appeared that smoking has a potentiating effect on the mutagenicity of urine from 
nurses exposed to cytostatic drugs (Fig. 1). It might be concluded therefore that 
smoking nurses, handling cytostatic agents, have a greater occupational risk than 
their non-smoking colleagues. 
It should be emphasized that all measures should be taken to protect smoking 
as well as non-smoking hospital employees from exposure to genotoxic cytostatic 
drugs. Rules for safe handling of cytostatic drugs are extensively described 
elsewhere (Yorkshire Regional Cancer Organisation 1980). 
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Addendum 
Several studies show a greater increase in the alkylating or genotoxic 
activity of cyclophosphamide in vitro after incubation with phenobarbital-
induced liver fractions than after incubation with control or polycyclic 
hydrocarbon-induced liver fractions. (Sladek 1972, Hales 19B0a, Hales 1980b, 
Hales 1981). It is known that phénobarbital and 3-methylcholanthrene induce 
different cytochromes of the monooxygenase system: cytochrome P450 and Ρ44Θ, 
respectively (Conney et al. 1973). 
The influence of cigarette smoking on drug metabolism in man is consistent 
with the known inductive effects of P448 stimulators in animal systems (Jusko, 
1979). It can be questioned now, whether induction of P448 may result in the 
excretion of more mutagens in urine after administration of cyclophosphamide. 
The data presented in table 4 show that pretreatment of rats with aroclor 
1254 resulted in an increase in urinary mutagenicity after exposure of rats 
to cyclophosphamide. This may be expected since aroclor 1254, a mixture of 
polychlorinated biphenyls, should induce hemeproteina that can also be 
induced by phénobarbital and 3-methylcholanthrene (Ryan et al. 1977). To 
evaluate the role of P448 induction in the excretion of mutagens in urine 
after exposure to cyclophosphamide, we have pretreated rats with 3-methyl-
cholanthrene and studied the urinary mutagenicity after the administration of 
cyclophosphamide. The results are shown in the table below. It can be seen 
that phénobarbital pretreatment as well as 3-methylcholanthrene pretreatment 
as well as pretreatment with aroclor 1254 resulted in a remarkable increase 
in urinary mutagenicity after exposure of rats to cyclophosphamide. 
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INFLUENCE OF DIFFERENT INDUCERS OF THE MONOOXYGENASE SYSTEM ON THE URINARY MUTAGENICITY OF RATS GIVEN CYCLOPHOSPHAMIDE 
Treatment 
a) Mutagenicity towards TAI00 (his revertants/plate) 
Urine from О 
Cyclophosphamide unpretreated 
rats 
3-methylcholanthrene 
pretreated rats · 
phenobar b i ta 1 
pretreated rats e) 
aroclor 1?54 
pretreated rats f) 
experiment 1 
experiment 2 
experiment 3 
125 + 9 
216 + 12 
262 + 9 
315 + 19 
608 + 22 
1240 + 30 
424 + 20 
42Θ + 22 
430 + 7 
52Θ + 44 
719 + 5 
1100 + 30 
saline 106 + 1 102 + β 7 3 + 3 9 3 + 5 
a) 
b) 
c) 
d) 
e) 
f) 
Male Wistar rats weighing about 200 g were injected intraperitoneally with cyclophosphamide (25 mg/kg) 
Mean values (+_ SEM) of three measurements of the same urine 
A 24-h urine sample was put through a XAD-2 column. The eluate was evaporated and the final residue was dissolved 
in 0.35 ml of DMSO; 0.1 ml of this solution was added per plate and assayed for mutagenicity with the Salmonella 
typhimurium strain TAI00 in the absence of S9 mix 
Rats received a single dose of 3-methylcholanthrene (80 mg/kg) 24 hrs before the administration of cyclophosphamide 
Rats received phénobarbital (75 mg/kg) 96, 72, 48 and 24 hrs before the administration of cyclophosphamide 
Rats received a single dose of aroclor 1254 (500 mg/kg) 5 days before the administration of cyclophosphamide 
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Chapter 7 
Exposure to mutagens of workers involved in the 
preservative treatment of wood with creosote 

GENOTOXIC EXPOSURE OF WORKERS CREOSOTING WOOD 
1 2 1 1 
R.P. Bos , C.T.J. Hulshof , J.L.G. Theuws and P.Th. Henderson 
Institute of Pharmacology, Toxicology Unit, University of Nijmegen, 
Nijmegen, The Netherlands 
2 
Occupational Health Service, Region Nijmegen, Nijmegen, The Netherlands 
ABSTRACT 
In a small wood preserving industry spot samples were taken from 
contaminated surfaces at several places and tested for mutagenicity. The 
results suggest that the application of a wipe-test can give a first 
indication of occupational exposure to mutagenic and carcinogenic substances, 
particularly when exposure occurs more via skin contact than via inhalation. 
One of the pesticide chemicals in use for the preservation of wood id the 
mutagenic creosote. It was found that mutagens appeared in urine of rats 
after intraperitoneal administration of creosote. In spite of these results, 
no increase in mutagenicity could be detected in urine of creosote-workers 
in relation to their work. 
INTRODUCTION 
Creosote is well known as one of the pesticide chemicals in use for wood 
preservation. It is a mixture of oils that are separated in the distillation 
of coal tar and consists principally of liquid and solid hydrocarbons. 
Because it is known that coal tar contains many polycyclic aromatic 
hydrocarbons, we were interested in the mutagenicity of creosote. Mutagenic 
properties of creosote were established with the Salmonella/microsome assay . 
Because of its mutagenicity, this substance might bring about a potential 
hazard to persons who are occupationally involved in the preservative 
treatment of wood. Production workers in the wood preserving industry can be 
Accepted for publication by the British Journal of Industrial Medicine 
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exposed to creosote not only by inhalation of vapours, but also through skin 
and eye contact. It is known that workers exposed to coal tar products are 
2 
at a high cancer risk . 
In the present study possibilities of detecting the exposure to creosote 
were explored. lit several places in the work area contaminated surfaces were 
examined for the presence of mutagens. In addition, since it was found that 
exposure of Wistar rats to creosote under experimental conditions leads to 
the excretion of mutagenic products in urine, an attempt was made to monitor 
creosote workers by measurements of urinary mutagenicity. 
MATERIALS AND METHODS 
ChemioaІв 
The creosote type PI that was used was from Cindu Chemicals B.V. (Uithoorn, 
The Netherlands). Bacterial θ-glucuronidase (type IX) was obtained from 
Sigma (St. Louis, U.S.A.). Amberlite, type XAD-2 was purchased from Serva 
(Heidelberg, FRG)_. Purified agar was from Difco Laboratories (Detroit, U.S.A.), 
nutrient broth No. 2 from Oxoid Ltd. (Basingstoke, England). All other 
chemicals used were of highest purity obtainable. 
Impregnation procese 
The preservative impregnation with creosote is accomplished by a pressure 
method (full-cell process). After a charge of wood is taken into a cylinder, 
an initial vacuum is applied for a period of at least 15 min. At the end of 
this period the vessel is filled with creosote having a temperature of at 
least 70 С (mostly 85-100 C), still maintaining the vacuum. Next, the vacuum 
2 
is released and pressure with a maximum of 10 kgf/cm is applied to the 
system. Pressure is maintained until the required gross absorption of creosote 
has been achieved (maximal 3 hours). This value varies depending upon the 
species being treated. At the end of the pressure cycle, the pressure is 
reduced to atmospheric level, the preservative returned to storage, and the 
treated wood often subjected to a final vacuum to remove excess creosote oil 
from the surface of the stock. The vacuum is released, the door of the vessel 
opened, and the treated wood removed. 
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Workers 
We have studied the possible exposure of three workers. One of them is 
the operator of the cylinder. The other two workers are moving the wood in 
and out of the cylinder. Especially the operator would be briefly exposed 
to creosote vapours when the cylinder door is opened after treatment. The 
workers can also be exposed to residual surface creosote through skin contact. 
Most of the time they are wearing gloves. 
iiutageniaity testing 
The mutagenicity test was performed according to Ames et al. with 
Salmonella typhimuriwn ТА9 and TA100. We used Oxoid nutrient broth instead 
of Difco nutrient broth. Rat liver S9 (9000 g supernatant) fractions were 
prepared from male Wistar rats, pretreated with aroclor 1254. S9 mix 
contained 0.1 ml S9 per ml. Every determination was done in triplicate. After 
incubation of the plates for 4 h at 37 С the number of revertant colonies 
was counted. 
Urinary mutagenicity 
RATS 
Male Wistar rats weighing about 200 g were purchased from TNO (Rijswijk, 
The Netherlands). The animals were housed individually in stainless steel 
metabolism cages, designed for the separate collection of urine and feces. 
The rats had free access to water and food (Hope Farms, Woerden, The 
Netherlands). Creosote, dissolved In olive oil, was injected 
intraperitoneally. Control rats received only olive oil. 
Urine samples were collected for 24 h and stored at -20 С until assayed. 
Before they were assayed, the individual samples were completed to 15 ml and 
sterilized by filtration through 0.2 urn membrane filters. 
Mutagenicity of the urine samples was determined using the Salmonella 
typhimurium strains ТА9 and ТА100 . 0.1 ml of a fullgrown suspension of the 
9 
bacteria {+_ 2 χ 10 bac t./ml) was added to the topagar, containing 0.3 ml 
of diluted urine, and was supplied with an activating enzyme system. This 
activating enzyme system consisted of either, 0.5 ml S9 mix, or 0.1 ml of a 
4 
sterile S-glucuronidase solution (1500 U/ml), or a combination of both · 
WORKERS 
Urine samples from the workers were gathered during ten consecutive days, 
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including two free weekends. During this period two portions urine were 
collected dayly: one sample overnight and one sample between 10.00 a.m. 
and 4.00 p.m. The mutagenicity was determined according to van Doom et al. . 
Monitoring of contaminated surfaoee 
For the detection of contamination of work areas with mutagenic creosote 
6 
we applied a method based on the method described by Simmon and Peirce . 
5 ml of acetone or alcohol were put on a surface and the solvent was mopped 
up with a Kleenex tissue. The tissue was extracted twice with 25 ml of 
acetone or alcohol. The acetone or alcohol was evaporated to dryness using a 
rotary evaporator. The total residue was dissolved in 5 ml of 
dimethylsulphoxide (DMSO). 0.1 ml of this solution was added per plate and 
assayed for mutagenicity with the Salmonella typhimuriwn tester strain TA98 
in the presence of S9 mix. Every determination was done in triplicate. After 
48 h of incubation of the plates at 37 С the number of revertant colonies 
was counted. 
RESULTS 
Mutagenicity of creosote 
Table 1 shows the experimental results in which the mutagenicity of 
TABLE 1 
MUTAGENICITY OF CREOSOTE 
Creosote Number of his revertants per plate 
(yg/plate) Strain 
TA98 TA100 
0 1 6 + 4 6 9 + 4 
2 17 + 1 8 7 + 9 
5 2 1 + 2 9 9 + 2 
20 134 + 9 284 + 12 
50 336 + 7 5 9 8 + 9 
a) Mean values + S.E.M. of determinations in triplicate 
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creosote was established. The mutagenicity was assayed using the Salmonella 
typhimurium strains ΤΑ9Θ and TA100 in the presence of S9 mix and expressed 
as number of revertant colonies per plate. 
Oeteation of mutagenic aubstancee in the work environment 
The work environment was examined on the presence of mutagenic substances. 
Spot samples from contaminated surfaces at several places were taken and 
tested for mutagenicity. These mutagenicity data are presented in table 2. 
TABLE 2 
CONTAMINATION WITH MUTAGENIC SUBSTANCES OF SOME SPOTS IN THE WORK 
ENVIRONMENTa 
Sample 
Number of his revertants/plate 
Solvent used for cleaning 
acetone alcohol 
spot 1 
spot 2 
spot 3 
spot 4 
spot 5 
negative control 
positive control 
510 + 29 
558 + 52 
435 + 31 
231 + 7 
181 + 9 
4 5 + 3 
c) 
395 + 8 
7 7 + 2 
109 + 5 
373 + 20 
23 + 1 
3 1 + 2 
324 + 8 
Spontaneous 1 9 + 2 
a) 
b) 
c) 
Experimental details were as mentioned in Materials and Methods. 
Mean values (+^  S.E.M.) of 3 determinations on the same sample. 
No value available because of a toxic effect on the bacteria. 
Spots No. 1,2,3 and 4 were on metal surfaces. Spot 1 and 2 were on a grip 
of the door of the Cylinder and on a handle very close to this door, resp. 
Spot 3 was on the banistairs about 3 m away from the cylinder. Spot 4 was on 
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a lorry used for the transport of wood in and out of the cylinder. Spot 5 
was on wood that was not treated with creosote. This wood was piled up about 
15 m away from the cylinder. A negative control was made from a surface of a 
clean table in our laboratory. A spot on the surface of creosoted wood served 
as a positive control. These results show that there is a contamination of 
the work environment with mutagenic substances. 
It can be remarked that extraction with acetone reveals higher mutagenic 
values than the extraction with alcohol 
Animal experiments 
Administration of creosote to rats (250 mg/kg body weight, i.p.) resulted 
in the appearance of mutagens in urine detectable with the strains TA98 and 
TA100 (table 3). The highest mutagenicity values were detected after the 
TABLE 3 
MUTAGENICITY TOWARDS THE SALMONELLA TYPHIMORIUM STRAINS TA98 AND TA100 OF 
URINE FROM A CREOSOTE-TREATED RAT AFTER THE ADDITION OF DIFFERENT ENZYME 
PREPARATIONS 
Number of his revertants/plate 
Treatment 
Creosote Control 
Addition TA9B TA100 TA98 TA 100 
None 43 + 2 
S9 mix 4 4 + 5 
S9 mix + B-glucuronidase 123 + 8 
ß-glucuronidase 7 6 + 1 1 
"'Mean values (+_ S.E.M.) of 3 measurements of the same urine. 
Rats were injected i.p. with a dose of 250 mg/kg. 
c) 
For experimental details see Materials and Methods. 
150 Units of ß-glucuronidase were used. 
addition of S9 mix in the presence of ß-glucuronidase to the urine. 
188 + 9 
202 + 8 
341 + 10 
275 + 18 
37 + 1 
39 + 4 
43 + 3 
47 + 2 
175 + 8 
151 + 3 
175 + 12 
166 + 2 
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Absence of mutagemaity in urine of creosote workers 
We were interested whether the workers involved in the preservative 
treatment of wood with creosote had mutagenic urine. We collected urine 
samples on 10 consecutive days. Using Salmonella typhimuriwn ΤΑ9Θ in the 
presence of S9 mix and B-glucuronidase, we failed to detect an increase in 
urinary mutagenicity that could be related to their work. 
DISCUSSION 
These results clearly show the presence of mutagenic substances in the 
work environment of a wood-preserving industry. Most likely this mutagenicity 
is due to the presence of creosote. 
The method used for monitoring the work environment for the presence of 
mutagens is very easy to be done. Our procedure is principally based on the 
method of Simmon and Peirce who introduced it to detect the spill of 
carcinogens and mutagens in laboratories. The present results suggest that 
the application in the work environment of this wipe-test could give a first 
indication of occupational exposure to mutagenic and carcinogenic substances. 
This might be important, particularly in those cases where exposure can occur 
rather via skin contact than via inhalation. 
In spite of the substantial contamination of the work environment with 
mutagenic substances, no increase in mutagenicity in urine of the workers 
was detected in relation to their work. On the other hand it was found that 
mutagens appeared in urine of rats after intraperitoneal administration of 
creosote. Most probably the absence of mutagens in urine of creosote workers 
has to be attributed to (1) a relative low level of exposure, for instance 
owing to the wearing of protective gloves, (2) a wrong choice of the time 
of taking urine samples, (3) insensitivity of the urinary mutagenicity assay. 
Presumably more selective methods of biological monitoring may give more 
information about the internal exposure 
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Addendum 
In this chapter it is demonstrated that mutagens appeared in urine of 
rats after intraperitoneal administration of creosote. In this way it is 
shown that rats who are exposed internally to creosote have mutagens in 
their urine. 
One of the main routes of entrance of creosote in workers might be via 
absorption through the skin. In relation to this it is interesting to 
know whether mutagens present in creosote can penetrate the skin. Wheeler 
et al. (19Θ1) showed that coal-tar treated psoriatic patients have mutagenic 
urine. This indicates that certain mutagens present in coal tar can 
penetrate the human skin to be excreted via the urine in a later stage. 
Creosote, a product derived from coal tar, may contain the mutagenic 
substances present in coal tar which can penetrate the skin. 
In an additional experiment (see table) we show that mutagens appeared 
in urine of rats after the administration of creosote on the skin. This 
means that mutagens present in creosote are able to pass through the skin 
of the rat. This observation and the finding of Wheeler et al. (1981) make 
it reasonable that human exposure to creosote via the skin in principle 
can result in mutagenicity in the urine. Whatever the reason might be, 
at any rate the absence of mutagenicity in the urine of creosote workers 
can not be explained by the inability of mutagens in creosote to penetrate 
the human skin. 
Wheeler LA, Saperstein MD, Lowe NJ, Mutagenicity of urine from psoriatic 
patients undergoing treatment with coal tar and ultraviolet light. 
J. Invest. Dermatol. 19811 77: 181-185. 
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MUTAGENICITY OF URINE FROM RATS AFTER ADMINISTRATION OF CREOSOTE Pi ON THE 
SKIN OR ORALLY 
Treatment Mutagenicity towards ΤΛ9Θ (his revertants per plate) 
Administration 
Creosote Pi On the skin orally 
Experiment 1 89 +_ 2 
Experiment 2 9 6 + 7 
Experiment 3 — -
Spontaneous 2 7 + 2 
For experimental details see Materials and Methods. 0.3 ml of diluted raturine 
was tested for mutagenicity in the presence of S9 mix and B-glucuronidase 
(150 U). Mean values {+_ SEM) of three measurements of the same urine. 
Male Wistar rats weighing about 200 g received a dose of creosote Pi 
(250 mg/kg) in solution in olive oil (0.1 nl) either on the close-shaven 
skin in the neck or per os. 
91 
104 
118 
+ 5 
+ 5 
+ 5 
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SUMMARY AND CONCLUSIONS 
The ability of many chemicals to induce cancer is connected with their 
genotoxic properties. These properties imply that such compounds can react 
with DNA. Genotoxicity of chemicals can be detected in so-called short-term 
assays. Among these, the Salmonella/mutagenicity assay is one of the most 
evaluated and most reliable short-term assays. 
In order to safeguard people effectively against the risk of cancer by 
chemicals, the knowledge of two kinds of data is of primary importance. 
First, one should have information about the intrinsic carcinogenic properties 
of chemical compounds. Secondly it is important that exposure to such 
chemicals can be recognized. 
Both aspects have been discussed in this thesis. On the one hand, 
investigations are mentioned in which the Salmonella/mutagenicity assay was 
applied to detect genotoxic properties of chemicals; on the other hand 
possibilities to determine exposure to carcinogenic chemicals with the aid 
of this assay were studied. 
PART 1 mainly deals with studies in vitro on the suitability of the 
Salmonella/mutagenicity assay, applied in several forms to detect mutagenic 
properties of chemical products. 
With the aid of the Salmonella/microsome assay it was found that creosote 
PI has mutagenic properties. This product is well known as a pesticide in use 
for wood preservation and was recently denoted as non-mutagenic in bacterial 
assays. The Salmonella/microsome assay was subsequently used in combination 
with chemico-analytical methods to characterize the mutagenic components of 
creosote. Concentrations of benzo(a)pyrene and benz(a)anthracene were found 
to be 0.18 and 1.1 per cent, respectively (chapter 1). 
Often, electrophilic compounds or intermediates are able to react with 
endogenous glutathione. After finding a decrease in the concentration of 
liver glutathione due to the administration of toluene or xylenes, we 
wondered whether these compounds or their metabolites might have mutagenic 
properties on account of their electrophilicity. However, no mutagenicity 
was detected in the Salmonella/microsome assay of these compounds or some 
of the suspect metabolites. This means that electrophilicity does not 
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necessarily imply mutagenicity (chapter 2). 
In view of the prediction of genotoxic activity in vivo, it is a 
relevant question to what extent the activity of the liver fraction, added 
in the Salmonella/microsome assay, reflects the biotransformation in vivo. 
We approached this problem by an investigation of the mutagenicities of two 
aromatic amines, 4-aminobiphenyl and benzidine, after bioactivation by the 
whole animal (HOST-MEDIATED ASSAY) and after bioactivation by a rat-liver S9 
fraction (SALMONELLA/MICROSOME ASSAY). In this connection we also studied 
effects of bioactivation in vitro using intact rat hepatocytes (SALMONELLA/ 
HEPATOCYTE ASSAY). Comparison of the various test results revealed substantial 
differences between the mutagenicity after metabolism in vivo and the 
mutagenicity after metabolism by a rat-liver S9 fraction. The mutagenic 
activity of the aromatic amines, measured after metabolism by intact rat 
hepatocytes, resembled the mutagenic activity after biotransformation in vivo 
more closely (chapter 3). 
The utility of isolated rat hepatocytes as the metabolic factor in short-
term mutagenicity assays was further evaluated by testing a number of well-
known premutagenic compounds in the commonly-used Salmonella/microsome assay 
and in the Saimonella/hepatocyte assay. In a qualitative sense the results 
obtained with the two systems were on the whole equivalent. In quantitative 
respect, for some compounds obviously divergent mutagenic values were 
recorded with the different procedures (chapter 3). 
Experiments in vivo are described in PART 2 of the thesis. Methods for the 
detection of mutagenic products in urine were developed and refined with the 
aid of animals having received precarcinogenic compounds. The chemical 
compounds used in this study were aromatic amines and azo dyes (benzidine-
based dyes) which can be activated to be mutagenic by a series of 
consecutive enzymatic reactions. It became evident that N-acetylation plays 
an important role in the bioactivation of these compounds. Urinary 
metabolites were well detectable as mutagens after metabolic activation with 
different liver-enzyme fractions in combination with 0-glucuronidase (chapter 
4). 
PART 3 of the thesis concerns investigations in which the applicability 
of the Salmonella/mutagenlcity assay to detect human exposure to genotoxic 
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Chemicals was studied. For detection of the so-called internal exposure, 
urine samples of persons potentially exposed to numerous chemical compounds 
- including unidentified mixtures - were screened for the presence of 
mutagens. In some cases the environment was tested for the presence of 
mutagenic compounds. 
The study described in chapter 5 clearly shows that smoking cigarettes 
results in an increase in urinary mutagenicity. The presence of thioether 
compounds (common detoxification products of electrophllic compounds) as 
well as the presence of mutagens in urine were significantly related to the 
amount of cigarettes smoked. An increase in urinary mutagenicity was also 
found in urine of so-called passive smokers. This observation strongly 
suggests that there is a causality in the association between increased 
cancer risk and passive smoking, as was found by other investigators. The 
increase in urinary mutagenicity due to the passive exposure to cigarette 
smoke is about 4% of the increase observed with the active smokers during 
the experiment. Judging from these data it is supposed that the increased 
risk of cancer for passive smokers is of the same order of magnitude 
(chapter 5). 
Many cytostatic drugs used in anti-cancer therapy were found to be 
genotoxic in short term assays. In accordance with this property some of them 
also appeared to be carcinogenic in experimental animals. For this reason 
these substances bring about a potential hazard to persons who are 
occupationally involved in the synthesis, formulation and administration of 
these drugs, e.g. during nursing of cancer patients. In the present study 
we have investigated the effect of exposure to cytostatic drugs on the 
mutagenicity of urine from hospital workers. A method was used in which 
direct effects of smoking were distinguished from effects due to exposure 
to cytostatic drugs. In the study of the effects of exposure to cytostatic 
drugs, it was found that the mutagenicity of urine from exposed smokers was 
significantly higher than that of the control smokers. In this respect 
exposed non-smokers did not differ from control smokers. These results 
suggest a synergistic action. On account of additional animal experiments it 
is supposed that this synergism is at'least partly due to the induction of 
enzymes involved in the mutagenic activation of cytostatic drugs. On the other 
hand, it canrrct be excluded that differences in working hygiene between 
smokers and non-smokers also play a role (chapter 6). 
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In chapter 7 a study about exposure to mutagenic substances of workers 
who are occupationally involved in the treatment of wood with creosote (see 
also chapter 1) is described. The application of a wipe-test obviously 
demonstrated the presence of mutagenic substances in the work environment. 
However, no increase in the urinary mutagenicity of creosote workers was 
detected in relation to their work, although administration of a relatively 
high dose of creosote (250 mg/kg) to rats resulted in the appearance of 
mutagens in urine. Prom this finding one must not conclude that no internal 
exposure has occurred during handling of the creosote. 
The latter example demonstrates that in some cases a negative response in 
the urinary mutagenicity test can make the interpretation - in terms of the 
subjects' genotoxic risk - problematic. Hence, the urinary mutagenicity 
assay should merely be considered as a signal-test. This implies that in 
case of a negative result, additional tests should be performed, analogously 
to the use of a battery of several short-term assays in the screening for 
carcinogenic potency of chemicals. Whenever possible, particularly when the 
environmental genotoxic chemicals are known, selective (chemico-analytical) 
methods may be preferable. According to the present understanding it is 
not possible to estimate the extent of genotoxic risks on account of urinary 
mutagenicity values. It seems valid, however, to appraise relative risks for 
groups of persons being exposed under comparable conditions to similar 
chemical products by comparison of values of the urinary mutagenicity. 
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SAMENVATTING EN CONCLUSIES 
Het ontstaan van kanker door chemicaliën hangt veelal samen met het feit 
dat de chemische stof in kwestie genotoxische eigenschappen bezit. Dit houdt 
in dat de stof op de een of andere wijze een interactie kan aangaan met DNA. 
Deze eigenschap laat zich opsporen met behulp van zogenaamde korte-termijn 
testen, waarvan de Salmonella/mutageniteitstest een van de meest geëvalueerde 
en een van de meest betrouwbare is gebleken. 
Wanneer men mensen, die mogelijkerwijs via het werk of op andere wijze 
veelvuldig met chemicaliën in contact komen, tracht te beschermen tegen een 
verhoogd risico op het krijgen van kanker, zijn twee soorten gegevens erg be-
langrijk. In de eerste plaats moet men kankerverwekkende eigenschappen van de 
betreffende chemische producten kunnen herkennen. In de tweede plaats is het 
van belang om in bepaalde situaties de mate van blootstelling aan kankerver-
wekkende stoffen te kunnen bepalen. 
In dit proefschrift wordt op beide aspecten ingegaan. De Salmonella/mutage-
niteitstest werd-gebruikt om genotoxische eigenschappen van chemicaliën vast 
te stellen, terwijl daarnaast mogelijkheden werden bestudeerd om in bepaalde 
situaties blootstelling aan mutagene c.q. potenieel carcinogene chemicaliën 
met behulp van deze test op te sporen. 
In DEEL 1 worden enkele in vitro studies beschreven, waarin o.a. de Salmo-
nella/mutageniteitstest onder verschillende condities wordt aangewend ter op-
sporing van mutagene eigenschappen van chemische producten. 
Met behulp van de Salmonella/microsoom test werd gevonden dat creosoot Pi, 
een tot nu toe veilig geacht houtverduurzamingsmiddel bestaande uit een meng-
sel van chemicaliën, duidelijk mutagene eigenschappen heeft. In tweede in-
stantie werd deze test gebruikt om in combinatie met chemisch-analytische 
methoden de mutagene componenten te karakteriseren. Op deze wijze werd de 
aanwezigheid van benzo(a)pyreen en benz(a)anthraceen bepaald in concentraties 
van resp. 0,18 en 1,1% (hoofdstuk 1). 
Electrofiele verbindingen of intermediairen zijn in het algemeen in staat 
te reageren met endogeen glutathion. Nadat was gebleken dat toediening van 
tolueen of xylenen aan ratten resulteerde in een afname van de concentratie 
van glutathion in de lever, rees de vraag of deze stoffen of hun metabolie-
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ten op grond van electrofiele eigenschappen ook een mutagene werking zouden 
hebben. Bij het testen van deze verbindingen en van enkele metabolieten werd 
geen mutageen effect geconstateerd. Het feit dat een chemische verbinding 
electrofiele eigenschappen heeft impliceert dus niet zonder meer een mutagene 
activiteit (hoofdstuk 2). 
Uit oogpunt van de predictieve waarde kan men zich afvragen in hoeverre 
de bio-activering, die in de Salmonella/microsoom test wordt uitgevoerd 
middels een bepaalde enzymfractie uit rattelever (S9 fractie), de biotrans-
formatie in г о weerspiegelt. Om dit te onderzoeken werd de mutageniteit 
bepaald van twee aromatische aminen, 4-aminobiphenyl en benzidine, zowel na 
bio-activering door het totale proefdier (HOST-MEDIATED TEST), als na bio-
activering in vitro door toevoeging van een zg. S9 fractie (SALMONELLA/ 
MICROSOOM TEST). Ter vergelijking werd tevens het effect onderzocht van in 
vitro bio-activering met behulp van geïsoleerde rattelevercellen (SALMONELLA/ 
HEPATOCYT TEST). Uit dit onderzoek bleek dat er aanzienlijke verschillen kun-
nen bestaan tussen de mutageniteit na in vivo metabolisme en de mutageniteit 
na metabolisme door de S9 fractie. De mutagene activering met behulp van ge-
isoleerde levercellen benaderde het meest de biotransformatie zoals die in 
het totale organisme plaatsvindt (hoofdstuk 3). 
Voor een verdere evaluatie van de bruikbaarheid van geïsoleerde levercel-
len als metabole factor bij de screening van mutagenen in vitro werd een aan-
tal bekende premutagene verbindingen onderzocht op mutageniteit in de stan-
daard Salmonella/microsoom test en in de bovengenoemde Salmonella/hepatocyt 
test. Over het algemeen werden er in kwalitatieve zin geen verschillen gevon-
den. In kwantitatieve zin werden echter voor sommige stoffen opmerkelijke 
verschillen geconstateerd (hoofdstuk 3). 
In DEEL 2 van het proefschrift worden met name in vivo experimenten be-
schreven. Met behulp van proefdieren, die precarcinogene stoffen kregen toe-
gediend, werden methoden voor het opsporen van mutagene producten in de uri-
ne ontwikkeld, c.q. geoptimaliseerd. De verbindingen die bij dit onderzoek 
werden gebruikt waren aromatische aminen en azo-kleurstoffen (zg. benzidine-
based dyes), welke op verschillende wijzen kunnen worden geactiveerd volgens 
een ingewikkeld patroon van opeenvolgende enzymreacties. De N-acetylering 
bleek hierbij een belangrijke rol te spelen. Mutagene metabolieten in de 
urine afkomstig van dit type verbindingen konden zeer goed worden gedetec-
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teerd na metabole activering, waarvoor verschillende leverenzymfracties, 
eventueel in combinatie met andere enzymen, werden gebruikt (hoofdstuk 4). 
DEEL 3 van dit proefschrift is gewijd aan onderzoek waarin de Salmonella/ 
mutageniteitstest werd toegepast bij het signaleren van mogelijke expositie 
van mensen aan genotoxische verbindingen. Het gaat in deze studies om bloot-
stellingen aan mengsels van chemicaliën. Urinemonsters van mogelijk geëxpo-
neerden werden onderzocht op de aanwezigheid van mutagenen als indicatie 
voor een "inwendige belasting". In enkele gevallen werd de omgeving getest 
op de aanwezigheid van mutagene stoffen. 
Het onderzoek laat duidelijk zien dat roken van sigaretten resulteert in 
een verhoging van de mutageniteit van urine (hoofdstuk 5). Zowel de aanwezig-
heid van thioethers (in het algemeen ontgiftingsproducten van electrofiele 
verbindingen) als de aanwezigheid van mutagenen in de urine bleek gecorre-
leerd te zijn met het aantal gerookte sigaretten. Ook in de urine van zg. 
passieve rokers werd een verhoging van de mutageniteit geconstateerd. Deze 
waarneming ondersteunt de resultaten van epidemiologische onderzoeken, waar-
in een relatie werd aangetoond tussen passief roken en een vergroot risico 
op het krijgen van longkanker. De stijging in de mutageniteit van de urine 
van passieve rokers is ongeveer 4% van het verschil in mutageniteit van de 
urine van de actieve rokers ten opzichte van niet-rokers. Mede op basis hier-
van wordt het vermoeden geuit dat het extra risico op het krijgen van long-
kanker voor passieve rokers in dezelfde orde van grootte ligt (hoofdstuk 5). 
Het is bekend dat veel cytostatica die gebruikt worden bij de chemothera-
pie van kanker genotoxisch zijn en op grond daarvan ook zelf in staat blijken 
tumoren te induceren. Bij de behandeling van kankerpatiënten vindt, alvorens 
de therapie wordt toegepast, een afweging van voor- en nadelen plaats. Geheel 
anders is de situatie echter voor hen die beroepsmatig met deze therapeutica 
omgaan. Bij een onderzoek naar een mogelijke "inwendige belasting" met 
cytostatica van verplegend personeel werden urinemonsters onderzocht op de 
aanwezigheid van mutageniteit (hoofdstuk 6). Bij dit onderzoek werd een zo-
danige testmethode gekozen dat directe effecten van roken konden worden on-
derscheiden van de effecten ten gevolge van blootstelling aan cytostatica. 
Met deze methode werd gevonden dat verplegend personeel dat rookt een ver-
hoogde mutageniteit van de urine had ten opzichte van controle-rokers. Een 
dergelijke verhoging werd niet waargenomen bij niet-rokend, verplegend per-
1Θ3 
soneel. Deze resultaten wijzen in de richting van een synergistische werking 
van roken O D de mutageniteit van urine bij blootstelling aan cytostatica. 
Op grond van dierexperimenten zou dit effect ten dele kunnen worden toe-
geschreven aan enzyminductie ten gevolge van het roken. Het is aannemelijk 
dat door een geïntensiveerde biotransformatie relatief meer van de cytosta-
tica als mutageen in de urine verschijnt. Daarnaast kan niet worden 
uitgesloten dat verschillen in arbeidshygiëne tussen rokers en niet-rokers 
ook een rol spelen. 
Hoofdstuk 7 betreft een onderzoek naar de expositie aan mutagenen van 
werknemers die regelmatig in aanraking komen met het genotoxische creosoot 
(zie hoofdstuk 1) in een houtverduurzamingsbedrijf. Door toepassing van 
een zogenaamde veegtest werd besmetting van de werkomgeving met mutagenen 
aangetoond. Hoewel een relatief hoge dosis (250 mg/kg) van creosoot toege-
diend aan ratten resulteerde in het verschijnen van mutagenen in de urine, 
werd geen verhoogde mutageniteit in de urine van werknemers gevonden in 
relatie tot de blootstelling tijdens het werk met het genotoxische conserve-
ringsmiddel. Een bevinding waaruit niet geconcludeerd mag worden dat er 
geen "inwendige belasting" heeft plaatsgevonden. 
Dit laatste voorbeeld illustreert dat een niet verhoogde mutageniteit van 
de urine moeilijk te interpreteren is in termen van genotoxische risico's. 
Een mutageniteitstest op urine dient derhalve te worden beschouwd als een 
signaal test. Dit impliceert dat bij een negatieve uitslag van de biologi-
sche monitoring van mutageniteit van de urine, bij blootstelling aan mengsels 
van chemicaliën, waaronder genotoxische producten worden vermoed, additionele 
testen moeten worden uitgevoerd in analogie met het gebruik van de zg. batte-
rij van korte-termijn testen die gehanteerd wordt bij het in vitro mutageni-
teitsonderzoek. Wanneer de mogelijk belastende factoren bekend zijn dient men 
het gebruik van meer selectieve (chemisch-analytische) bepalingen te overwegen. 
Kwantificering van het eventuele genotoxische risico op grond van de muta-
geniteit van urine is vooralsnog niet mogelijk. Wel kunnen in geval van verge-
lijkbare exposities relatieve risico's worden bepaald voor groepen van perso-
nen door de mutageniteitswaarden van urine met elkaar te vergelijken (zie bij-
voorbeeld hoofdstuk 5). 
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STELLINGEN 
1. Bij de toepassing van niet-selectieve bepalingen voor 'biologische 
monitoring', zoals de thioethertest en de mutageniteitstest op urine, 
mag uit een negatieve uitkomst niet worden geconcludeerd dat geen of 
een te verwaarlozen blootstelling aan respectievelijk electrofiele en 
mutagene verbindingen heeft plaatsgevonden. 
R. van Doom et al. (1981), Arm. Οασιφ. Нуд. 24, 77-92. 
T. Heinonen et al. (1983), Int. Avoh. Oaaup Environ. Health 52, 
11-16. 
Dit proefschrift. 
2. In de bedrij fshygiëne dient meer aandacht te worden geschonken aan de 
ontwikkeling van methoden voor 'environmental monitoring' van contaminaties 
van de werkomgeving, die aanleiding kunnen geven tot expositie via de 
huid. Dit geldt met name voor die gevallen waarvoor geen adequate 
methoden van biologische monitoring voor handen zijn. 
Dit proefschrift. 
3. Het feit dat Pasquini et al. geen verschil vinden tussen de mutageniteit 
van urine van rokers en van niet-rokers, duidt er op dat de door hen uit-
gevoerde bepaling te ongevoelig is. 
H. Pasquini et al. (1982), Int. Arch. Occup. Environ. Health 50, 
287-395. 
Dit proefschrift. 
4. Het feit dat reeds 200 jaar geleden beroepskanker voor schoorsteenvegers 
werd vastgesteld, en dit risico voor de hedendaagse schoorsteenvegers nog 
steeds actueel is, geeft duidelijk aan, dat de kloof tussen wetenschappelijk 
onderzoek en vertaling van resultaten daarvan naar en door de samenleving 
moeilijk te overbruggen is. 
P. Pott, Cancer scroti, In: Chirurgical observations. Houes, Clarke 
and Collins, London, 1775, pp. 63-68. 
С. Hogstedt et al. (1982), Scand. J. Work Environ. Health 8, suppl. 1, 
72-78. 
E.S. Hansen (19831, Am. J. Epidemiol. 117, 160-164. 
5. Het onderbrengen van de hydratatie van epoxides bij de fase 1 reacties van 
de biotransformatie is niet consequent. Analoog aan conjugaties als glucuro-
nidering en sulfatering is additie van water te beschouwen als een synthese 
en dient daarom te worden gekenmerkt als een fase 2 reactie. 
J.A. Timbrell, Principles of Biochemical Toxicology, Taylor & Francis 
LTD, London, 1982. 
R.T. Williams, Detoxication Mechanisms, Chapman i Hall LTD, London 
1959. 
6. Daar het krijgen van kanker voor een belangrijk deel te wijten is aan de 
gevolgde leefwijze, is het van belang bij de kankerpreventie veel meer 
aandacht te besteden aan het geven van duidelijke voorlichting over 
individuele mogelijkheden cm het kankerrisico te verkleinen. De 'van alles 
krijg je kanker' mentaliteit dient te verdwijnen. 
Я. Doll and R. Peto (1981), J. Nati. Canoer Inst. 66, 1192-1265. 
7. Op grond van een onlangs gesuggereerd mechanisme voor de carcinogene 
werking van asbest, zou deze stof moeten worden gekenmerkt als een indirect 
genotoxisch carcinogeen en niet als een epigenetisch carcinogeen. 
V.E. Archer and G.K. Livingston, In: W.N. Rom: Environmental and 
Occupational Medicine. Little, Brown and Company, Boston, 1983, p. 63. 
J.H. Weieburger and G.M. Williama,(1983), Unviron. Health Perspect. 
50, 233-245. 
8. Het aantal colonies van gereverteerde bacteriën, dat in de conventionele 
Ames test als criterium voor mutagenitelt wordt gebruikt, laat slechts een 
momentopname zien van de interactie tussen bacteriën en de testsubstantie. 
Toepassing van methoden waarbij een continue registratie van de bacteriën-
groei plaatsvindt, verdient de voorkeur. In dit opzicht biedt de onlangs 
ontwikkelde 'Hutascreen' aanzienlijke voordelen. 
X. Falck, Method for the Performance of a Mutagenicity Teat, PCT Pat. 
Appi. No. PCT/FI83/00S3. 
9. Het de thans in gebruik zijnde methoden voor biologische monitoring van 
blootstelling aan mutagene en carcinogene stoffen, is het niet mogelijk 
uitspraken te doen ten aanzien van het uiteindelijke risico op gezondheids-
schade in kwantitatieve zin. 
Proceedinga of the International Seminar on Methode of Monitoring 
Human Exposure to Carcinogenic and Mutagenic Agenta, 12-15 december 1983, 
Espoo, Finland. 
10. De bruikbaarheid van mosselen als bioaccumulatoren van milieuverontreinigende 
stoffen pleit niet voor de consumptie ervan. 
11. Om rokers te beschermen tegen mogelijke gezondheidsschade tengevolge van het 
roken, gaat men over tot de productie van filtersigaretten en sigaretten met 
een lager teergehalte. Om 'passieve rokers' enigszins te beschermen, zou men 
gezien de hoge 'sidestream/mainstrearn' ratio voor veel toxische bestanddelen 
van sigaretterook, sigaretten moeten ontwikkelen die geen 'sidestream smoke' 
produceren. 
И. Iwainaky and K. Wineel (1981), Z. Erkrank. Atm.- Org, 157, 90-102, 
Nijmegen, 16 februari 1984 
Rob Bos 


